{
    "questions": [
        {
            "id": "5a75eb6483b0d9ea66000004",
            "body": "What is Blount's disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19370370",
                "http://www.ncbi.nlm.nih.gov/pubmed/25932193",
                "http://www.ncbi.nlm.nih.gov/pubmed/15481748",
                "http://www.ncbi.nlm.nih.gov/pubmed/27583129",
                "http://www.ncbi.nlm.nih.gov/pubmed/20609637",
                "http://www.ncbi.nlm.nih.gov/pubmed/23610758",
                "http://www.ncbi.nlm.nih.gov/pubmed/880738",
                "http://www.ncbi.nlm.nih.gov/pubmed/8657465",
                "http://www.ncbi.nlm.nih.gov/pubmed/7670990",
                "http://www.ncbi.nlm.nih.gov/pubmed/9174455"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370",
                    "text": "BACKGROUND Blount's disease is a multi-planar deformity affecting the pediatric population which leads to varus alignment of the lower extremities.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25932193",
                    "text": "Blount's disease is an uncommon disorder of postero-medial proximal tibial physis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 82,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15481748",
                    "text": "Blount's disease or congenital tibia vara is a clinical entity characterized by tibia bowing, tibia torsion, and beaking of the medial tibia metaphysis on plain radiograph.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27583129",
                    "text": "Blount's disease is a progressive form of genu varum due to asymmetrical inhibition of the postero medial portion of the proximal tibial epiphysis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20609637",
                    "text": "INTRODUCTION In stage\u00a01 of all currently accepted classifications for infantile tibia vara, the diagnosis is difficult between physiological bowing and true Blount's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23610758",
                    "text": "Infantile Blount's disease is a condition that causes genu varum and internal tibial torsion.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/880738",
                    "text": "A family is described with infantile Blount's disease (tibia vara) following an autosomal dominant mode of inheritance.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/880738",
                    "text": "It is speculated that infantile Blount's disease may be inherited as an autosomal dominant condition with variable penetrance, and that genetic factors have been noted only infrequently, as parents may have improved with age or have been affected only mildly.",
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 526,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8657465",
                    "text": "In view of the spontaneous recovery of all investigated patients, it must be doubted whether a diagnosis of infantile tibia vara can be made in early infancy, and whether infantile Blount's disease is a diagnosis in its own right.",
                    "offsetInBeginSection": 672,
                    "offsetInEndSection": 902,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7670990",
                    "text": "We postulate the hypothesis of the etiopathogenesis of the infantile type of Blount's disease as a disease related to a dysplastic linkage between epiphysis and metaphysis.",
                    "offsetInBeginSection": 95,
                    "offsetInEndSection": 267,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6a2dcab750ff4455000023",
            "body": "Which are the constitutive parts of a Genomic Regulatory Block (GRB)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22666536",
                "http://www.ncbi.nlm.nih.gov/pubmed/17387144",
                "http://www.ncbi.nlm.nih.gov/pubmed/19374772",
                "http://www.ncbi.nlm.nih.gov/pubmed/21619633",
                "http://www.ncbi.nlm.nih.gov/pubmed/22962458",
                "http://www.ncbi.nlm.nih.gov/pubmed/22234889",
                "http://www.ncbi.nlm.nih.gov/pubmed/17989259",
                "http://www.ncbi.nlm.nih.gov/pubmed/18047696",
                "http://www.ncbi.nlm.nih.gov/pubmed/28343901",
                "http://www.ncbi.nlm.nih.gov/pubmed/19969543"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666536",
                    "text": "The Sonic Hedgehog (Shh) genomic regulatory block (GRB) is one of the best functionally characterized examples, with several discrete enhancers reported within its introns, vast upstream gene-free region and neighboring genes (Lmbr1 and Rnf32).",
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 436,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144",
                    "text": "We termed these chromosomal segments genomic regulatory blocks (GRBs).",
                    "offsetInBeginSection": 916,
                    "offsetInEndSection": 986,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144",
                    "text": "Reporter insertions distal to zebrafish developmental regulatory genes pax6.1/2, rx3, id1, and fgf8 and miRNA genes mirn9-1 and mirn9-5 recapitulate the expression patterns of these genes even if located inside or beyond bystander genes, suggesting that the regulatory domain of a developmental regulatory gene can extend into and beyond adjacent transcriptional units.",
                    "offsetInBeginSection": 546,
                    "offsetInEndSection": 915,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144",
                    "text": "Bystander genes are not specifically under the control of the regulatory elements that drive the target genes and are expressed in patterns that are different from those of the target genes.",
                    "offsetInBeginSection": 355,
                    "offsetInEndSection": 545,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19374772",
                    "text": "BACKGROUND Genomic regulatory blocks (GRBs) are chromosomal regions spanned by highly conserved non-coding elements (HCNEs), most of which serve as regulatory inputs of one target gene in the region.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 199,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21619633",
                    "text": "They are therefore functionally related to a number of key protein coding developmental genes, that form genomic regulatory blocks (GRBs) with arrays of highly conserved non-coding elements (HCNEs) functioning as long-range enhancers that collaboratively regulate the expression of their target genes.",
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 557,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21619633",
                    "text": "Furthermore these predictions include miRNAs of the miR-9 family, which are the only experimentally verified GRB target miRNAs.",
                    "offsetInBeginSection": 1937,
                    "offsetInEndSection": 2064,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22962458",
                    "text": "These elements are organized as large clusters, so-called gene regulatory blocks (GRBs) around key developmental genes.",
                    "offsetInBeginSection": 315,
                    "offsetInEndSection": 434,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22234889",
                    "text": "Developmental genes are regulated by complex, distantly located cis-regulatory modules (CRMs), often forming genomic regulatory blocks (GRBs) that are conserved among vertebrates and among insects.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17989259",
                    "text": "These arrays span key developmental regulatory genes, forming genomic regulatory blocks (GRBs).",
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 381,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a735cdc3b9d13c708000004",
            "body": "In November 2017,  in what phase  was  the clinical trial for the drug SYL040012?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24025752",
                "http://www.ncbi.nlm.nih.gov/pubmed/28493171",
                "http://www.ncbi.nlm.nih.gov/pubmed/28760727",
                "http://www.ncbi.nlm.nih.gov/pubmed/17621880",
                "http://www.ncbi.nlm.nih.gov/pubmed/28627277",
                "http://www.ncbi.nlm.nih.gov/pubmed/29099483",
                "http://www.ncbi.nlm.nih.gov/pubmed/28671135",
                "http://www.ncbi.nlm.nih.gov/pubmed/29067343",
                "http://www.ncbi.nlm.nih.gov/pubmed/28351167",
                "http://www.ncbi.nlm.nih.gov/pubmed/16037862"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752",
                    "text": "The objective of this study was to evaluate ocular tolerance, safety, and effect on intraocular pressure (IOP) of a topically administered small interfering RNA; SYL040012, on healthy volunteers.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493171",
                    "text": "Atezolizumab, approved in May 2016, and nivolumab, approved in February 2017, are the first Food and Drug Administration (FDA)-approved immune-checkpoint inhibitors in bladder cancer for platinum-pretreated patients based on phase II data.",
                    "offsetInBeginSection": 1282,
                    "offsetInEndSection": 1521,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28760727",
                    "text": "RESULTS Recruitment for the first phase of this project commenced in November 2016, and the phase will run from February to November 2017.",
                    "offsetInBeginSection": 2157,
                    "offsetInEndSection": 2295,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28760727",
                    "text": "TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12616001243404p; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371422 (Archived by WebCite at http://www.webcitation.org/ 6rmlEiM1L).",
                    "offsetInBeginSection": 2590,
                    "offsetInEndSection": 2823,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17621880",
                    "text": "A phase I/II clinical trial in CTCL and CBCL was recently completed, and in November 2006 Transgene initiated a phase II clinical trial in CBCL.",
                    "offsetInBeginSection": 209,
                    "offsetInEndSection": 353,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28627277",
                    "text": "Areas covered: A search for phase 1 and 2 acne treatment trials in the US National Institutes of Health database of clinical trials and the European Medicines Agency database with the key words 'acne' and 'treatment' was carried out, on 6 January 2017.",
                    "offsetInBeginSection": 517,
                    "offsetInEndSection": 769,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28671135",
                    "text": "METHODS All HD clinical trials registered in the WHO International Clinical Trials Search Portal, from inception to May 2017, were analyzed.",
                    "offsetInBeginSection": 488,
                    "offsetInEndSection": 628,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28671135",
                    "text": "CONCLUSIONS Although HD is a rare condition, 99 HD trials were identified in a comprehensive clinical trial registry.",
                    "offsetInBeginSection": 1684,
                    "offsetInEndSection": 1801,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29067343",
                    "text": "METHODS We assessed the agents in the AD pipeline as documented in clinicaltrials.gov for phase I, phase II, and phase III, accessed 1/5/2017.",
                    "offsetInBeginSection": 163,
                    "offsetInEndSection": 305,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28351167",
                    "text": "DATA SOURCES Searches of PubMed (1966 to February 2017) and Cochrane Library (1999 to February 2017) were conducted using the terms talimogene laherparepvec, T-VEC, OncoVEX, immunotherapy, melanoma, and oncolytic virus.",
                    "offsetInBeginSection": 217,
                    "offsetInEndSection": 436,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a777ab9faa1ab7d2e00000a",
            "body": "What is the drug target(s) for Belsomra?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25336862",
                "http://www.ncbi.nlm.nih.gov/pubmed/29066641",
                "http://www.ncbi.nlm.nih.gov/pubmed/27390287",
                "http://www.ncbi.nlm.nih.gov/pubmed/27471419",
                "http://www.ncbi.nlm.nih.gov/pubmed/17016423",
                "http://www.ncbi.nlm.nih.gov/pubmed/17883836",
                "http://www.ncbi.nlm.nih.gov/pubmed/21689470",
                "http://www.ncbi.nlm.nih.gov/pubmed/25861037",
                "http://www.ncbi.nlm.nih.gov/pubmed/20011153",
                "http://www.ncbi.nlm.nih.gov/pubmed/23317822"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25336862",
                    "text": "Idelalisib (Zydelig) for certain types of leukemia and lymphoma, peginterferon beta-1a (Plegridy) for relapsing forms of multiple sclerosis, and suvorexant (Belsomra) for insomnia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27390287",
                    "text": "Starting from suvorexant (trade name Belsomra), we successfully identified interesting templates leading to potent dual orexin receptor antagonists (DORAs) via a scaffold-hopping approach.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27471419",
                    "text": "Dual orexin receptor antagonists represent a new class of medications for the treatment of insomnia, which block the binding of wakefulness-promoting neuropeptides orexin A and orexin B to their respective receptor sites.",
                    "offsetInBeginSection": 557,
                    "offsetInEndSection": 778,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27471419",
                    "text": "Suvorexant (Belsomra) is the first dual orexin receptor antagonist to be approved in the US and Japan and has demonstrated efficacy in decreasing time to sleep onset and increasing total sleep time.",
                    "offsetInBeginSection": 779,
                    "offsetInEndSection": 977,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27471419",
                    "text": "Suvorexant is not likely to replace benzodiazepines or nonbenzodiazepine receptor antagonists as a first-line sleep agent but does represent a novel option for the treatment of patients with chronic insomnia.",
                    "offsetInBeginSection": 1622,
                    "offsetInEndSection": 1830,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17016423",
                    "text": "What is a drug target?",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 22,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17883836",
                    "text": "In the current study, based on the properties of known drug targets, we have developed a sequence-based drug target prediction method for fast identification of novel drug targets.",
                    "offsetInBeginSection": 657,
                    "offsetInEndSection": 837,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17883836",
                    "text": "Identifying potential drug targets is the first step in the process of modern drug discovery for developing novel therapeutic agents.",
                    "offsetInBeginSection": 193,
                    "offsetInEndSection": 326,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20011153",
                    "text": "UNLABELLED A Genomic Target Database (GTD) has been developed having putative genomic drug targets for human bacterial pathogens.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23317822",
                    "text": "In apicomplexan parasites, the apicoplast is a suitable target for established and novel drugs.",
                    "offsetInBeginSection": 724,
                    "offsetInEndSection": 819,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8861eb8cb19eca6b000001",
            "body": "List the two most important synaptic markers.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27906174",
                "http://www.ncbi.nlm.nih.gov/pubmed/25755633",
                "http://www.ncbi.nlm.nih.gov/pubmed/22206847",
                "http://www.ncbi.nlm.nih.gov/pubmed/22609570",
                "http://www.ncbi.nlm.nih.gov/pubmed/7783952",
                "http://www.ncbi.nlm.nih.gov/pubmed/26776762",
                "http://www.ncbi.nlm.nih.gov/pubmed/26017624",
                "http://www.ncbi.nlm.nih.gov/pubmed/24205365",
                "http://www.ncbi.nlm.nih.gov/pubmed/8783274",
                "http://www.ncbi.nlm.nih.gov/pubmed/10888735"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25755633",
                    "text": "Synaptic failure and neurofibrillary degeneration are two major neuropathological substrates of cognitive dysfunction in Alzheimer's disease (AD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847",
                    "text": "The protein and messenger RNA (mRNA) levels of 7 synaptic markers (complexin-1, complexin-2, synaptophysin, synaptobrevin, syntaxin, synaptosomal-associated protein 25 (SNAP-25), and septin-5) were compared in the brains of nondemented and demented individuals ranging from 70 to 103 years of age.",
                    "offsetInBeginSection": 660,
                    "offsetInEndSection": 957,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22609570",
                    "text": "Insulin-like growth factor-1 (IGF1) and its active peptide (1-3)IGF1 modulate brain growth and plasticity and are candidate molecules for treatment of brain disorders.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7783952",
                    "text": "Of these latter proteins, one is integral (synaptophysin) the other peripheral (synapsin I) to the synaptic vesicle membranes.",
                    "offsetInBeginSection": 294,
                    "offsetInEndSection": 420,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24205365",
                    "text": "GluA2-containing AMPA receptors and their association with protein kinase M zeta (PKM\u03b6) and post-synaptic density-95 (PSD-95) are important for learning, memory and synaptic plasticity processes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8783274",
                    "text": "In the retina, dystrophin has been localized in the outer plexiform layer where dystrophin co-localizes with postsynaptic markers of photoreceptor synaptic complexes.",
                    "offsetInBeginSection": 412,
                    "offsetInEndSection": 578,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8783274",
                    "text": "Mutations in the gene encoding for dystrophin, a membrane-associated cytoskeletal protein of muscle and several non-muscle cells, are the cause of Duchenne muscular dystrophy and Becker muscular dystrophy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8783274",
                    "text": "These findings indicate a more general role of this dystrophin-associated membrane protein in synaptic functions.",
                    "offsetInBeginSection": 1580,
                    "offsetInEndSection": 1693,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8783274",
                    "text": "In the present study we addressed the question of whether two major dystrophin-associated integral membrane proteins of the muscular plasma membrane, beta-dystroglycan and adhalin, are also present in photoreceptor synaptic complexes.",
                    "offsetInBeginSection": 579,
                    "offsetInEndSection": 813,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10888735",
                    "text": "The markers applied were from three major groups: 1) antibodies against calcium-binding proteins, such as calbindin, parvalbumin, recoverin, or caldendrin; 2) antibodies that recognize specific transmitter systems, such as glycine, gamma-aminobutyric acid, or acetylcholine; and 3) antibodies that recognize transmitter receptors and show their aggregation at specific synapses.",
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 822,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75ee7e83b0d9ea66000005",
            "body": "List symptoms of the Zieve's syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7110955",
                "http://www.ncbi.nlm.nih.gov/pubmed/2616809",
                "http://www.ncbi.nlm.nih.gov/pubmed/8819039",
                "http://www.ncbi.nlm.nih.gov/pubmed/26203455",
                "http://www.ncbi.nlm.nih.gov/pubmed/464793",
                "http://www.ncbi.nlm.nih.gov/pubmed/8645520",
                "http://www.ncbi.nlm.nih.gov/pubmed/11761804",
                "http://www.ncbi.nlm.nih.gov/pubmed/2355237",
                "http://www.ncbi.nlm.nih.gov/pubmed/425850",
                "http://www.ncbi.nlm.nih.gov/pubmed/548954"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7110955",
                    "text": "Zieve's syndrome therefore is not benign but precedes acute alcoholic hepatitis episodes on a normal, fibrotic or cirrhotic liver.",
                    "offsetInBeginSection": 508,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7110955",
                    "text": "Zieve's syndrome, characterized by jaundice, hyperlipaemia and haemolytic anaemia, usually develops in young, chronically alcoholic subjects with enlarged fatty liver.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2616809",
                    "text": "The clinical manifestations of the syndrome contains no pathognomonic symptoms and suggests rather cholecystopathy.",
                    "offsetInBeginSection": 132,
                    "offsetInEndSection": 247,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8819039",
                    "text": "Zieve's syndrome consists of transient haemolytic anaemic, jaundice, hyperlipidaemia and alcohol-induced liver disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/464793",
                    "text": "The Zieve's syndrome consists of the transient association of cholestatic jaundice, hemolytic anemia, hyperlipemia, in a chronic alcoholic.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8645520",
                    "text": "Jaundice, hyperlipidemia and haemolytic anemia define Zieve's Syndrome (Z.S.)",
                    "offsetInBeginSection": 692,
                    "offsetInEndSection": 769,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11761804",
                    "text": "We report a case of recurrent Zieve's syndrome, consisting of jaundice, hemolytic anemia and hyperlipoproteinemia, initiated by alcohol abuse.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2355237",
                    "text": "Zieve's syndrome (hyperlipidaemia, anaemia and fatty liver degeneration) may rarely occur with intracranial haemorrhage.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/425850",
                    "text": "Four patients presented with a typical Zieve's syndrome.",
                    "offsetInBeginSection": 320,
                    "offsetInEndSection": 376,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/548954",
                    "text": "A patient with Zieve's syndrome is described.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 45,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7636d39e632bc066000004",
            "body": "Which R packages have been developed for the discovery of mutational signatures in cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27091472",
                "http://www.ncbi.nlm.nih.gov/pubmed/29028923",
                "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
                "http://www.ncbi.nlm.nih.gov/pubmed/29145625",
                "http://www.ncbi.nlm.nih.gov/pubmed/26163694",
                "http://www.ncbi.nlm.nih.gov/pubmed/28669865",
                "http://www.ncbi.nlm.nih.gov/pubmed/28968631",
                "http://www.ncbi.nlm.nih.gov/pubmed/26630308",
                "http://www.ncbi.nlm.nih.gov/pubmed/15059910",
                "http://www.ncbi.nlm.nih.gov/pubmed/26438695"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27091472",
                    "text": "RESULTS MutSpec includes a set of tools that perform variant annotation and use advanced statistics for the identification of mutation signatures present in cancer genomes and for comparing the obtained signatures with those published in the COSMIC database and other sources.",
                    "offsetInBeginSection": 699,
                    "offsetInEndSection": 975,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923",
                    "text": "Results We proposed two complementary ways of measuring confidence and stability of decomposition results and applied them to analyze mutational signatures in breast cancer genomes.",
                    "offsetInBeginSection": 882,
                    "offsetInEndSection": 1063,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
                    "text": "RESULTS Here we present a new method for the statistical estimation of mutational signatures based on an empirical Bayesian treatment of the NMF model.",
                    "offsetInBeginSection": 749,
                    "offsetInEndSection": 900,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
                    "text": "These signatures have been identified from high throughput sequencing data generated from cancer genomes by using non-negative matrix factorisation (NMF) techniques.",
                    "offsetInBeginSection": 191,
                    "offsetInEndSection": 356,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29145625",
                    "text": "Deciphering mutational signatures in cancer is a new topic in cancer research.",
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 334,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29145625",
                    "text": "mSignatureDB (http://tardis.cgu.edu.tw/msignaturedb) integrates R packages and in-house scripts to determine the contributions of the published signatures in 15 780 individual tumors from 73 TCGA/ICGC cancer projects, making comparison of signature patterns within and between projects become possible.",
                    "offsetInBeginSection": 875,
                    "offsetInEndSection": 1177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968631",
                    "text": "The study of these DNA fingerprints, termed mutational signatures, holds important potential for furthering our understanding of the causes and evolution of cancer, and can provide insights of relevance for cancer prevention and treatment.",
                    "offsetInBeginSection": 154,
                    "offsetInEndSection": 393,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15059910",
                    "text": "iFLP allows the high-throughput discovery and tracing of mutational signatures in human cells, precancerous lesions, and primary or metastatic tumors and the assessment of the number and heterogeneity of low-level mutations in surgical samples.",
                    "offsetInBeginSection": 1491,
                    "offsetInEndSection": 1735,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15059910",
                    "text": "Using iFLP, widespread, low-level mutations at mutation frequency 10(-2)-10(-4) were discovered in genes located on different chromosomes, e.g., OGG1, MSH2, PTEN, beta-catenin, Bcl-2, P21, ATK3, and Braf, in human colon cancer cells that harbor mismatch repair deficiency whereas mismatch repair-proficient cells were mutation free.",
                    "offsetInBeginSection": 767,
                    "offsetInEndSection": 1099,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26438695",
                    "text": "An application to leukemia patient primary cell models demonstrated how the target deconvolution approach offers functional insights into patient-specific addiction patterns, such as those indicative of their receptor-type tyrosine-protein kinase FLT3 internal tandem duplication (FLT3-ITD) status and co-addiction partners, which may lead to clinically actionable, personalized drug treatment developments.",
                    "offsetInBeginSection": 1421,
                    "offsetInEndSection": 1828,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8dc57ffcd1d6a10c000025",
            "body": "Are the human bombesin receptors, GRPR and NMBR, frequently overexpressed G-protein-coupled-receptors by lung-cancers?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23096238",
                "http://www.ncbi.nlm.nih.gov/pubmed/12959933",
                "http://www.ncbi.nlm.nih.gov/pubmed/10828496",
                "http://www.ncbi.nlm.nih.gov/pubmed/8018339",
                "http://www.ncbi.nlm.nih.gov/pubmed/19628633",
                "http://www.ncbi.nlm.nih.gov/pubmed/11463790",
                "http://www.ncbi.nlm.nih.gov/pubmed/26030739",
                "http://www.ncbi.nlm.nih.gov/pubmed/12021405",
                "http://www.ncbi.nlm.nih.gov/pubmed/24349381",
                "http://www.ncbi.nlm.nih.gov/pubmed/10679759"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23096238",
                    "text": "Mammalian bombesin-like peptides neuromedin B (NMB) and gastrin-releasing peptide (GRP) act by activating NMB receptors (NMBR, BBl) and GRP receptors (GRPR,BB2), respectively.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23096238",
                    "text": "These two bombesin receptors are members of the G-protein-coupled receptor (GPCR) superfamily.In the brain, NMBR and GRPR are highly expressed in the brain areas involved in memory processing and emotional responses, such as the hippocampus and the amygdaloid nuclei.",
                    "offsetInBeginSection": 176,
                    "offsetInEndSection": 443,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12959933",
                    "text": "Dexamethasone and bombesin increased GRPR mRNA, bombesin downregulated NMBR, and neither agent affected BRS-3.",
                    "offsetInBeginSection": 1077,
                    "offsetInEndSection": 1187,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12959933",
                    "text": "To test the hypothesis that such effects are mediated by known mammalian bombesin receptors [gastrin-releasing peptide (GRP)/bombesin-preferring receptor (GRPR), neuromedin B (NMB) receptor (NMBR), and the orphan bombesin receptor subtype-3 (BRS-3)], we analyzed the ontogeny of GRPR, NMBR, and BRS-3 gene expression in mouse lung.",
                    "offsetInBeginSection": 148,
                    "offsetInEndSection": 479,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496",
                    "text": "In this study, we used the reverse transcription-polymerase chain reaction (RT-PCR) method to evaluate the mRNA expression of three bombesin receptor subtypes: gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), in 22 specimens of human epithelial ovarian cancer and in two human ovarian cancer lines.",
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 668,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8018339",
                    "text": "Three receptors have been identified for bombesin and its analogs, namely gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3).",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 448,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19628633",
                    "text": "The mammalian bombesin (Bn) peptides, neuromedin B (NMB) and gastrin-releasing peptide (GRP), have widespread actions in many tissues, and their effects are mediated by two closely related G-protein-coupled receptors, the NMBR and GRPR.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26030739",
                    "text": "We purified peptide E as a low-affinity ligand for hBRS3, which was also found to be an agonist for the other two mammalian bombesin receptors such as gastrin-releasing peptide receptor (GRPR) and neuromedin B receptor (NMBR).",
                    "offsetInBeginSection": 1361,
                    "offsetInEndSection": 1587,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24349381",
                    "text": "The neuromedin B receptor (NMB-R), a member of the mammalian bombesin receptor family, is frequently overexpressed in various tumors.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10679759",
                    "text": "Three bombesin receptor subtypes, termed gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), have been identified in rodents and humans.",
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 366,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7602be83b0d9ea6600000f",
            "body": "Describe King\u2013Kopetzky syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25709171",
                "http://www.ncbi.nlm.nih.gov/pubmed/11441785",
                "http://www.ncbi.nlm.nih.gov/pubmed/835533",
                "http://www.ncbi.nlm.nih.gov/pubmed/20609160",
                "http://www.ncbi.nlm.nih.gov/pubmed/2188546",
                "http://www.ncbi.nlm.nih.gov/pubmed/18592912",
                "http://www.ncbi.nlm.nih.gov/pubmed/12002153",
                "http://www.ncbi.nlm.nih.gov/pubmed/20446161",
                "http://www.ncbi.nlm.nih.gov/pubmed/9296644",
                "http://www.ncbi.nlm.nih.gov/pubmed/3631650"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/835533",
                    "text": "It is suggested that this syndrome is inherited as an autosomal-recessive condition.",
                    "offsetInBeginSection": 265,
                    "offsetInEndSection": 349,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20609160",
                    "text": "Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE) syndrome is a recently described syndrome similar to Proteus syndrome but lacking the progressive or distorting bony overgrowth of Proteus syndrome.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 233,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20609160",
                    "text": "We describe a neonate with features of CLOVE syndrome and nevus unius lateris.",
                    "offsetInBeginSection": 234,
                    "offsetInEndSection": 312,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2188546",
                    "text": "The authors report six of these very rare syndromes discovered among their patients: a KID syndrome, a Leopard syndrome, a Norrie syndrome, a Jervell and Lange Nielsen syndrome, a recently described entity called CEE with deafness and an External Neuro-Cochleo-Pancreatic syndrome which would not appear to have been previously described.",
                    "offsetInBeginSection": 511,
                    "offsetInEndSection": 849,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18592912",
                    "text": "The Peutz-Jeghers syndrome, the Juvenile plyposys syndrome, the PTEN hamartomatous tumor syndrome, and other less frequent hamartomatous syndroms are described.",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 434,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18592912",
                    "text": "Several hereditary syndromes with multiple digestive hamartomatous polyps are described; they are produced by germline mutations.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12002153",
                    "text": "Two sibs from an inbred Arab family are described with an autosomal syndrome of choanal atresia, hypothelia/athelia and thyroid gland anomalies overlapping Bamforth syndrome, ANOTHER syndrome and methimazole embryopathy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 220,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446161",
                    "text": "This paper discusses the contribution of Spanish neurologist Manuel Peraita (1908-1950) to the study of deficiency neuropathy in the setting of the Spanish Civil War (1936-1939).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9296644",
                    "text": "It belongs to acrocephalosyndactyly syndromes.",
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9296644",
                    "text": "In 1964, Pfeiffer described a syndrome consisting of craniosynostosis, broad thumbs, broad great toes, and partial soft tissue syndactyly of the hands and feet.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67c284b750ff4455000011",
            "body": "What is GenomeVIP?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28522612"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "GenomeVIP orchestrates the analysis of whole-genome and exome sequence data using a set of robust and popular task-specific tools, including VarScan, GATK, Pindel, BreakDancer, Strelka, and Genome STRiP, through a web interface.",
                    "offsetInBeginSection": 790,
                    "offsetInEndSection": 1018,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "GenomeVIP has been used for genomic analysis in large-data projects such as the TCGA PanCanAtlas and in other projects, such as the ICGC Pilots, CPTAC, ICGC-TCGA DREAM Challenges, and the 1000 Genomes SV Project.",
                    "offsetInBeginSection": 1019,
                    "offsetInEndSection": 1231,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "Here, we introduce the Genome Variant Investigation Platform (GenomeVIP), an open-source framework for performing genomics variant discovery and annotation using cloud- or local high-performance computing infrastructure.",
                    "offsetInBeginSection": 569,
                    "offsetInEndSection": 789,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "Identifying genomic variants is a fundamental first step toward the understanding of the role of inherited and acquired variation in disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "The accelerating growth in the corpus of sequencing data that underpins such analysis is making the data-download bottleneck more evident, placing substantial burdens on the research community to keep pace.",
                    "offsetInBeginSection": 142,
                    "offsetInEndSection": 348,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "Here, we demonstrate GenomeVIP's ability to provide high-confidence annotated somatic, germline, and de novo variants of potential biological significance using publicly available data sets.",
                    "offsetInBeginSection": 1232,
                    "offsetInEndSection": 1422,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "As a result, the search for alternative approaches to the traditional \"download and analyze\" paradigm on local computing resources has led to a rapidly growing demand for cloud-computing solutions for genomics analysis.",
                    "offsetInBeginSection": 349,
                    "offsetInEndSection": 568,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a981e66fcd1d6a10c00002f",
            "body": "According to guidelines, insulin resistance is one risk factor in the diagnosis of metabolic syndrome, name 3 more risk factors.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16762931",
                "http://www.ncbi.nlm.nih.gov/pubmed/15547646",
                "http://www.ncbi.nlm.nih.gov/pubmed/12643148",
                "http://www.ncbi.nlm.nih.gov/pubmed/16505579",
                "http://www.ncbi.nlm.nih.gov/pubmed/21068471",
                "http://www.ncbi.nlm.nih.gov/pubmed/17456293",
                "http://www.ncbi.nlm.nih.gov/pubmed/17125447",
                "http://www.ncbi.nlm.nih.gov/pubmed/19108808",
                "http://www.ncbi.nlm.nih.gov/pubmed/15940204",
                "http://www.ncbi.nlm.nih.gov/pubmed/11276389"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15547646",
                    "text": "Insulin resistance is the key factor for the clustering of risk factors characterizing the metabolic syndrome.",
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 382,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12643148",
                    "text": "Also, there is new and better understanding of the complex dyslipidemias and other risk factors strongly associated with the metabolic syndrome, which greatly increase the risk of clinical atherosclerotic events.",
                    "offsetInBeginSection": 394,
                    "offsetInEndSection": 606,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16505579",
                    "text": "Soon, metabolic syndrome will overtake cigarette smoking as the number one risk factor for heart disease among the US population.",
                    "offsetInBeginSection": 1182,
                    "offsetInEndSection": 1311,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16505579",
                    "text": "The syndrome has been given several names, including- the metabolic syndrome, the insulin resistance syndrome, the plurimetabolic syndrome, and the deadly quartet.",
                    "offsetInBeginSection": 75,
                    "offsetInEndSection": 238,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21068471",
                    "text": "This article provides a comprehensive discussion of metabolic risk factors, the history of MetS, and its diagnosis, epidemiology, etiology, pathophysiology, and treatment.",
                    "offsetInBeginSection": 616,
                    "offsetInEndSection": 787,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17125447",
                    "text": "Abdominal adiposity is considered high-risk fat, and it is associated with insulin resistance, hyperglycemia, dyslipidemia, hypertension, and prothrombotic and/or proinflammatory states.",
                    "offsetInBeginSection": 905,
                    "offsetInEndSection": 1091,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17125447",
                    "text": "First-line therapy for individuals with metabolic syndrome should be directed to the major CVD risk factors, namely, elevated low-density lipoprotein cholesterol levels, hypertension, and diabetes, and it should emphasize lifestyle modification.",
                    "offsetInBeginSection": 1226,
                    "offsetInEndSection": 1471,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17125447",
                    "text": "Until additional research better defines the most appropriate therapies, conventional cardiovascular risk factors, such as lipid levels, blood pressure, and diabetes, should be managed in individuals with metabolic syndrome according to nationally accepted clinical guidelines.",
                    "offsetInBeginSection": 1472,
                    "offsetInEndSection": 1749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19108808",
                    "text": "The metabolic syndrome has 5 criteria: central obesity, hypertriglyceridemia, low high-density lipoprotein (HDL) levels, fasting hyperglycemia, and hypertension.",
                    "offsetInBeginSection": 1021,
                    "offsetInEndSection": 1182,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11276389",
                    "text": "The metabolic syndrome is a complex association of several risk factors including insulin resistance, dyslipidemia, and essential hypertension.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76080683b0d9ea66000015",
            "body": "Is cilengitide effective for treatment of glioblastoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24442484",
                "http://www.ncbi.nlm.nih.gov/pubmed/25163906",
                "http://www.ncbi.nlm.nih.gov/pubmed/23354807",
                "http://www.ncbi.nlm.nih.gov/pubmed/21739168",
                "http://www.ncbi.nlm.nih.gov/pubmed/22866207",
                "http://www.ncbi.nlm.nih.gov/pubmed/24014381",
                "http://www.ncbi.nlm.nih.gov/pubmed/22976135",
                "http://www.ncbi.nlm.nih.gov/pubmed/17277694",
                "http://www.ncbi.nlm.nih.gov/pubmed/23060541",
                "http://www.ncbi.nlm.nih.gov/pubmed/26935578"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24442484",
                    "text": "The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT \u2192 TMZ) in newly diagnosed glioblastoma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168",
                    "text": "Cilengitide is a cyclic pentapeptide that is a specific inhibitor of the \u03b1v\u03b23 and \u03b1v\u03b25 integrins.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22866207",
                    "text": "A foundation of encouraging preclinical studies led to a well-designed clinical development plan that culminated in a pivotal phase III study of cilengitide in combination with radiation therapy and temozolomide chemotherapy for newly diagnosed glioblastoma patients.",
                    "offsetInBeginSection": 545,
                    "offsetInEndSection": 812,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22866207",
                    "text": "Although several integrin inhibitors are under clinical evaluation, cilengitide is the most clinically advanced and is emerging as a prototype for this class of anticancer therapy.",
                    "offsetInBeginSection": 364,
                    "offsetInEndSection": 544,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014381",
                    "text": "BACKGROUND Cilengitide, an \u03b1v integrin antagonist, has demonstrated activity in recurrent adult glioblastoma (GBM).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014381",
                    "text": "CONCLUSIONS We conclude that cilengitide is not effective as a single agent for refractory pediatric HGG.",
                    "offsetInBeginSection": 1417,
                    "offsetInEndSection": 1522,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22976135",
                    "text": "Among them, cilengitide is a novel integrin antagonist for the treatment of glioblastoma.",
                    "offsetInBeginSection": 648,
                    "offsetInEndSection": 737,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22976135",
                    "text": "Cilengitide is currently being assessed in phase III trials for patients with glioblastoma multiforme and in phase II trials for other types of cancers, demonstrating promising therapeutic outcomes to date.",
                    "offsetInBeginSection": 1016,
                    "offsetInEndSection": 1222,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23060541",
                    "text": "Cilengitide, a cyclized Arg-Gly-Glu(RGD)-containing pentapeptide that selectively blocks activation of the \u03b1v\u03b23 and \u03b1v\u03b25 integrins has shown encouraging activity in patients with glioblastoma as single agent, and in association with standard RT and temozolomide.",
                    "offsetInBeginSection": 1122,
                    "offsetInEndSection": 1388,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935578",
                    "text": "This phase II study investigated the efficacy and safety of combining the selective integrin inhibitor cilengitide with a combination of metronomic temozolomide and procarbazine for these patients.",
                    "offsetInBeginSection": 132,
                    "offsetInEndSection": 329,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6a3464b750ff4455000026",
            "body": "Which algorithm has been developed in order to improve multiple circular sequence alignment using refined sequences?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28088189",
                "http://www.ncbi.nlm.nih.gov/pubmed/19627599",
                "http://www.ncbi.nlm.nih.gov/pubmed/16086841",
                "http://www.ncbi.nlm.nih.gov/pubmed/7796270",
                "http://www.ncbi.nlm.nih.gov/pubmed/8590178",
                "http://www.ncbi.nlm.nih.gov/pubmed/17137519",
                "http://www.ncbi.nlm.nih.gov/pubmed/11934745",
                "http://www.ncbi.nlm.nih.gov/pubmed/18616828",
                "http://www.ncbi.nlm.nih.gov/pubmed/25101328",
                "http://www.ncbi.nlm.nih.gov/pubmed/27505054"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189",
                    "text": "RESULTS We present MARS, a new heuristic method for improving Multiple circular sequence Alignment using Refined Sequences.",
                    "offsetInBeginSection": 917,
                    "offsetInEndSection": 1040,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189",
                    "text": "A solution for these inconsistencies would be to identify a suitable rotation (cyclic shift) for each sequence; these refined sequences may in turn lead to improved multiple sequence alignments using the preferred multiple sequence alignment program.",
                    "offsetInBeginSection": 664,
                    "offsetInEndSection": 914,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189",
                    "text": "CONCLUSIONS Analysing multiple sequences simultaneously is fundamental in biological research and multiple sequence alignment has been found to be a popular method for this task.",
                    "offsetInBeginSection": 1729,
                    "offsetInEndSection": 1907,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599",
                    "text": "RESULTS In this paper we propose an efficient algorithm that identifies the most interesting region to cut circular genomes in order to improve phylogenetic analysis when using standard multiple sequence alignment algorithms.",
                    "offsetInBeginSection": 876,
                    "offsetInEndSection": 1101,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599",
                    "text": "Researchers interested in aligning circular DNA sequences must first rotate them to the \"right\" place using an essentially manual process, before they can use multiple sequence alignment tools.",
                    "offsetInBeginSection": 680,
                    "offsetInEndSection": 873,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599",
                    "text": "CONCLUSION The results show that a circularization and rotation pre-processing step significantly improves the efficiency of public available multiple sequence alignment algorithms when used in the alignment of circular DNA sequences.",
                    "offsetInBeginSection": 1796,
                    "offsetInEndSection": 2030,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16086841",
                    "text": "CONCLUSION We have implemented a genetic algorithm in parallel mode to optimize multiple genomic sequence alignments initially generated by various alignment tools.",
                    "offsetInBeginSection": 2174,
                    "offsetInEndSection": 2338,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16086841",
                    "text": "We describe a new program, GenAlignRefine, which improves the overall quality of global multiple alignments by using a genetic algorithm to improve local regions of alignment.",
                    "offsetInBeginSection": 846,
                    "offsetInEndSection": 1021,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7796270",
                    "text": "To date, most multiple alignment systems have employed a tree-based algorithm, which combines the results of two-way dynamic programming in a tree-like order of sequence similarity.",
                    "offsetInBeginSection": 72,
                    "offsetInEndSection": 253,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18616828",
                    "text": "RESULTS The performance of the proposed algorithm is validated via comparison to popular progressive multiple alignment approaches, ClustalW and T-Coffee, and to the more recently developed algorithms MAFFT, MUSCLE, Kalign, and PSAlign using the BAliBASE 3.0 database of amino acid alignment files and a set of longer sequences generated by Rose software.",
                    "offsetInBeginSection": 469,
                    "offsetInEndSection": 824,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a74e9ad0384be955100000a",
            "body": "What is a SERM?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11795362",
                "http://www.ncbi.nlm.nih.gov/pubmed/24667357",
                "http://www.ncbi.nlm.nih.gov/pubmed/12036407",
                "http://www.ncbi.nlm.nih.gov/pubmed/10629380",
                "http://www.ncbi.nlm.nih.gov/pubmed/24930824",
                "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
                "http://www.ncbi.nlm.nih.gov/pubmed/26343247",
                "http://www.ncbi.nlm.nih.gov/pubmed/16951478",
                "http://www.ncbi.nlm.nih.gov/pubmed/18824103",
                "http://www.ncbi.nlm.nih.gov/pubmed/17448265"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11795362",
                    "text": "The SERM tamoxifen acts as an estrogen antagonist in the breast in that it prevents and treats breast cancer, but it acts as an estrogen agonist in the endometrium, where it can induce cancer.",
                    "offsetInBeginSection": 222,
                    "offsetInEndSection": 414,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24667357",
                    "text": "One such example is the tissue selective estrogen complex, which partners a SERM with 1 or more estrogens, with the aim of blending the desired estrogen-receptor agonist activities of estrogens on vasomotor symptoms, vulvar-vaginal atrophy, and loss of bone mass with the tissue selectivity of a SERM.",
                    "offsetInBeginSection": 1065,
                    "offsetInEndSection": 1366,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12036407",
                    "text": "Tamoxifen is a SERM that acts as an oestrogen antagonist in breast tissue and is currently being used for the treatment and prevention of breast cancer.",
                    "offsetInBeginSection": 486,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12036407",
                    "text": "Oestrogen and another SERM, raloxifene, have been shown to prevent osteoporosis.",
                    "offsetInBeginSection": 759,
                    "offsetInEndSection": 839,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10629380",
                    "text": "Raloxifene is a SERM with a chemical structure different from triphenylethylenes.",
                    "offsetInBeginSection": 1366,
                    "offsetInEndSection": 1447,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24930824",
                    "text": "Tamoxifen, a pioneering selective estrogen receptor modulator (SERM), has long been a therapeutic choice for all stages of estrogen receptor (ER)-positive breast cancer.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24930824",
                    "text": "It appears that acquired resistance to SERM is initially able to utilize either E2 or a SERM as the growth stimulus in the SERM-resistant breast tumors.",
                    "offsetInBeginSection": 691,
                    "offsetInEndSection": 843,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
                    "text": "A new target in treating postmenopausal osteoporosis is the tissue estrogen complex or the pairing of a SERM with a conjugated estrogen known as a tissue selective estrogen complex (TSEC).",
                    "offsetInBeginSection": 1528,
                    "offsetInEndSection": 1716,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
                    "text": "Several agents are available in the U.S., including bisphosphonates, hormone therapy, calcitonin, parathyroid hormone and the selective estrogen receptor modulator (SERM) raloxifene.",
                    "offsetInBeginSection": 675,
                    "offsetInEndSection": 857,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16951478",
                    "text": "Prevention of vertebral fractures by a SERM, raloxifene (RLX), in osteoporotic postmenopausal women has been well established.",
                    "offsetInBeginSection": 340,
                    "offsetInEndSection": 466,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7610ca83b0d9ea6600001b",
            "body": "What is the role of nimotuzumab in treatment of pontine glioma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25926743",
                "http://www.ncbi.nlm.nih.gov/pubmed/24696052",
                "http://www.ncbi.nlm.nih.gov/pubmed/24847085",
                "http://www.ncbi.nlm.nih.gov/pubmed/23754473",
                "http://www.ncbi.nlm.nih.gov/pubmed/21171927",
                "http://www.ncbi.nlm.nih.gov/pubmed/23043252",
                "http://www.ncbi.nlm.nih.gov/pubmed/27379495",
                "http://www.ncbi.nlm.nih.gov/pubmed/19903064",
                "http://www.ncbi.nlm.nih.gov/pubmed/21858608",
                "http://www.ncbi.nlm.nih.gov/pubmed/23926436"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743",
                    "text": "We found that nimotuzumab with or without radiotherapy, chemotherapy in newly diagnosed or recurrent HGG, such as glioblastoma multiforme (GBM), anaplastic astrocytomas (AA), and diffuse intrinsic pontine glioma (DIPG), might improve the response rate or the survival time.",
                    "offsetInBeginSection": 499,
                    "offsetInEndSection": 772,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743",
                    "text": "We review the humanized epidermal growth factor receptor (EGFR) and the major EGFR target drugs in HGG treatments, focusing on the EGFR antibody nimotuzumab as a new therapeutic strategy in HGG.",
                    "offsetInBeginSection": 304,
                    "offsetInEndSection": 498,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052",
                    "text": "Findings on the role of EGFR signaling in the onset of childhood DIPG prompted the use of nimotuzumab, an anti-EGFR monoclonal antibody.",
                    "offsetInBeginSection": 92,
                    "offsetInEndSection": 228,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052",
                    "text": "Radiotherapy is the only treatment definitely indicated for diffuse pontine gliomas (DIPG).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 91,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052",
                    "text": "Assuming a potential synergy with both radiotherapy and vinorelbine, a pilot phase 2 protocol was launched that combined nimotuzumab with concomitant radiation and vinorelbine.",
                    "offsetInBeginSection": 229,
                    "offsetInEndSection": 405,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24847085",
                    "text": "CONCLUSIONS Modest activity of nimotuzumab in DIPG, which has been shown previously, was confirmed: A small subset of DIPG patients appeared to benefit from anti-EGFR antibody treatment.",
                    "offsetInBeginSection": 1499,
                    "offsetInEndSection": 1685,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754473",
                    "text": "Primary metastatic diffuse intrinsic pontine glioma (DIPG) is relatively rare and associated with a dismal prognosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21171927",
                    "text": "The activity of nimotuzumab, a humanized anti-EGFR monoclonal antibody, was therefore studied within a Phase II trial in 47 relapsing pediatric patients with DIPG and high-grade gliomas, showing an interesting, persistent response, especially in the first group treated.",
                    "offsetInBeginSection": 571,
                    "offsetInEndSection": 841,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27379495",
                    "text": "Targeted therapy protocols included radiation therapy along with treatment by erlotinib, cilengitide, or an association of nimotuzumab and vinblastine.",
                    "offsetInBeginSection": 864,
                    "offsetInEndSection": 1015,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19903064",
                    "text": "Emerging trials suggest a promising role for nimotuzumab as a therapeutic agent in patients with high-grade gliomas.",
                    "offsetInBeginSection": 537,
                    "offsetInEndSection": 653,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6a35b7b750ff4455000027",
            "body": "What is libgapmis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24564250"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "libgapmis is based on an algorithm computing a modified version of the traditional dynamic-programming matrix for sequence alignment.",
                    "offsetInBeginSection": 1240,
                    "offsetInEndSection": 1373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "The open-source code of libgapmis is available at http://www.exelixis-lab.org/gapmis.",
                    "offsetInBeginSection": 2289,
                    "offsetInEndSection": 2374,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "CONCLUSIONS We present libgapmis, a library for extending pairwise short-read alignments.",
                    "offsetInBeginSection": 1942,
                    "offsetInEndSection": 2031,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "We show that libgapmis is better-suited and more efficient than existing algorithms for this task.",
                    "offsetInBeginSection": 2032,
                    "offsetInEndSection": 2130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "RESULTS In this article, we present libgapmis, a library for extending pairwise short-read alignments.",
                    "offsetInBeginSection": 1042,
                    "offsetInEndSection": 1144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "The fact that the reads are rather short and that the gap occurrence frequency observed in various studies is rather low suggest that aligning (parts of) those reads with a single gap is in fact desirable.",
                    "offsetInBeginSection": 834,
                    "offsetInEndSection": 1039,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "After aligning a substring of the reference sequence against the high-quality prefix of a short read--the seed--an important problem is to find the best possible alignment between a substring of the reference sequence succeeding and the remaining suffix of low quality of the read--extend.",
                    "offsetInBeginSection": 544,
                    "offsetInEndSection": 833,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "BACKGROUND A wide variety of short-read alignment programmes have been published recently to tackle the problem of mapping millions of short reads to a reference genome, focusing on different aspects of the procedure such as time and memory efficiency, sensitivity, and accuracy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 279,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "The seed-and-extend strategy is applied in most short-read alignment programmes.",
                    "offsetInBeginSection": 463,
                    "offsetInEndSection": 543,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "The library also provides the user the flexibility to split the read into fragments, based on the observed gap occurrence frequency and the length of the read, thereby allowing for a variable, but bounded, number of gaps in the alignment.",
                    "offsetInBeginSection": 1701,
                    "offsetInEndSection": 1939,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76016683b0d9ea6600000d",
            "body": "Down's syndrome occurs when an individual has an extra copy or part of a copy of chromosome 21, yes or no?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19458618",
                "http://www.ncbi.nlm.nih.gov/pubmed/19212162",
                "http://www.ncbi.nlm.nih.gov/pubmed/25738006",
                "http://www.ncbi.nlm.nih.gov/pubmed/28959732",
                "http://www.ncbi.nlm.nih.gov/pubmed/11399108",
                "http://www.ncbi.nlm.nih.gov/pubmed/1838097",
                "http://www.ncbi.nlm.nih.gov/pubmed/7763760",
                "http://www.ncbi.nlm.nih.gov/pubmed/26243569",
                "http://www.ncbi.nlm.nih.gov/pubmed/7881232",
                "http://www.ncbi.nlm.nih.gov/pubmed/15176487"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458618",
                    "text": "Furthermore, we show that the modest increase in expression afforded by a single extra transgenic copy of Dscr1 is sufficient to confer significant suppression of tumour growth in mice, and that such resistance is a consequence of a deficit in tumour angiogenesis arising from suppression of the calcineurin pathway.",
                    "offsetInBeginSection": 600,
                    "offsetInEndSection": 916,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19212162",
                    "text": "Down syndrome is a genetic disorder, occurring when an individual has all or part of an extra copy of chromosome 21.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25738006",
                    "text": "Downs syndrome (DS) occurs due to an extra copy of chromosome 21.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 65,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11399108",
                    "text": "The augmented antioxidant protection resulting from an extra copy of chromosome 21 may, with time, selectively protect human oocytes from apoptosis, increasing their proportion with age, explaining the higher incidence of this disease.",
                    "offsetInBeginSection": 872,
                    "offsetInEndSection": 1107,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1838097",
                    "text": "Analysis of individual distribution of satellite between homologues of chromosome 21 provides new possibilities for determination of the origin of extra chromosome in the patients with trisomy 21.",
                    "offsetInBeginSection": 802,
                    "offsetInEndSection": 998,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7763760",
                    "text": "The extra copy of chromosome 21 could alter growth regulation and biochemical mechanisms, so we examined quantitatively some DS phenotypical aspects to detect possible differences from those of controls.",
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 427,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26243569",
                    "text": "Down syndrome, which arises in individuals carrying an extra copy of chromosome 21, is associated with a greatly increased risk of early-onset Alzheimer disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7881232",
                    "text": "Thus, possession of an extra copy of chromosome 21 may confer protection against bipolar disorder.",
                    "offsetInBeginSection": 403,
                    "offsetInEndSection": 501,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15176487",
                    "text": "DS is the most common human chromosomal abnormality caused by an extra copy of chromosome 21 and is characterized by somatic anomalies and mental retardation.",
                    "offsetInBeginSection": 410,
                    "offsetInEndSection": 568,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15176487",
                    "text": "Quantitative analysis of hypothetical protein FLJ10849, hypothetical protein FLJ20113, and activator of hsp90 ATPase homologue 1 (AHA1) revealed levels comparable between DS and controls.",
                    "offsetInBeginSection": 1187,
                    "offsetInEndSection": 1374,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7615af83b0d9ea6600001f",
            "body": "Is vorinostat effective for glioblastoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20135194",
                "http://www.ncbi.nlm.nih.gov/pubmed/24576944",
                "http://www.ncbi.nlm.nih.gov/pubmed/29016887",
                "http://www.ncbi.nlm.nih.gov/pubmed/19307505",
                "http://www.ncbi.nlm.nih.gov/pubmed/22086447",
                "http://www.ncbi.nlm.nih.gov/pubmed/23996800",
                "http://www.ncbi.nlm.nih.gov/pubmed/22028388",
                "http://www.ncbi.nlm.nih.gov/pubmed/19635146",
                "http://www.ncbi.nlm.nih.gov/pubmed/22090453",
                "http://www.ncbi.nlm.nih.gov/pubmed/22923449"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194",
                    "text": "Histone deacetylase (HDAC) inhibitors represent a promising class of anti-cancer agents that are actively being evaluated in the context of clinical trials in solid tumors, including glioblastoma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194",
                    "text": "The effects of the HDAC inhibitor vorinostat and SN38, which is the active metabolite of the topoisomerase I inhibitor CPT-11, was evaluated using the clonogenic assay.",
                    "offsetInBeginSection": 694,
                    "offsetInEndSection": 862,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576944",
                    "text": "We present two patients with glioblastoma multiforme who developed severe hemolytic anemia shortly after initiating therapy with vorinostat, a pan-active histone deacetylase inhibitor, while on prophylactic dapsone.",
                    "offsetInBeginSection": 827,
                    "offsetInEndSection": 1042,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576944",
                    "text": "Patients undergoing treatment for glioblastoma multiforme are routinely placed on prophylactic treatment for Pneumocystis jirovecii pneumonia because of significant therapy-induced lymphopenia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19307505",
                    "text": "PURPOSE Vorinostat, a histone deacetylase inhibitor, represents a rational therapeutic target in glioblastoma multiforme (GBM).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086447",
                    "text": "Histone deacetylase inhibitors (HDACIs) represent a class of agents that can modulate gene expression to reduce tumor growth, and we and others have noted some antiglioma activity from HDACIs, such as vorinostat, although insufficient to warrant use as monotherapy.",
                    "offsetInBeginSection": 81,
                    "offsetInEndSection": 346,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22028388",
                    "text": "A MTD for the combination of vorinostat with bevacizumab and CPT-11 has been established, although it has poor long-term tolerability.",
                    "offsetInBeginSection": 1147,
                    "offsetInEndSection": 1281,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19635146",
                    "text": "Ongoing and planned studies will further evaluate the potential of vorinostat in combination therapy, including combinations with radiation, in patients with diverse malignancy types, including non-small-cell lung cancer, glioblastoma multiforme, multiple myeloma, and myelodysplastic syndrome.",
                    "offsetInBeginSection": 1515,
                    "offsetInEndSection": 1809,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22090453",
                    "text": "Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown evidence of single-agent activity in glioblastoma (GBM), and in preclinical studies, we have demonstrated significant synergistic cytotoxicity between HDAC inhibitors and proteasome inhibitors in GBM cell lines.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 273,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22923449",
                    "text": "A phase I/II trial of vorinostat with radiotherapy and concomitant TMZ in newly diagnosed glioblastoma is underway.",
                    "offsetInBeginSection": 1527,
                    "offsetInEndSection": 1642,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6a7869b750ff4455000028",
            "body": "Describe SNP2TFBS",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
                "http://www.ncbi.nlm.nih.gov/pubmed/2209143",
                "http://www.ncbi.nlm.nih.gov/pubmed/26579876",
                "http://www.ncbi.nlm.nih.gov/pubmed/11441785",
                "http://www.ncbi.nlm.nih.gov/pubmed/17230075",
                "http://www.ncbi.nlm.nih.gov/pubmed/19855297",
                "http://www.ncbi.nlm.nih.gov/pubmed/18349498",
                "http://www.ncbi.nlm.nih.gov/pubmed/8140769",
                "http://www.ncbi.nlm.nih.gov/pubmed/18428249",
                "http://www.ncbi.nlm.nih.gov/pubmed/24193825"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11441785",
                    "text": "Using a similar term to describe different forms of pathology leads to a muddle.",
                    "offsetInBeginSection": 135,
                    "offsetInEndSection": 215,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11441785",
                    "text": "In this paper, we describe \"Clerambault's syndrome\" and \"Kandinsky-Clerambault's syndrome\" and discuss and clarify the confusion surrounding these different syndromes.",
                    "offsetInBeginSection": 216,
                    "offsetInEndSection": 383,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17230075",
                    "text": "Describe common techniques for flap monitoring.",
                    "offsetInBeginSection": 421,
                    "offsetInEndSection": 468,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18349498",
                    "text": "We propose describing a manipulative technique using 6 characteristics: Rate of force application: Describe the rate at which the force was applied.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18349498",
                    "text": "Relative structural movement: Describe which structure or region was intended to remain stable and which structure or region was intended to move, with the moving structure or region being named first and the stable segment named second, separated by the word \"on.\"",
                    "offsetInBeginSection": 581,
                    "offsetInEndSection": 846,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8140769",
                    "text": "The authors describe another subtype of antigen HLA-B27, described as HLA-B27P3.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18428249",
                    "text": "Several support protocols describe methods for adenovirus growth and purification, biotinylation, inactivation with psoralen, and quantitation of the adenovirus particles.",
                    "offsetInBeginSection": 279,
                    "offsetInEndSection": 450,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We describe first a field deployable mass spectrometer, based on an ion trap analyzer, and variants of that system.",
                    "offsetInBeginSection": 375,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We describe four sensing and characterization technologies recently developed at Los Alamos National Laboratory; a select set of mass spectral and optical techniques is emphasized.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We then describe a hand-held, battery-operated optical spectrometer, usable in either absorption, or fluorescence excitation mode.",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 621,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7706b79e632bc066000009",
            "body": "What is trismus?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26058916",
                "http://www.ncbi.nlm.nih.gov/pubmed/28122104",
                "http://www.ncbi.nlm.nih.gov/pubmed/9063134",
                "http://www.ncbi.nlm.nih.gov/pubmed/24151558",
                "http://www.ncbi.nlm.nih.gov/pubmed/23154328",
                "http://www.ncbi.nlm.nih.gov/pubmed/24985733",
                "http://www.ncbi.nlm.nih.gov/pubmed/20236743",
                "http://www.ncbi.nlm.nih.gov/pubmed/2090084",
                "http://www.ncbi.nlm.nih.gov/pubmed/24669774",
                "http://www.ncbi.nlm.nih.gov/pubmed/25303582"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26058916",
                    "text": "Trismus is characterized by a reduced ability to open the mouth, directly affecting many aspects of daily life, such as chewing, swallowing, speaking and maintaining oral hygiene.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26058916",
                    "text": "Radiotherapy in the head and neck area is identified as one of the most frequent causes of trismus in head and neck cancer (HNC) patients.",
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 398,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28122104",
                    "text": "In conclusion, exercise with TheraBite improved MIO and trismus-related symptoms in patients with trismus secondary to head and neck cancer.",
                    "offsetInBeginSection": 1050,
                    "offsetInEndSection": 1190,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28122104",
                    "text": "Trismus is a common symptom in patients with head and neck cancer that affects many aspects of daily life negatively.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24151558",
                    "text": "Trismus pseudocamptodactyly syndrome is a very rare autosomal dominant inherited disorder characterized by the inability to completely open the mouth (trismus) and the presence of abnormally short tendon units causing the fingers to curve (camptodactyly).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23154328",
                    "text": "In conclusion, involvement of buccal region, ablative surgery, radiotherapy, and recurrence are provocative factors of trismus.",
                    "offsetInBeginSection": 797,
                    "offsetInEndSection": 924,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23154328",
                    "text": "Trismus is a common problem among oral cancer patients.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 55,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236743",
                    "text": "Trismus is a serious problem for some patients after oral and oropharyngeal cancer, and it has a detrimental impact on quality of life and function.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25303582",
                    "text": "Trismus can occur following trauma, surgery, radiation therapy, infection, inflammatory diseases, temporomandibular disorders (TMD) or less commonly as a result of malignancy.",
                    "offsetInBeginSection": 59,
                    "offsetInEndSection": 234,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25303582",
                    "text": "Trismus is a restriction in the ability to open the mouth.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 58,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67ab79b750ff445500000b",
            "body": "CURB65 score is used for stratification of which disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28168816",
                "http://www.ncbi.nlm.nih.gov/pubmed/20529344",
                "http://www.ncbi.nlm.nih.gov/pubmed/20920140",
                "http://www.ncbi.nlm.nih.gov/pubmed/18304365",
                "http://www.ncbi.nlm.nih.gov/pubmed/16928720",
                "http://www.ncbi.nlm.nih.gov/pubmed/22501026",
                "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                "http://www.ncbi.nlm.nih.gov/pubmed/24573987",
                "http://www.ncbi.nlm.nih.gov/pubmed/29161297",
                "http://www.ncbi.nlm.nih.gov/pubmed/23434895"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20529344",
                    "text": "METHODS We assessed clinical parameters and five biomarkers, the precursor levels of adrenomedullin (ADM), endothelin-1 (ET1), atrial-natriuretic peptide (ANP), anti-diuretic hormone (copeptin), and procalcitonin in patients with LRTI and CAP enrolled in the multicenter ProHOSP study.",
                    "offsetInBeginSection": 232,
                    "offsetInEndSection": 517,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20920140",
                    "text": "The CURB65 score was as effective in predicting early mortality in our cohort of acute COPD exacerbations as it was in previous cohorts with community acquired pneumonia.",
                    "offsetInBeginSection": 1509,
                    "offsetInEndSection": 1679,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20920140",
                    "text": "The CURB65 score was developed to predict mortality risk in community acquired pneumonia.",
                    "offsetInBeginSection": 228,
                    "offsetInEndSection": 317,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "CONCLUSIONS The new CURB65-A risk score combining CURB65 risk classes with ProADM cut-off values accurately predicts adverse events and mortality in patients with CAP and non-CAP-LRTI.",
                    "offsetInBeginSection": 1744,
                    "offsetInEndSection": 1928,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "We aimed to derive a practical algorithm combining the CURB65 score with ProADM-levels in patients with community-acquired pneumonia (CAP) and non-CAP-LRTI.",
                    "offsetInBeginSection": 162,
                    "offsetInEndSection": 318,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "RESULTS CURB65 and ProADM predicted both adverse events and mortality similarly well in CAP and non-CAP-LRTI.",
                    "offsetInBeginSection": 658,
                    "offsetInEndSection": 767,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "The combined CURB65-A risk score provided better prediction of death and adverse events than the CURB65 score in the entire cohort and in CAP and non-CAP-LRTI patients.",
                    "offsetInBeginSection": 768,
                    "offsetInEndSection": 936,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "A composite score (CURB65-A) was created combining CURB65 classes with ProADM cut-offs to further risk-stratify patients.",
                    "offsetInBeginSection": 534,
                    "offsetInEndSection": 655,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "If outpatient treatment was recommended for CURB65-A risk class I and short hospitalization for CURB65-A risk class II, 17.9% and 40.8% of 1217 hospitalized patients could have received ambulatory treatment or a short hospitalization, respectively.",
                    "offsetInBeginSection": 1493,
                    "offsetInEndSection": 1741,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23434895",
                    "text": "ProADM has shown higher accuracy for short-term and long-term adverse outcome prediction and improves prognostic accuracy when combined with current clinical risk scores, that is, Pneumonia Severity Index, the CURB65 (confusion, uremia, respiratory rate, blood pressure, age at least 65 years) score, and Risk of Early Admission to ICU, compared to applying the respective score alone.",
                    "offsetInBeginSection": 992,
                    "offsetInEndSection": 1377,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6cfe27b750ff4455000029",
            "body": "What is SMiLE-seq?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28092692",
                "http://www.ncbi.nlm.nih.gov/pubmed/27239334",
                "http://www.ncbi.nlm.nih.gov/pubmed/18657049",
                "http://www.ncbi.nlm.nih.gov/pubmed/29122820",
                "http://www.ncbi.nlm.nih.gov/pubmed/24389415",
                "http://www.ncbi.nlm.nih.gov/pubmed/19429690",
                "http://www.ncbi.nlm.nih.gov/pubmed/19690166",
                "http://www.ncbi.nlm.nih.gov/pubmed/16168340",
                "http://www.ncbi.nlm.nih.gov/pubmed/28135749",
                "http://www.ncbi.nlm.nih.gov/pubmed/25195479"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692",
                    "text": "Here, we present a novel, semiautomated protein-DNA interaction characterization technology, selective microfluidics-based ligand enrichment followed by sequencing (SMiLE-seq).",
                    "offsetInBeginSection": 127,
                    "offsetInEndSection": 303,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692",
                    "text": "SMiLE-seq is neither limited by DNA bait length nor biased toward strong affinity binders; it probes the DNA-binding properties of TFs over a wide affinity range in a fast and cost-effective fashion.",
                    "offsetInBeginSection": 304,
                    "offsetInEndSection": 503,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692",
                    "text": "We validated SMiLE-seq by analyzing 58 full-length human, mouse, and Drosophila TFs from distinct structural classes.",
                    "offsetInBeginSection": 504,
                    "offsetInEndSection": 621,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18657049",
                    "text": "Collectively, these results indicate that SMILE isoforms regulate the inhibition of ER transactivation by SHP in a cell-type-specific manner and act as a novel transcriptional co-regulator in ER signalling.",
                    "offsetInBeginSection": 1353,
                    "offsetInEndSection": 1559,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18657049",
                    "text": "We have determined that the SMILE gene generates two isoforms [SMILE-L (long isoform of SMILE) and SMILE-S (short isoform of SMILE)].",
                    "offsetInBeginSection": 291,
                    "offsetInEndSection": 424,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24389415",
                    "text": "Small heterodimer partner interacting leucine zipper protein (SMILE) is an orphan nuclear receptor and a member of the bZIP family of proteins.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19429690",
                    "text": "Moreover, SMILE interacts with specific HDACs (histone deacetylases) and SMILE-mediated repression is released by HDAC inhibitor trichostatin A, in a NR-specific manner.",
                    "offsetInBeginSection": 836,
                    "offsetInEndSection": 1005,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19690166",
                    "text": "SMILE (small heterodimer partner interacting leucine zipper protein) has been identified as a corepressor of the glucocorticoid receptor, constitutive androstane receptor, and hepatocyte nuclear factor 4alpha.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19690166",
                    "text": "Interestingly, the repression of SMILE on ERRgamma is released by SIRT1 inhibitors, a catalytically inactive SIRT1 mutant, and SIRT1 small interfering RNA but not by histone protein deacetylase inhibitor.",
                    "offsetInBeginSection": 645,
                    "offsetInEndSection": 849,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19690166",
                    "text": "Overall, these findings implicate SMILE as a novel corepressor of ERRgamma and recruitment of SIRT1 as a novel repressive mechanism for SMILE and ERRgamma inverse agonist.",
                    "offsetInBeginSection": 1641,
                    "offsetInEndSection": 1812,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a77072c9e632bc06600000a",
            "body": "What is craniosynostosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29093661",
                "http://www.ncbi.nlm.nih.gov/pubmed/17980312",
                "http://www.ncbi.nlm.nih.gov/pubmed/27622416",
                "http://www.ncbi.nlm.nih.gov/pubmed/24082921",
                "http://www.ncbi.nlm.nih.gov/pubmed/26910679",
                "http://www.ncbi.nlm.nih.gov/pubmed/21811467",
                "http://www.ncbi.nlm.nih.gov/pubmed/18344207",
                "http://www.ncbi.nlm.nih.gov/pubmed/24071792",
                "http://www.ncbi.nlm.nih.gov/pubmed/22939693",
                "http://www.ncbi.nlm.nih.gov/pubmed/22038757"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29093661",
                    "text": "Syndromic forms of craniosynostosis arise from mutations in genes belonging to the Fibroblast Growth Factor Receptor (FGFR) family and the interconnected molecular pathways in most cases.",
                    "offsetInBeginSection": 361,
                    "offsetInEndSection": 548,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27622416",
                    "text": "Prenatal ultrasound`s detection rate of craniosynostosis is low.",
                    "offsetInBeginSection": 735,
                    "offsetInEndSection": 799,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26910679",
                    "text": "Among various craniosynostosis forms, sagittal nonsyndromic craniosynostosis is the most prevalent.",
                    "offsetInBeginSection": 114,
                    "offsetInEndSection": 213,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26910679",
                    "text": "FGFR1-3 mutational hotspots and the entire TWIST1, RAB23, and BMP2 coding regions were screened because of their known roles in human nonsyndromic or syndromic sagittal craniosynostosis, expression patterns, and/or animal model studies.",
                    "offsetInBeginSection": 615,
                    "offsetInEndSection": 851,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21811467",
                    "text": "Moreover, it suggests that haploinsufficiency of Twist1 gene, a target of canonical Wnt-signaling, and inhibitor of chondrogenesis, mimics conditions of inactive canonical Wnt-signaling leading to craniosynostosis.",
                    "offsetInBeginSection": 1475,
                    "offsetInEndSection": 1689,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21811467",
                    "text": "Saethre-Chotzen syndrome is a genetic condition characterized by craniosynostosis.",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 200,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21811467",
                    "text": "The Saethre-Chotzen syndrome, which is defined by loss-of-function mutations in the TWIST gene, is the second most prevalent craniosynostosis.",
                    "offsetInBeginSection": 201,
                    "offsetInEndSection": 343,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21811467",
                    "text": "In conclusion, this study reveals that coronal craniosynostosis in Twist1(+/-) mice occurs through endochondral ossification.",
                    "offsetInBeginSection": 1349,
                    "offsetInEndSection": 1474,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24071792",
                    "text": "RESULTS The incidence rate of craniosynostosis was highest for first-degree relatives of probands with metopic craniosynostosis (6.4%), followed by those with complex craniosynostosis (4.9%), sagittal craniosynostosis (3.8%), lambdoid craniosynostosis (3.9%), and coronal craniosynostosis (0.7%).",
                    "offsetInBeginSection": 457,
                    "offsetInEndSection": 753,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038757",
                    "text": "Other FGFR3 mutations result in various skeletal dysplasias: achondroplasia, hypochondroplasia, and thanatophoric dysplasia.",
                    "offsetInBeginSection": 483,
                    "offsetInEndSection": 607,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67b152b750ff445500000e",
            "body": "Describe nursemaid's elbow injury.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19657259",
                "http://www.ncbi.nlm.nih.gov/pubmed/27294496",
                "http://www.ncbi.nlm.nih.gov/pubmed/21317693",
                "http://www.ncbi.nlm.nih.gov/pubmed/11153321",
                "http://www.ncbi.nlm.nih.gov/pubmed/7560033",
                "http://www.ncbi.nlm.nih.gov/pubmed/7773660",
                "http://www.ncbi.nlm.nih.gov/pubmed/20971397",
                "http://www.ncbi.nlm.nih.gov/pubmed/17763294",
                "http://www.ncbi.nlm.nih.gov/pubmed/19468873",
                "http://www.ncbi.nlm.nih.gov/pubmed/12093966"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259",
                    "text": "Activities such as swinging a child by the hands or pulling on the pronated upper extremity can cause nursemaid's elbow.",
                    "offsetInBeginSection": 324,
                    "offsetInEndSection": 444,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259",
                    "text": "Nursemaid's elbow is a common injury in young children that can often be prevented.",
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 227,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496",
                    "text": "This article also reviews successful reduction maneuvers for nursemaid's elbow.",
                    "offsetInBeginSection": 803,
                    "offsetInEndSection": 882,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496",
                    "text": "Nursemaid's elbow and elbow fractures are both common causes of acute elbow pain, but the mechanism of injury is quite different.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317693",
                    "text": "Nursemaid's elbow (subluxation of the radial head) is a common pediatric upper extremity injury encountered in the emergency and urgent care settings.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11153321",
                    "text": "Nursemaid's elbow, also known as a pulled elbow or a subluxated radial head, may result from the specific activities described above and is the most common dislocation injury handled by pediatricians.",
                    "offsetInBeginSection": 520,
                    "offsetInEndSection": 720,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7560033",
                    "text": "Acute annular ligament interposition into the radiocapitellar joint (\"nursemaid's elbow\") is a common injury in children younger than 5 years.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7773660",
                    "text": "Subluxation of the radial head, or \"nursemaid's elbow,\" is a common injury among children aged 1 to 4 years.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19468873",
                    "text": "Youth baseball pitchers and throwers are particularly at risk for overuse injuries of the elbow, most of which are related to an injury mechanism termed \"valgus extension overload\".",
                    "offsetInBeginSection": 427,
                    "offsetInEndSection": 608,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12093966",
                    "text": "Annular ligament displacement (ALD)--also termed radial head subluxation, nursemaid's elbow, or pulled elbow--can be successfully diagnosed and treated over the telephone by properly trained medical professionals instructing nonmedical caretakers.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 247,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d08d5b750ff445500002c",
            "body": "Which stapled peptide has been designed to target Ctf4?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                "http://www.ncbi.nlm.nih.gov/pubmed/26673461",
                "http://www.ncbi.nlm.nih.gov/pubmed/25848797",
                "http://www.ncbi.nlm.nih.gov/pubmed/25921752",
                "http://www.ncbi.nlm.nih.gov/pubmed/27057630",
                "http://www.ncbi.nlm.nih.gov/pubmed/21088491",
                "http://www.ncbi.nlm.nih.gov/pubmed/28496125",
                "http://www.ncbi.nlm.nih.gov/pubmed/25084543",
                "http://www.ncbi.nlm.nih.gov/pubmed/28939823",
                "http://www.ncbi.nlm.nih.gov/pubmed/26159518"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "Herein, we report the design, optimization, and validation of double-click stapled peptides encoding the Ctf4-interacting peptide (CIP) of the replicative helicase subunit Sld5.",
                    "offsetInBeginSection": 313,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "By screening stapling positions in the Sld5 CIP, we identified an unorthodox i,i+6 stapled peptide with improved, submicromolar binding to Ctf4.",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 635,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "The mode of interaction with Ctf4 was confirmed by a crystal structure of the stapled Sld5 peptide bound to Ctf4.",
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "The stapled Sld5 peptide was able to displace the Ctf4 partner DNA polymerase\u2005\u03b1 from the replisome in yeast extracts.",
                    "offsetInBeginSection": 750,
                    "offsetInEndSection": 870,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "The Ctf4/AND-1 protein hub, which links DNA replication, repair, and chromosome segregation, represents a novel target for the synthetic lethality approach.",
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 312,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26673461",
                    "text": "On the basis of the cocrystal structure of RAP1/TRF2 complex, we have developed first-in-class triazole-stapled peptides that block the protein-protein interaction between RAP1 and TRF2.",
                    "offsetInBeginSection": 468,
                    "offsetInEndSection": 654,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25921752",
                    "text": "Six all-hydrocarbon-stapled Cdt1 MBD-derived peptides have been designed and synthesized to perturb the Cdt1-Mcm6 interaction, which is involved in DNA replication.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27057630",
                    "text": "Our results demonstrate both the high level of structural p53 mimicry employed by PM2 to engage HDM2, and the potential resilience of stapled peptide antagonists to mutations in target proteins.",
                    "offsetInBeginSection": 1038,
                    "offsetInEndSection": 1232,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27057630",
                    "text": "Interrogation of a large collection of randomly mutated HDM2 proteins failed to identify point mutations that could selectively abrogate binding by a stapled peptide inhibitor (PM2).",
                    "offsetInBeginSection": 671,
                    "offsetInEndSection": 853,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27057630",
                    "text": "Stapled peptides represent a novel class of antagonists capable of inhibiting therapeutically relevant protein-protein interactions.",
                    "offsetInBeginSection": 321,
                    "offsetInEndSection": 453,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a773c50faa1ab7d2e000002",
            "body": "Has ATF4 transcription factor been linked to cancer and neoplastic transformation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                "http://www.ncbi.nlm.nih.gov/pubmed/21338441",
                "http://www.ncbi.nlm.nih.gov/pubmed/26961881",
                "http://www.ncbi.nlm.nih.gov/pubmed/12213216",
                "http://www.ncbi.nlm.nih.gov/pubmed/17466566",
                "http://www.ncbi.nlm.nih.gov/pubmed/18034322",
                "http://www.ncbi.nlm.nih.gov/pubmed/26657730",
                "http://www.ncbi.nlm.nih.gov/pubmed/17297441",
                "http://www.ncbi.nlm.nih.gov/pubmed/28843961",
                "http://www.ncbi.nlm.nih.gov/pubmed/14695187"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "text": "Here, we report that ATF4 promotes oncogene-induced neoplastic transformation by suppressing the expression of cellular senescence-associated genes.",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 409,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "text": "Many cancers overexpress ATF4, a stress-induced transcription factor that promotes cell survival under hypoxic conditions and other stresses of the tumor microenvironment, but the potential contributions of ATF4 to oncogenesis itself have been little explored.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 260,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "text": "In wild-type cells these oncogenes induced expression of the murine Atf4 gene along with the cyclin-dependent kinase inhibitor Cdkn2a, which encodes the cell senescence-associated proteins p16INK4 and p19ARF.",
                    "offsetInBeginSection": 563,
                    "offsetInEndSection": 771,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338441",
                    "text": "These include mitogen-activated protein kinase kinase (MAPKK), CCAAT/enhancer-binding protein (C/EBP), activating transcription factor 4 (ATF4) and C/EBP-homologous protein (CHOP).",
                    "offsetInBeginSection": 234,
                    "offsetInEndSection": 414,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26961881",
                    "text": "In Per2 mutant and Cry1/2-null cells, the introduction of oncogenes induced expression of ATF4, a potent repressor of cell senescence-associated proteins p16INK4a and p19ARF.",
                    "offsetInBeginSection": 1001,
                    "offsetInEndSection": 1175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12213216",
                    "text": "H-ras transformation of MCF-10a cells resulted in upregulation of MAP kinase and PI 3-kinase signals, upregulation of sterol regulatory element binding protein 1 (SREBP-1) transcription factor levels, and upregulation of FAS expression and FA synthesis.",
                    "offsetInBeginSection": 659,
                    "offsetInEndSection": 912,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17466566",
                    "text": "ATF4 expression is upregulated in cancer.",
                    "offsetInBeginSection": 971,
                    "offsetInEndSection": 1012,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17466566",
                    "text": "Activating transcription factor 4 (ATF4) belongs to the ATF/CREB (activating transcription factor/cyclic AMP response element binding protein) family of basic region-leucine zipper (bZip) transcription factors, which have the consensus binding site cAMP responsive element (CRE).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 279,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17297441",
                    "text": "We have previously reported that activating transcription factor 4 (ATF4) is upregulated in cisplatin-resistant cells and plays a role in cisplatin resistance.",
                    "offsetInBeginSection": 124,
                    "offsetInEndSection": 283,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28843961",
                    "text": "Activating transcription factor 4 (ATF4), an endoplasmic reticulum stress-inducible transcription factor, plays important roles in cancer progression and resistance to therapy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68eabab750ff4455000015",
            "body": "Is there an association between Klinefelter syndrome and breast cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22274665",
                "http://www.ncbi.nlm.nih.gov/pubmed/3111653",
                "http://www.ncbi.nlm.nih.gov/pubmed/7841064",
                "http://www.ncbi.nlm.nih.gov/pubmed/1690312",
                "http://www.ncbi.nlm.nih.gov/pubmed/21246928",
                "http://www.ncbi.nlm.nih.gov/pubmed/9283592",
                "http://www.ncbi.nlm.nih.gov/pubmed/11976824",
                "http://www.ncbi.nlm.nih.gov/pubmed/16106025",
                "http://www.ncbi.nlm.nih.gov/pubmed/20698148",
                "http://www.ncbi.nlm.nih.gov/pubmed/15626018"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7841064",
                    "text": "Many case reports have suggested an association between Klinefelter syndrome (KS) and cancer, but studies of the cancer incidence in larger groups of men with KS are lacking.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1690312",
                    "text": "While the association of Klinefelter's syndrome and breast cancer is well known, only recently an increased incidence of mediastinal germ cell tumors in this syndrome has been established, which again is demonstrated in this case report.",
                    "offsetInBeginSection": 285,
                    "offsetInEndSection": 522,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21246928",
                    "text": "Klinefelter syndrome has been consistently associated with breast cancer in men (MBC).",
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21246928",
                    "text": "Klinefelter syndrome, in which patients carry XXY chromosome, may be present in men with breast cancer for this reason they often develop gynecomastia.",
                    "offsetInBeginSection": 1285,
                    "offsetInEndSection": 1436,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9283592",
                    "text": "Patients with a 47,XXY karyotype (Klinefelter syndrome) appear to have an increased risk of developing cancer, especially male breast cancer and germ cell tumors, but rarely malignant hematologic disorders.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11976824",
                    "text": "Since the early 1960s, numerous reports have appeared of an increased risk of malignant neoplasms among patients with Klinefelter syndrome.",
                    "offsetInBeginSection": 439,
                    "offsetInEndSection": 578,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16106025",
                    "text": "CONCLUSIONS These results support a hormonal etiology for breast cancer in men and for prostate cancer and suggest that men with Klinefelter syndrome may be at substantially elevated risks for non-Hodgkin lymphoma, breast cancer, and, perhaps, lung cancer.",
                    "offsetInBeginSection": 1368,
                    "offsetInEndSection": 1624,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16106025",
                    "text": "Compared with the general population, men with Klinefelter syndrome had higher mortality from lung cancer (SMR = 1.5, 95% CI = 1.0 to 2.0), breast cancer (SMR = 57.8, 95% CI = 18.8 to 135.0), and non-Hodgkin lymphoma (SMR = 3.5, 95% CI = 1.6 to 6.6) and lower mortality from prostate cancer (SMR = 0, 95% CI = 0 to 0.7).",
                    "offsetInBeginSection": 737,
                    "offsetInEndSection": 1057,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20698148",
                    "text": "Patients with 47, XXY karyotype (Klinefelter syndrome) appear to have increased risk of developing cancer, especially male breast cancer, germ cell tumours and non Hodgkin lymphomas, but rarely acute myeloid leukaemia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 218,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15626018",
                    "text": "The occurrence of mediastinal germ cell tumor and breast cancer have been repeatedly reported in men with Klinefelter syndrome (KS) but this association is debated controversially for patients with hematologic malignancies.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 223,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d1733b750ff4455000030",
            "body": "Which resource contains accurate enhancer predictions in the developing limb?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                "http://www.ncbi.nlm.nih.gov/pubmed/22077990",
                "http://www.ncbi.nlm.nih.gov/pubmed/21637758",
                "http://www.ncbi.nlm.nih.gov/pubmed/29159193",
                "http://www.ncbi.nlm.nih.gov/pubmed/22080555",
                "http://www.ncbi.nlm.nih.gov/pubmed/15212693",
                "http://www.ncbi.nlm.nih.gov/pubmed/21347315",
                "http://www.ncbi.nlm.nih.gov/pubmed/24995410",
                "http://www.ncbi.nlm.nih.gov/pubmed/26091399",
                "http://www.ncbi.nlm.nih.gov/pubmed/15718899"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                    "text": "Here we present the Limb-Enhancer Genie (LEG), a collection of highly accurate, genome-wide predictions of enhancers in the developing limb, available through a user-friendly online interface.",
                    "offsetInBeginSection": 415,
                    "offsetInEndSection": 607,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                    "text": "We predict limb enhancers using a combination of >50 published limb-specific datasets and clusters of evolutionarily conserved transcription factor binding sites, taking advantage of the patterns observed at previously in vivo validated elements.",
                    "offsetInBeginSection": 608,
                    "offsetInEndSection": 854,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                    "text": "Moreover, we describe general features that can guide the type of datasets to include when predicting tissue-specific enhancers genome-wide, while providing an accessible resource to the general biological community and facilitating the functional interpretation of genetic studies of limb malformations.",
                    "offsetInBeginSection": 1285,
                    "offsetInEndSection": 1589,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21637758",
                    "text": "The pipeline combines both the accurate computational genome-wide prediction of neuronal specific cis-regulatory modules (CRMs) and a newly developed experimental setup to rapidly obtain transgenic lines in a cost-effective and highly reproducible manner.",
                    "offsetInBeginSection": 585,
                    "offsetInEndSection": 840,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159193",
                    "text": "While further work is needed to potentially incorporate sensory and cognitive factors, the algorithm can be used within days of stroke to provide accurate predictions of upper limb functional outcomes at 3\u00a0months after stroke.",
                    "offsetInBeginSection": 1451,
                    "offsetInEndSection": 1678,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15212693",
                    "text": "CONCLUSION Phospho.ELM will be a valuable tool both for molecular biologists working on protein phosphorylation sites and for bioinformaticians developing computational predictions on the specificity of phosphorylation reactions.",
                    "offsetInBeginSection": 1247,
                    "offsetInEndSection": 1476,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21347315",
                    "text": "To overcome this problem, we develop a novel computational method that combines accurate quantification of 2D limb bud morphologies and growth modeling to analyze mouse clonal data of early limb development.",
                    "offsetInBeginSection": 559,
                    "offsetInEndSection": 766,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26091399",
                    "text": "Integrating shape features with a machine-learning algorithm AdaBoost, we developed an enhancer predicting method, DELTA (Distal Enhancer Locating Tool based on AdaBoost).",
                    "offsetInBeginSection": 721,
                    "offsetInEndSection": 892,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26091399",
                    "text": "We show that DELTA significantly outperforms current enhancer prediction methods in prediction accuracy on different datasets and can predict enhancers in one cell type using models trained in other cell types without loss of accuracy.",
                    "offsetInBeginSection": 893,
                    "offsetInEndSection": 1128,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15718899",
                    "text": "Although as accurate as the Moseley method, the multiplier method seems to be quicker and simpler to use and requires only one data point for predicting limb length at maturity.",
                    "offsetInBeginSection": 835,
                    "offsetInEndSection": 1012,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7877c0faa1ab7d2e00000c",
            "body": "What is the first line treatment for sarcoidosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26357609",
                "http://www.ncbi.nlm.nih.gov/pubmed/28696638",
                "http://www.ncbi.nlm.nih.gov/pubmed/26478443",
                "http://www.ncbi.nlm.nih.gov/pubmed/26419478",
                "http://www.ncbi.nlm.nih.gov/pubmed/26120005",
                "http://www.ncbi.nlm.nih.gov/pubmed/26330764",
                "http://www.ncbi.nlm.nih.gov/pubmed/23196575",
                "http://www.ncbi.nlm.nih.gov/pubmed/10719453",
                "http://www.ncbi.nlm.nih.gov/pubmed/27598883",
                "http://www.ncbi.nlm.nih.gov/pubmed/27846819"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609",
                    "text": "For symptomatic patients, the first line treatment includes corticosteroids or ursodeoxycholic acid.",
                    "offsetInBeginSection": 892,
                    "offsetInEndSection": 992,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28696638",
                    "text": "Systemic corticosteroids are the first line treatment in sarcoidosis.",
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 392,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26419478",
                    "text": "While corticosteroids remain the first line of treatment, tumour necrosis factor alpha (TNF-\u03b1) inhibitors have been investigated as one potential steroid sparing treatment for sarcoidosis.",
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 311,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26419478",
                    "text": "Paradoxically, in some patients treated with biologic TNF-\u03b1 inhibitors for other diseases, treatment can induce the development of sarcoidosis.",
                    "offsetInBeginSection": 541,
                    "offsetInEndSection": 685,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26120005",
                    "text": "This case reports a rare presentation of preschool sarcoidosis as well as the novel and successful use of pulse methylprednisolone in paediatric pulmonary sarcoidosis.",
                    "offsetInBeginSection": 505,
                    "offsetInEndSection": 672,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26330764",
                    "text": "Rituximab is an anti-CD20 chimeric monoclonal antibody, currently used for the treatment of B cell malignancies and systemic autoimmune diseases.",
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 474,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26330764",
                    "text": "Provided that steroids represent the gold standard as a first line treatment, many immune suppressants drugs are currently used in the disease management.",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 272,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23196575",
                    "text": "For patients who are refractory to or intolerant of corticosteroid therapy, second-line agents include azathioprine, methotrexate, cyclosporine, cyclophosphamide, and mycophenolate mofetil (MMF).",
                    "offsetInBeginSection": 1008,
                    "offsetInEndSection": 1203,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10719453",
                    "text": "TREATMENT Corticosteroid therapy is given as first line treatment with a satisfactory effect in most cases.",
                    "offsetInBeginSection": 817,
                    "offsetInEndSection": 924,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27598883",
                    "text": "Oral corticosteroids are the first line of treatment.",
                    "offsetInBeginSection": 1211,
                    "offsetInEndSection": 1264,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68f005b750ff4455000016",
            "body": "Which personality disorder is treated using dialectical behavior therapy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17496179",
                "http://www.ncbi.nlm.nih.gov/pubmed/16173357",
                "http://www.ncbi.nlm.nih.gov/pubmed/7977884",
                "http://www.ncbi.nlm.nih.gov/pubmed/20579633",
                "http://www.ncbi.nlm.nih.gov/pubmed/25373068",
                "http://www.ncbi.nlm.nih.gov/pubmed/21114345",
                "http://www.ncbi.nlm.nih.gov/pubmed/27642799",
                "http://www.ncbi.nlm.nih.gov/pubmed/9603574",
                "http://www.ncbi.nlm.nih.gov/pubmed/15930077",
                "http://www.ncbi.nlm.nih.gov/pubmed/20425311"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17496179",
                    "text": "OBJECTIVE The authors describe the use of dialectical behavior therapy (DBT) in treating borderline personality disorder during psychiatry residency, and assess the status of DBT education within psychiatry residencies in the United States.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 240,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357",
                    "text": "Treatment outcome data for Dialectical Behavior Therapy of borderline personality disorder and Trauma Model Therapy of dissociative identity disorder are reviewed.",
                    "offsetInBeginSection": 177,
                    "offsetInEndSection": 340,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7977884",
                    "text": "CONCLUSIONS These results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.",
                    "offsetInBeginSection": 882,
                    "offsetInEndSection": 1106,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20579633",
                    "text": "A central component of Dialectical Behavior Therapy (DBT) is the teaching of specific behavioral skills with the aim of helping individuals with Borderline Personality Disorder (BPD) replace maladaptive behaviors with skillful behavior.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25373068",
                    "text": "CONTEXT Dialectical Behavior Therapy (DBT) is an evidence-based therapy developed for the treatment of suicidal behaviors and disorders characterized by emotional and behavioral dyscontrol that is effective in veteran populations.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21114345",
                    "text": "OBJECTIVE At present, the most frequently investigated psychosocial intervention for borderline personality disorder (BPD) is dialectical behavior therapy (DBT).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27642799",
                    "text": "Dialectical behavior therapy (DBT) was originally developed by Marsha Linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, DBT is also increasingly being recommended for the treatment of CD and APD.",
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 646,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9603574",
                    "text": "Dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15930077",
                    "text": "OBJECTIVE The aim of this study was to determine the efficacy and safety of dialectical behavior therapy plus olanzapine compared with dialectical behavior therapy plus placebo in patients with borderline personality disorder.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 226,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20425311",
                    "text": "The strongest evidence from clinical trials favors dialectical behavior therapy and mentalization-based treatment.",
                    "offsetInBeginSection": 180,
                    "offsetInEndSection": 294,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d186db750ff4455000031",
            "body": "Is there any role of Dlx1 and Dlx2 transcription factors in cortical interneurons?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29028947",
                "http://www.ncbi.nlm.nih.gov/pubmed/17582322",
                "http://www.ncbi.nlm.nih.gov/pubmed/17259176",
                "http://www.ncbi.nlm.nih.gov/pubmed/28821666",
                "http://www.ncbi.nlm.nih.gov/pubmed/19026749",
                "http://www.ncbi.nlm.nih.gov/pubmed/16766712",
                "http://www.ncbi.nlm.nih.gov/pubmed/18728693",
                "http://www.ncbi.nlm.nih.gov/pubmed/10934256",
                "http://www.ncbi.nlm.nih.gov/pubmed/12724837",
                "http://www.ncbi.nlm.nih.gov/pubmed/16007083"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028947",
                    "text": "The postnatal functions of the Dlx1&2 transcription factors in cortical interneurons (CINs) are unknown.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17582322",
                    "text": "In this issue of Neuron, Rubenstein and colleagues demonstrate that the homeobox proteins Dlx1 and Dlx2 promote interneuron migration in part by preventing the premature expression of PAK3, a serine/threonine kinase that is later involved in neurite outgrowth and other aspects of interneuron maturation.",
                    "offsetInBeginSection": 172,
                    "offsetInEndSection": 476,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176",
                    "text": "Dlx1/Dlx2 null mice die at birth with an abnormal cortical phenotype, including impaired differentiation and migration of GABAergic interneurons to the neocortex.",
                    "offsetInBeginSection": 79,
                    "offsetInEndSection": 241,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176",
                    "text": "This is the first report that DLX1 or DLX2 can function as transcriptional repressors.",
                    "offsetInBeginSection": 967,
                    "offsetInEndSection": 1053,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28821666",
                    "text": "DLX1 and/or DLX2 activated the transcription of both Gad genes, and defects in Dlx function disrupted the differentiation of GABAergic interneurons with global reduction in GABA levels in the forebrains of the Dlx1/Dlx2 double knock-out mouse in vivo Identification of Gad genes as direct Dlx transcriptional targets is significant; it extends our understanding of Dlx gene function in the developing forebrain beyond the regulation of tangential interneuron migration to the differentiation of GABAergic interneurons arising from the basal telencephalon, and may help to unravel the pathogenesis of several developmental brain disorders.SIGNIFICANCE STATEMENT GABA is the major inhibitory neurotransmitter in the brain.",
                    "offsetInBeginSection": 1014,
                    "offsetInEndSection": 1734,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28821666",
                    "text": "We have discovered that specific promoter regulatory elements of glutamic acid decarboxylase isoforms (Gad1 and Gad2), which regulate GABA synthesis from the excitatory neurotransmitter glutamate, are direct transcriptional targets of both DLX1 and DLX2 homeoproteins in vivo Further gain- and loss-of-function studies in vitro and in vivo demonstrated that both DLX1 and DLX2 are necessary and sufficient for Gad gene expression.",
                    "offsetInBeginSection": 583,
                    "offsetInEndSection": 1013,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026749",
                    "text": "DLX1 and DLX2 transcription factors are necessary for forebrain GABAergic neuron differentiation, migration, and survival.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16766712",
                    "text": "Toward elucidating the mechanisms underlying the generation of interneuron diversity, we have studied in mice the expression patterns in differentiating and mature neocortical interneurons of 8 transcription factors, including 6 homeobox (Dlx1, Dlx2, Dlx5, Arx, Lhx6, Cux2), 1 basic helix-loop-helix, (NPAS1), and 1 bZIP (MafB).",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 589,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10934256",
                    "text": "Similar analysis of mice lacking the Mash1 basic helix-loop-helix (bHLH) or both the Dlx1 and Dlx2 homeodomain transcription factors demonstrates that these genes are required for the differentiation of striatal interneurons.",
                    "offsetInBeginSection": 1083,
                    "offsetInEndSection": 1308,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12724837",
                    "text": "Our results support a possible role for Dlx1 and Dlx2 in inner retinal development and in the terminal differentiation and/or maintenance of INL interneurons and ganglion cells in the adult.",
                    "offsetInBeginSection": 1206,
                    "offsetInEndSection": 1396,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a79d0b8faa1ab7d2e00000d",
            "body": "What cellular process are okazaki fragments associated with?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/14693726",
                "http://www.ncbi.nlm.nih.gov/pubmed/23451868",
                "http://www.ncbi.nlm.nih.gov/pubmed/12806117",
                "http://www.ncbi.nlm.nih.gov/pubmed/21278448",
                "http://www.ncbi.nlm.nih.gov/pubmed/22918592",
                "http://www.ncbi.nlm.nih.gov/pubmed/14690413",
                "http://www.ncbi.nlm.nih.gov/pubmed/20178844",
                "http://www.ncbi.nlm.nih.gov/pubmed/18635534",
                "http://www.ncbi.nlm.nih.gov/pubmed/12228807",
                "http://www.ncbi.nlm.nih.gov/pubmed/25814667"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23451868",
                    "text": "Substrate specificity allows FEN1 to process intermediates of Okazaki fragment maturation, long-patch base excision repair, telomere maintenance, and stalled replication fork rescue.",
                    "offsetInBeginSection": 206,
                    "offsetInEndSection": 388,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12806117",
                    "text": "Because of this peculiarity the major role of the DNA polymerase alpha-primase complex (pol-prim) is in the initiation of DNA replication at chromosomal origins and in the discontinuous synthesis of Okazaki fragments on the lagging strand of the replication fork.",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 537,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448",
                    "text": "Therefore, efficient processing of Okazaki fragments is vital for DNA replication and cell proliferation.",
                    "offsetInBeginSection": 263,
                    "offsetInEndSection": 368,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448",
                    "text": "During this process, primase-synthesized RNA/DNA primers are removed, and Okazaki fragments are joined into an intact lagging strand DNA.",
                    "offsetInBeginSection": 369,
                    "offsetInEndSection": 506,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22918592",
                    "text": "Processing of Okazaki fragments to complete lagging strand DNA synthesis requires coordination among several proteins.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20178844",
                    "text": "The Pif1 helicase and Dna2 helicase/nuclease contribute to the maturation process by elongating the flap displaced by pol delta.",
                    "offsetInBeginSection": 648,
                    "offsetInEndSection": 776,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18635534",
                    "text": "In contrast, Okazaki fragments in eukaryotes are quite short, 100-250 bp, and thus the eukaryotic lagging strand polymerase does not require a high degree of processivity.",
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 543,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12228807",
                    "text": "These include temperature sensitivity, Okazaki fragment processing, a mutator phenotype, a G2/M cell cycle arrest, minichromosome loss, and methyl methane sulfonate sensitivity.",
                    "offsetInBeginSection": 967,
                    "offsetInEndSection": 1144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12228807",
                    "text": "RNA primer removal from Okazaki fragments during lagging-strand replication and the excision of damaged DNA bases requires the action of structure-specific nucleases, such as the mammalian flap endonuclease 1 (FEN-1).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 217,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25814667",
                    "text": "During replication, Okazaki fragment maturation is a fundamental process that joins discontinuously synthesized DNA fragments into a contiguous lagging strand.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68f633b750ff4455000019",
            "body": "Is creatinine assessment included in the MELD score?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27480755",
                "http://www.ncbi.nlm.nih.gov/pubmed/15482344",
                "http://www.ncbi.nlm.nih.gov/pubmed/24601755",
                "http://www.ncbi.nlm.nih.gov/pubmed/23293714",
                "http://www.ncbi.nlm.nih.gov/pubmed/22380485",
                "http://www.ncbi.nlm.nih.gov/pubmed/17370333",
                "http://www.ncbi.nlm.nih.gov/pubmed/20827408",
                "http://www.ncbi.nlm.nih.gov/pubmed/22178107",
                "http://www.ncbi.nlm.nih.gov/pubmed/18482269",
                "http://www.ncbi.nlm.nih.gov/pubmed/27779785"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344",
                    "text": "The MELD score has a short-term prognostic yield that is better than what is provided by both the CTP and CTP creatinine-modified scores, even in cirrhotic patients who are not critically ill.",
                    "offsetInBeginSection": 1912,
                    "offsetInEndSection": 2104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344",
                    "text": "However, the MELD score proved to be better at defining patients' prognosis in the short-term as compared with both the traditional CTP score (P=0.012) and the creatinine-modified CTP (P=0.047).",
                    "offsetInBeginSection": 1404,
                    "offsetInEndSection": 1598,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24601755",
                    "text": "The MELD-Bicarbonate equation, which included three variables (international normalized ratio, creatinine level, and HCO3 level), showed better prognostic value than the original MELD score in critically ill patients with cirrhosis.",
                    "offsetInBeginSection": 1362,
                    "offsetInEndSection": 1594,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714",
                    "text": "CONCLUSION Incorporating eGFR obtained by the 6-variable MDRD equation into the MELD score showed an equal predictive performance in in-hospital mortality compared to a creatinine-based MELD score.",
                    "offsetInBeginSection": 3159,
                    "offsetInEndSection": 3356,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714",
                    "text": "MELD-MDRD-6 included 6-variable MDRD eGFR as one of the variables and showed an improvement over MELD score, as suggested by an increase in chi-square (2293.82 vs 2198.32) and a decrease in -2 log (likelihood) (2810.77 vs 2664.79).",
                    "offsetInBeginSection": 2353,
                    "offsetInEndSection": 2584,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714",
                    "text": "Finally, when serum creatinine was replaced by CKD-EPI eGFR, it showed a slight improvement compared to the original MELD score (chi-square: 2199.16, -2 log (likelihood): 2773.07).",
                    "offsetInBeginSection": 2585,
                    "offsetInEndSection": 2765,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714",
                    "text": "MELD-MDRD-4 excluded serum creatinine, with the coefficients refit among the remaining 3 variables, i.e., total bilirubin, INR and 4-variable MDRD eGFR.",
                    "offsetInBeginSection": 2014,
                    "offsetInEndSection": 2166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17370333",
                    "text": "Univariate analysis showed that age, duration of jaundice, jaundice-encephalopathy interval (JEI), grade of encephalopathy, presence of cerebral edema, bilirubin, prothrombin time, creatinine, and MELD score were significantly different between survivors and nonsurvivors.",
                    "offsetInBeginSection": 787,
                    "offsetInEndSection": 1059,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20827408",
                    "text": "Changes in MELD score simple during the admission, which were calculated by CRE and TBI [3.8 \u00d7 log (bilirubin (mg/dl)] + 9.6 \u00d7 log [Creatinine (mg/dl) + 6.43], were significant predictor for patients with type 1 HRS.",
                    "offsetInBeginSection": 1423,
                    "offsetInEndSection": 1641,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22178107",
                    "text": "MELD score, CKD-EPI formula creatinine-based eGFR and cystatin C-based eGFR were evaluated in 100 cirrhotic patients.",
                    "offsetInBeginSection": 466,
                    "offsetInEndSection": 583,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d196db750ff4455000032",
            "body": "Which resource has been developed in order to study the transcriptional regulation of GABAergic cell fate?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27710791",
                "http://www.ncbi.nlm.nih.gov/pubmed/24643195",
                "http://www.ncbi.nlm.nih.gov/pubmed/24370451",
                "http://www.ncbi.nlm.nih.gov/pubmed/26843111",
                "http://www.ncbi.nlm.nih.gov/pubmed/28912684",
                "http://www.ncbi.nlm.nih.gov/pubmed/27068104",
                "http://www.ncbi.nlm.nih.gov/pubmed/17910758",
                "http://www.ncbi.nlm.nih.gov/pubmed/22397680",
                "http://www.ncbi.nlm.nih.gov/pubmed/17678855",
                "http://www.ncbi.nlm.nih.gov/pubmed/15337318"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27710791",
                    "text": "Thus, these subpallial enhancer transgenic lines are data and tool\u00a0resources to study transcriptional regulation of GABAergic cell fate.",
                    "offsetInBeginSection": 896,
                    "offsetInEndSection": 1033,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24643195",
                    "text": "Our data show that GABAergic inducing activity of Ascl1 requires the direct transcriptional regulation of Ptf1a, providing therefore a new piece of the network governing neurotransmitter subtype specification during retinogenesis.",
                    "offsetInBeginSection": 1219,
                    "offsetInEndSection": 1449,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24643195",
                    "text": "We showed that it is necessary for retinal GABAergic cell genesis and sufficient in overexpression experiments to bias a subset of retinal precursor cells towards a GABAergic fate.",
                    "offsetInBeginSection": 510,
                    "offsetInEndSection": 690,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24370451",
                    "text": "The basic helix-loop-helix (bHLH) transcriptional activator Ptf1a determines inhibitory GABAergic over excitatory glutamatergic neuronal cell fate in progenitors of the vertebrate dorsal spinal cord, cerebellum and retina.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 222,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26843111",
                    "text": "In order to study its role in the regulation of vestibulo-motor development, we investigated a transgenic mouse expressing Isl1 under the Pax2 promoter control (Tg +/- ).",
                    "offsetInBeginSection": 282,
                    "offsetInEndSection": 452,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28912684",
                    "text": "To explore the transcriptional regulation of the development of cerebellar inhibitory neurons, we examined the role of Tfap2A and Tfap2B in the specification of GABAergic neuronal subtypes in mice.",
                    "offsetInBeginSection": 230,
                    "offsetInEndSection": 427,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17910758",
                    "text": "Therefore, we investigated whether Ptf1a promotes the fate of these two cell types or acts directly as a GABAergic subtype determination factor.",
                    "offsetInBeginSection": 1145,
                    "offsetInEndSection": 1289,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22397680",
                    "text": "In PrV of Lmx1b knockout mice (-/-), initial specification of glutamatergic vs. GABAergic cell fate is normal until embryonic day 14.5.",
                    "offsetInBeginSection": 506,
                    "offsetInEndSection": 641,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22397680",
                    "text": "Other experiments suggest that Lmx1b acts to suppress Pax2, a promoter of GABAergic cell fate, in a cell-autonomous manner, which may be a mechanism for maintaining a functional balance of glutamatergic and GABAergic cell types in development.",
                    "offsetInBeginSection": 1411,
                    "offsetInEndSection": 1654,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17678855",
                    "text": "We show that Dlx homeobox transcription factors, required for GABAergic interneuron production, repress oligodendrocyte precursor cell (OPC) formation by acting on a common progenitor to determine neuronal versus oligodendroglial cell fate acquisition.",
                    "offsetInBeginSection": 300,
                    "offsetInEndSection": 552,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a79d195faa1ab7d2e00000e",
            "body": "Is celiac disease caused by gliadin-induced transglutaminase-2 (TG2)-dependent events ?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24240659",
                "http://www.ncbi.nlm.nih.gov/pubmed/22314661",
                "http://www.ncbi.nlm.nih.gov/pubmed/22878839",
                "http://www.ncbi.nlm.nih.gov/pubmed/15290344",
                "http://www.ncbi.nlm.nih.gov/pubmed/15511629",
                "http://www.ncbi.nlm.nih.gov/pubmed/27613408",
                "http://www.ncbi.nlm.nih.gov/pubmed/26503953",
                "http://www.ncbi.nlm.nih.gov/pubmed/15876458",
                "http://www.ncbi.nlm.nih.gov/pubmed/18793760",
                "http://www.ncbi.nlm.nih.gov/pubmed/28737923"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659",
                    "text": "The present study examined the capability of different oat cultivars of activating the gliadin-induced transglutaminase-2 (TG2)-dependent events in some in vitro models of CD.",
                    "offsetInBeginSection": 275,
                    "offsetInEndSection": 450,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22878839",
                    "text": "Gluten-derived gliadin peptides are deamidated by transglutaminase 2 (TG2), leading to an immune response in the small-intestinal mucosa.",
                    "offsetInBeginSection": 198,
                    "offsetInEndSection": 335,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22878839",
                    "text": "TG2 inhibitors have therefore been suggested as putative drugs for celiac disease.",
                    "offsetInBeginSection": 336,
                    "offsetInEndSection": 418,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15290344",
                    "text": "The discovery that type 2 transglutaminase (TG2) is the main, if not the sole, target of the endomysium CD-specific autoantibodies assigned to this enzyme a master regulator role of CD.",
                    "offsetInBeginSection": 222,
                    "offsetInEndSection": 407,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15511629",
                    "text": "Deamidation may be catalysed by intestinal tissue transglutaminase (TG2), a protein which is also the main autoantigen in celiac disease.",
                    "offsetInBeginSection": 195,
                    "offsetInEndSection": 332,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27613408",
                    "text": "Type 2 transglutaminase (TG2) has an important pathogenic role in celiac disease (CD), an inflammatory intestinal disease that is caused by the ingestion of gluten-containing cereals.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503953",
                    "text": "Autoantibodies specific for the enzyme transglutaminase 2 (TG2) are a hallmark of the gluten-sensitive enteropathy celiac disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15876458",
                    "text": "Celiac disease (CD) is a complex small intestinal disorder due to a dysregulated immune response to wheat gliadin and related proteins which leads to a small intestinal enteropathy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 181,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18793760",
                    "text": "The in vivo deamidation of gliadin peptides plays an important role in the immunopathogenesis of celiac disease (CD).",
                    "offsetInBeginSection": 112,
                    "offsetInEndSection": 229,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18793760",
                    "text": "Transglutaminase 2 (TG2) catalyzes cross-linking or deamidation of glutamine residues in peptides and proteins.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68f965b750ff445500001a",
            "body": "Clue cells are characteristics to which causative bacteria of vaginitis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3497132",
                "http://www.ncbi.nlm.nih.gov/pubmed/6610607",
                "http://www.ncbi.nlm.nih.gov/pubmed/10932748",
                "http://www.ncbi.nlm.nih.gov/pubmed/21524046",
                "http://www.ncbi.nlm.nih.gov/pubmed/11845812",
                "http://www.ncbi.nlm.nih.gov/pubmed/3872256",
                "http://www.ncbi.nlm.nih.gov/pubmed/6607525",
                "http://www.ncbi.nlm.nih.gov/pubmed/6336135",
                "http://www.ncbi.nlm.nih.gov/pubmed/15474248",
                "http://www.ncbi.nlm.nih.gov/pubmed/4000776"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132",
                    "text": "The specific aetiologies of vaginitis are many.",
                    "offsetInBeginSection": 111,
                    "offsetInEndSection": 158,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132",
                    "text": "Vaginitis of undetermined aetiology is more complex and is characterized by a purulent vaginal discharge, a pH of 4.0-4.6, numerous WBC's, and a high concentration of bacteria.",
                    "offsetInBeginSection": 823,
                    "offsetInEndSection": 999,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132",
                    "text": "One of the most common entities, however, is \"non-specific vaginitis\" which can be subdivided into: Gardnerella vaginitis, anaerobic vaginosis, and vaginitis of undetermined aetiology.",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 343,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10932748",
                    "text": "Lactobacillus populations, which are usually dominant in healthy women, are replaced by a polymicrobial group of organisms that includes G. vaginalis, anaerobic Gram-negative rods such as Prevotella species, Peptostreptococcus species, Mycoplasma hominis, Ureaplasma urealyticum, and often Mobiluncus species.",
                    "offsetInBeginSection": 479,
                    "offsetInEndSection": 788,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21524046",
                    "text": "Bacterial vaginosis, trichomoniasis, and vulvovaginal candidiasis are the most common infectious causes of vaginitis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11845812",
                    "text": "Aerobic vaginitis was diagnosed if smears were deficient in lactobacilli, positive for cocci or coarse bacilli, positive for parabasal epithelial cells, and/or positive for vaginal leucocytes (plus their granular aspect).",
                    "offsetInBeginSection": 549,
                    "offsetInEndSection": 770,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6607525",
                    "text": "Gardnerella-associated vaginosis (Hemophilus vaginalis vaginitis, nonspecific vaginitis) is the most common cause of vaginal discharge and odor.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6607525",
                    "text": "The diagnosis is further confirmed when a microscopic examination of the discharge mixed with normal saline shows a virtual pure culture of tiny bacteria many of which are found clinging to vaginal epithelial cells forming the so-called \"clue cells\".",
                    "offsetInBeginSection": 590,
                    "offsetInEndSection": 840,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6336135",
                    "text": "Examination of Gram-stained vaginal smears obtained from infected pig-tailed macaques failed to demonstrate clue cells, a feature which is pathognomonic of non-specific vaginitis in humans.",
                    "offsetInBeginSection": 209,
                    "offsetInEndSection": 398,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/4000776",
                    "text": "Nonspecific vaginitis, one of the most common causes of vaginitis in adults, is a polymicrobial infection in which vaginal anaerobes act synergistically with Gardnerella vaginalis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d1db1b750ff4455000033",
            "body": "What is the purpose of the FaceBase consortium?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21458441",
                "http://www.ncbi.nlm.nih.gov/pubmed/27287806",
                "http://www.ncbi.nlm.nih.gov/pubmed/26168040",
                "http://www.ncbi.nlm.nih.gov/pubmed/24303230",
                "http://www.ncbi.nlm.nih.gov/pubmed/24124010",
                "http://www.ncbi.nlm.nih.gov/pubmed/19785207",
                "http://www.ncbi.nlm.nih.gov/pubmed/9682580",
                "http://www.ncbi.nlm.nih.gov/pubmed/11532163",
                "http://www.ncbi.nlm.nih.gov/pubmed/19455246",
                "http://www.ncbi.nlm.nih.gov/pubmed/27648088"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21458441",
                    "text": "The FaceBase Consortium consists of ten interlinked research and technology projects whose goal is to generate craniofacial research data and technology for use by the research community through a central data management and integrated bioinformatics hub.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806",
                    "text": "The FaceBase Consortium, funded by the National Institute of Dental and Craniofacial Research, National Institutes of Health, is designed to accelerate understanding of craniofacial developmental biology by generating comprehensive data resources to empower the research community, exploring high-throughput technology, fostering new scientific collaborations among researchers and human/computer interactions, facilitating hypothesis-driven research and translating science into improved health care to benefit patients.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 521,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806",
                    "text": "The resources generated by the FaceBase projects include a number of dynamic imaging modalities, genome-wide association studies, software tools for analyzing human facial abnormalities, detailed phenotyping, anatomical and molecular atlases, global and specific gene expression patterns, and transcriptional profiling over the course of embryonic and postnatal development in animal models and humans.",
                    "offsetInBeginSection": 522,
                    "offsetInEndSection": 924,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26168040",
                    "text": "The NIH FACEBASE consortium was established in part to create a central resource for craniofacial researchers.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26168040",
                    "text": "This FACEBASE resource is designed to promote discovery by the craniofacial research community.",
                    "offsetInBeginSection": 1241,
                    "offsetInEndSection": 1336,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24303230",
                    "text": "We introduce the Ontology of Craniofacial Development and Malformation (OCDM), a project of the NIH-funded FaceBase consortium, whose goal is to gather data from multiple species, at levels ranging from genes to gross anatomy, in order to understand the causes of craniofacial abnormalities.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 291,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24124010",
                    "text": "The OCDM is a project of the NIDCR-sponsored FaceBase Consortium, whose goal is to promote and enable research into the genetic and epigenetic causes of specific craniofacial abnormalities through the provision of publicly accessible, integrated craniofacial data.",
                    "offsetInBeginSection": 333,
                    "offsetInEndSection": 597,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9682580",
                    "text": "The purpose of this article is to describe the evolution and implementation of the Northern New Jersey Nursing Education consortium--a consortium of seven member institutions established in 1992.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11532163",
                    "text": "Herein, we describe the structure of the Consortium, pointing out the inherent strengths of linking together multiple independent sites for the purpose of banking HIV-infected nervous system tissues.",
                    "offsetInBeginSection": 521,
                    "offsetInEndSection": 720,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27648088",
                    "text": "PURPOSE Aim of the COBRA (Consortium for Brachytherapy Data Analysis) project is to create a multicenter group (consortium) and a web-based system for standardized data collection.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a79d25dfaa1ab7d2e00000f",
            "body": "Does wheat belongs to the genus Avena, yes or no?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24226111",
                "http://www.ncbi.nlm.nih.gov/pubmed/8984007",
                "http://www.ncbi.nlm.nih.gov/pubmed/12669804",
                "http://www.ncbi.nlm.nih.gov/pubmed/18356948",
                "http://www.ncbi.nlm.nih.gov/pubmed/24202677",
                "http://www.ncbi.nlm.nih.gov/pubmed/25120168",
                "http://www.ncbi.nlm.nih.gov/pubmed/24310196",
                "http://www.ncbi.nlm.nih.gov/pubmed/25188288",
                "http://www.ncbi.nlm.nih.gov/pubmed/869897",
                "http://www.ncbi.nlm.nih.gov/pubmed/29083384"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984007",
                    "text": "A cloned repetitive sequence, pAvKB30, obtained from an Avena vaviloviana (AB genome) genomic library, along with two polymerase chain reaction products derived from the conserved region of the reverse transcriptase (RT) gene of retrotransposons, were characterized molecularly and cytologically.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 296,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984007",
                    "text": "The cloned DNA fragment was a dispersed repeat present in all Avena species used in this study (A. strigosa, A. clauda, A. vaviloviana, A. magna, and A. sativa).",
                    "offsetInBeginSection": 297,
                    "offsetInEndSection": 458,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12669804",
                    "text": "The DNA sequence of an extracellular (EXC) domain of an oat (Avena sativa L.) receptor-like kinase (ALrk10) gene was amplified from 23 accessions of 15 Avena species (6 diploid, 6 tetraploid, and 3 hexaploid).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18356948",
                    "text": "These results could explain the roles of A. clauda, A. longiglumis, and A. atlantica in the evolution of the genus Avena.",
                    "offsetInBeginSection": 2178,
                    "offsetInEndSection": 2299,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25120168",
                    "text": "The present results identify a novel protein family affecting cereal kernel texture and would further elucidate the phylogenetic evolution of Avena genus.",
                    "offsetInBeginSection": 1334,
                    "offsetInEndSection": 1488,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188288",
                    "text": "Two uncorrelated nucleotide sequences, chloroplast intergenic spacer psbA-trnH and acetyl CoA carboxylase gene (Acc1), were used to perform phylogenetic analyses in 75 accessions of the genus Avena, representing 13 diploids, seven tetraploid, and four hexaploids by maximum parsimony and Bayesian inference.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 307,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188288",
                    "text": "The haplotype that seems to represent the D genome clustered with the tetraploid species Avena murphyi and Avena maroccana, which supported the CD genomic designation instead of AC for A. murphyi and A. maroccana.",
                    "offsetInBeginSection": 1022,
                    "offsetInEndSection": 1235,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188288",
                    "text": "Phylogenic analyses based on the chloroplast intergenic spacer psbA-trnH confirmed that the A genome diploid might be the maternal donor of species of the genus Avena.",
                    "offsetInBeginSection": 308,
                    "offsetInEndSection": 475,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29083384",
                    "text": "The water-insoluble storage proteins of cereals (prolamins) are called \"gluten\" in wheat, barley, and rye, and \"avenins\" in oat.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29083384",
                    "text": "The avenins in the genus Avena (cultivated oat as well as various wild species of which gene bank accessions were analyzed) are free of the known CD immunogenic epitopes from wheat, barley, and rye.",
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 603,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68fd01b750ff445500001b",
            "body": "What is included in the fourth generation HIV test?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24342480",
                "http://www.ncbi.nlm.nih.gov/pubmed/23984592",
                "http://www.ncbi.nlm.nih.gov/pubmed/29062724",
                "http://www.ncbi.nlm.nih.gov/pubmed/28846743",
                "http://www.ncbi.nlm.nih.gov/pubmed/24342477",
                "http://www.ncbi.nlm.nih.gov/pubmed/11595590",
                "http://www.ncbi.nlm.nih.gov/pubmed/25464967",
                "http://www.ncbi.nlm.nih.gov/pubmed/16908076",
                "http://www.ncbi.nlm.nih.gov/pubmed/19320855",
                "http://www.ncbi.nlm.nih.gov/pubmed/22174065"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592",
                    "text": "To evaluate its performance to diagnose acute HIV infection (AHI), E4G was compared with fourth generation Ag/Ab ELISA test kits, a third generation PA test kit, WB and real-time PCR for the testing of 25 AHI clinical specimens.",
                    "offsetInBeginSection": 721,
                    "offsetInEndSection": 949,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592",
                    "text": "In 2008, the Espline HIV Ag/Ab test kit (E4G, Fujirebio Inc. Japan) was marketed in Japan belonging to the fourth generation of HIV test kits characterized by its ability to detect both viral antigens (Ag) and anti-HIV-1/2 antibodies (Ab).",
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 611,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29062724",
                    "text": "CONCLUSION The fourth generation DC offered no advantage over current third generation RT in the diagnosis of HIV infection.",
                    "offsetInBeginSection": 1654,
                    "offsetInEndSection": 1778,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29062724",
                    "text": "Determine Combo (DC) is the first fourth generation RT that detects both p24 antigen (p24Ag) and HIV antibodies (Ab), theoretically reducing the window period and increasing detection rates.",
                    "offsetInBeginSection": 215,
                    "offsetInEndSection": 405,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11595590",
                    "text": "This second diagnostic window was caused by the absence of HIV specific antibodies and the decline of HIV p24 antigen concentrations below the detection limits of the fourth generation assays.",
                    "offsetInBeginSection": 1068,
                    "offsetInEndSection": 1260,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25464967",
                    "text": "RESULTS Fourth generation immunoassays identified 34 out of 39 HIV early infections using dried serum spot, whereas the Determine\u2122 HIV-1/2 rapid test detected 24 out of 39 HIV positive serum (87.2% vs 61.5% respectively, p = 0.009).",
                    "offsetInBeginSection": 686,
                    "offsetInEndSection": 920,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25464967",
                    "text": "CONCLUSION Fourth generation Ag/Ab immunoassays performed on dried serum spot had good performance for HIV testing during the early phases of HIV infection.",
                    "offsetInBeginSection": 1304,
                    "offsetInEndSection": 1460,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16908076",
                    "text": "The LG HIV Ag-Ab Plus, a new fourth generation diagnostic assay for HIV infection, was evaluated in comparison to the Enzygnost HIV Integral, an established fourth generation HIV assay.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19320855",
                    "text": "All HIV-1-positive samples were reactive by the three fourth-generation systems.",
                    "offsetInBeginSection": 1098,
                    "offsetInEndSection": 1178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22174065",
                    "text": "The use of a point-of-care test, as well as fourth generation HIV tests and HIV RNA in combination, can still miss seroconversion in the 'eclipse' phase of the infection as these tests are not designed to detect the earliest phase of infection.",
                    "offsetInBeginSection": 230,
                    "offsetInEndSection": 474,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d2558b750ff4455000036",
            "body": "Does Uc.160 promote cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                "http://www.ncbi.nlm.nih.gov/pubmed/20802525",
                "http://www.ncbi.nlm.nih.gov/pubmed/27261573",
                "http://www.ncbi.nlm.nih.gov/pubmed/26540342",
                "http://www.ncbi.nlm.nih.gov/pubmed/27117702",
                "http://www.ncbi.nlm.nih.gov/pubmed/26804165",
                "http://www.ncbi.nlm.nih.gov/pubmed/28759035",
                "http://www.ncbi.nlm.nih.gov/pubmed/28857253",
                "http://www.ncbi.nlm.nih.gov/pubmed/28822708",
                "http://www.ncbi.nlm.nih.gov/pubmed/26261546"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "text": "CONCLUSIONS These results indicate that Uc.160+ could possibly have a tumor suppressive role in GC.",
                    "offsetInBeginSection": 1498,
                    "offsetInEndSection": 1597,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "text": "Uc.160+, a T-UCR reported to be downregulated in human cancer, has not been examined in GC.",
                    "offsetInBeginSection": 399,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20802525",
                    "text": "Among the T-UCRs that were reactivated upon drug treatment, Uc.160+, Uc283+A and Uc.346+ were found to undergo specific CpG island hypermethylation-associated silencing in cancer cells compared with normal tissues.",
                    "offsetInBeginSection": 1280,
                    "offsetInEndSection": 1494,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27261573",
                    "text": "These findings suggested miR-1301 promoted prostate cancer proliferation by inhibiting PPP2R2C, and might a therapeutic target for prostate cancer.",
                    "offsetInBeginSection": 1137,
                    "offsetInEndSection": 1284,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27261573",
                    "text": "microRNAs play critical roles in the development and progression of prostate cancer.",
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 237,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26540342",
                    "text": "Previous studies have shown that hTERT can promote tumor invasion and metastasis of gastric cancer, liver cancer and esophageal cancer.",
                    "offsetInBeginSection": 271,
                    "offsetInEndSection": 406,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26540342",
                    "text": "Taken together, our findings suggest that hTERT can promote cancer metastasis by stimulating EMT through the ZEB1 pathway and therefore inhibiting them may prevent cancer progression.",
                    "offsetInBeginSection": 1065,
                    "offsetInEndSection": 1248,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27117702",
                    "text": "Here we find that METTL3 promotes translation of certain mRNAs including epidermal growth factor receptor (EGFR) and the Hippo pathway effector TAZ in human cancer cells.",
                    "offsetInBeginSection": 148,
                    "offsetInEndSection": 318,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28857253",
                    "text": "Taken together, we demonstrated a TP73-AS1/miR-200a/ZEB1 regulating loop in breast cancer cells, which promote cancer cell invasion and migration through regulating E-cadherin and Twist expression.",
                    "offsetInBeginSection": 801,
                    "offsetInEndSection": 998,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26261546",
                    "text": "Breast cancer is the most common cancer in women around the world.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8712af61bb38fb24000002",
            "body": "What is the link between psoriatic arthritis and depression",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27221798",
                "http://www.ncbi.nlm.nih.gov/pubmed/19151962",
                "http://www.ncbi.nlm.nih.gov/pubmed/27258525",
                "http://www.ncbi.nlm.nih.gov/pubmed/21794775",
                "http://www.ncbi.nlm.nih.gov/pubmed/28507445",
                "http://www.ncbi.nlm.nih.gov/pubmed/28320454",
                "http://www.ncbi.nlm.nih.gov/pubmed/24407907",
                "http://www.ncbi.nlm.nih.gov/pubmed/23908539",
                "http://www.ncbi.nlm.nih.gov/pubmed/22015150",
                "http://www.ncbi.nlm.nih.gov/pubmed/16546593"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27221798",
                    "text": "Many epidemiological studies have shown that psoriasis is associated with psoriatic arthritis as well as cardiovascular and metabolic diseases.",
                    "offsetInBeginSection": 83,
                    "offsetInEndSection": 226,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27258525",
                    "text": "Further stratified analyses revealed a more rapid and significant reduction in depression/insomnia in those undergoing continuous biologics therapy, younger than 45 years, without psoriatic arthritis and not taking concomitant methotrexate, when compared with their counterparts.The results suggest that biologics therapy may be associated with reduced rates of depression and insomnia, and a reduced rate of regular antidepressants use in psoriasis patients.",
                    "offsetInBeginSection": 1174,
                    "offsetInEndSection": 1633,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775",
                    "text": "CONCLUSION The prevalence of anxiety symptoms and the prevalence of depression symptoms are high among patients suffering psoriatic arthritis in the studied population.",
                    "offsetInBeginSection": 1439,
                    "offsetInEndSection": 1607,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28507445",
                    "text": "CONCLUSION Prevalence of fatigue was moderate to intense in <25% of patients with psoriatic arthritis.",
                    "offsetInBeginSection": 1722,
                    "offsetInEndSection": 1824,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28320454",
                    "text": "Peripheral arthritis is the most common symptom of psoriatic arthritis and patients also frequently experience involvement of the entheses, spine, skin, and nails.",
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 365,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28320454",
                    "text": "Risks also arise from comorbidities that are associated with psoriatic arthritis such as cardiovascular disease, obesity, diabetes mellitus, and gastrointestinal inflammation.",
                    "offsetInBeginSection": 876,
                    "offsetInEndSection": 1051,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28320454",
                    "text": "Psoriatic arthritis is a part of the family of diseases referred to as spondyloarthropathies, a diverse group of chronic inflammatory disorders with common clinical, radiographic, and genetic features.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24407907",
                    "text": "The use of pressure algometry in the evaluation of chronic pain in patients affected by rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis that display comorbid depression could represent an additional and integrative method to improve pain/depression overlap management or research.",
                    "offsetInBeginSection": 1367,
                    "offsetInEndSection": 1669,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23908539",
                    "text": "However, the other manifestations of psoriatic disease including metabolic syndrome, atherosclerotic cardiovascular disease, depression, poor self-esteem, and self-destructive habits including obesity, smoking and excess alcohol consumption are underappreciated.",
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 390,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16546593",
                    "text": "Physical manifestations include unsightly, scaly, pruritic plaques and inflamed joints for patients with psoriatic arthritis.",
                    "offsetInBeginSection": 165,
                    "offsetInEndSection": 290,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6900ebb750ff445500001d",
            "body": "Which disease is diagnosed using the Finkelstein's test?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15680568",
                "http://www.ncbi.nlm.nih.gov/pubmed/23340762",
                "http://www.ncbi.nlm.nih.gov/pubmed/26538761",
                "http://www.ncbi.nlm.nih.gov/pubmed/9763259",
                "http://www.ncbi.nlm.nih.gov/pubmed/19477618",
                "http://www.ncbi.nlm.nih.gov/pubmed/1402284",
                "http://www.ncbi.nlm.nih.gov/pubmed/15792200",
                "http://www.ncbi.nlm.nih.gov/pubmed/12723309",
                "http://www.ncbi.nlm.nih.gov/pubmed/12087803",
                "http://www.ncbi.nlm.nih.gov/pubmed/24139754"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568",
                    "text": "PURPOSE Finkelstein's test is the classic diagnostic test for de Quervain's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340762",
                    "text": "The purpose of the study was to compare the accuracy of the Eichhoff's test and wrist hyperflexion and abduction of the thumb test to diagnose correctly de Quervain's disease by comparing clinical findings using those tests with the results on ultrasound.",
                    "offsetInBeginSection": 633,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340762",
                    "text": "To compare the Eichhoff's test with a new test, the wrist hyperflexion and abduction of the thumb test, we set up a prospective study over a period of three years for a cohort of 100 patients (88 women, 12 men) presenting spontaneous pain over the radial side of the styloid of the radius (de Quervain tendinopathy).",
                    "offsetInBeginSection": 316,
                    "offsetInEndSection": 632,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26538761",
                    "text": "The clinical criteria used were Finkelstein's test, tenderness over radial styloid (Ritchie's tenderness scale), grip strength, pain (visual analog scale [VAS]) and radiological criteria was ultrasonographic assessment of change in thickness of APL and EPB tendon sheath.",
                    "offsetInBeginSection": 828,
                    "offsetInEndSection": 1099,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26538761",
                    "text": "MATERIALS AND METHODS Thirty patients clinically diagnosed de Quervains tenosynovitis were included in the study and randomly assigned to two groups.",
                    "offsetInBeginSection": 535,
                    "offsetInEndSection": 684,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19477618",
                    "text": "PURPOSE OF THE STUDY To demonstrate the application of MDT to a patient with a thumb problem, which was diagnosed as de Quervain's disease.",
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 406,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15792200",
                    "text": "Three different descriptions of Finkelstein's test were used as described in current literature.",
                    "offsetInBeginSection": 726,
                    "offsetInEndSection": 822,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15792200",
                    "text": "We also found that Finkelstein's test was inaccurately described in literature since Leao's incorrect description in 1958 (quoting Eichhoff's manoeuvre) and the mistake persisted for over 50 years before it could be accredited.",
                    "offsetInBeginSection": 1099,
                    "offsetInEndSection": 1326,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12087803",
                    "text": "CONCLUSIONS In the case of workers over 50 years of age whose jobs have the characteristics described here, Finkelstein's test should be performed on occasion of occupational health surveillance to screen for the arising of the disease.",
                    "offsetInBeginSection": 815,
                    "offsetInEndSection": 1051,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24139754",
                    "text": "The purpose of this study was to describe the technique and usefulness of ultrasound-guided intrasheath injection of triamcinolone in the treatment of de Quervain's disease (dQD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e1280b750ff4455000037",
            "body": "For which type of cancer can uc.189 be used as a potential prognostic biomarker?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28941722",
                "http://www.ncbi.nlm.nih.gov/pubmed/26847605",
                "http://www.ncbi.nlm.nih.gov/pubmed/26202601",
                "http://www.ncbi.nlm.nih.gov/pubmed/20661575",
                "http://www.ncbi.nlm.nih.gov/pubmed/24057814",
                "http://www.ncbi.nlm.nih.gov/pubmed/25649770",
                "http://www.ncbi.nlm.nih.gov/pubmed/26989022",
                "http://www.ncbi.nlm.nih.gov/pubmed/24165311",
                "http://www.ncbi.nlm.nih.gov/pubmed/19424625",
                "http://www.ncbi.nlm.nih.gov/pubmed/27528797"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722",
                    "text": "Uc.189 might be considered as a novel molecule involved in ESCC progression, which provides a potential prognostic biomarker and therapeutic target.",
                    "offsetInBeginSection": 1124,
                    "offsetInEndSection": 1272,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722",
                    "text": "High expression of uc.189 might reflect poor prognosis of ESCC and indicate a potential diagnostic target in ESCC patients.",
                    "offsetInBeginSection": 1000,
                    "offsetInEndSection": 1123,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26847605",
                    "text": "CONCLUSIONS MALAT1 could serve as a potential prognostic biomarker in various cancers and may be a potential therapeutic target for the treatment and early detection of recurrence.",
                    "offsetInBeginSection": 1450,
                    "offsetInEndSection": 1630,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26202601",
                    "text": "Here, we have used a network-based exploration approach to identify a multi-cancer gene expression biomarker highly connected by ESR1, PRKACA, LRP1, JUN and SMAD2 that can be predictive of clinical outcome in 12 types of cancer from The Cancer Genome Atlas (TCGA) repository.",
                    "offsetInBeginSection": 527,
                    "offsetInEndSection": 802,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26202601",
                    "text": "Comparisons with cancer-type specific and other multi-cancer biomarkers in TCGA and other datasets showed that the performance of the proposed multi-cancer biomarker is superior, making the proposed approach and multi-cancer biomarker potentially useful in research and clinical settings.",
                    "offsetInBeginSection": 1062,
                    "offsetInEndSection": 1350,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20661575",
                    "text": "We and others have identified EMMPRIN as a prognostic biomarker in a variety of tumor diseases.",
                    "offsetInBeginSection": 477,
                    "offsetInEndSection": 572,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26989022",
                    "text": "In conclusion, TMPRSS4 is a novel independent prognostic biomarker regulated by epigenetic changes in SCC and a potential therapeutic target in this tumor type, where targeted therapy is still underdeveloped.",
                    "offsetInBeginSection": 1255,
                    "offsetInEndSection": 1463,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26989022",
                    "text": "Here, we have used several cohorts of NSCLC patients to analyze the prognostic value of both protein expression and DNA promoter methylation status of the prometastatic serine protease TMPRSS4.",
                    "offsetInBeginSection": 482,
                    "offsetInEndSection": 675,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26989022",
                    "text": "Similarly, aberrant hypomethylation in tumors, which correlates with high TMPRSS4 expression, is an independent prognostic predictor in SCC.",
                    "offsetInBeginSection": 873,
                    "offsetInEndSection": 1013,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19424625",
                    "text": "We propose that PRL-3 expression can have a clinical potential as a prognostic biomarker that may facilitate the development of adjuvant chemotherapy for advanced gastric cancer with stage I disease.",
                    "offsetInBeginSection": 1475,
                    "offsetInEndSection": 1674,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a87140a61bb38fb24000003",
            "body": "What is Chronic Wasting Disease (CWD) in deer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12680636",
                "http://www.ncbi.nlm.nih.gov/pubmed/16439622",
                "http://www.ncbi.nlm.nih.gov/pubmed/17553219",
                "http://www.ncbi.nlm.nih.gov/pubmed/17020952",
                "http://www.ncbi.nlm.nih.gov/pubmed/18387626",
                "http://www.ncbi.nlm.nih.gov/pubmed/15542685",
                "http://www.ncbi.nlm.nih.gov/pubmed/27575545",
                "http://www.ncbi.nlm.nih.gov/pubmed/28193766",
                "http://www.ncbi.nlm.nih.gov/pubmed/27711208",
                "http://www.ncbi.nlm.nih.gov/pubmed/27870037"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16439622",
                    "text": "The emergence of chronic wasting disease (CWD) in deer and elk in an increasingly wide geographic area, as well as the interspecies transmission of bovine spongiform encephalopathy to humans in the form of variant Creutzfeldt Jakob disease, have raised concerns about the zoonotic potential of CWD.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 298,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16439622",
                    "text": "Here bioassays in transgenic mice expressing cervid prion protein revealed the presence of infectious prions in skeletal muscles of CWD-infected deer, demonstrating that humans consuming or handling meat from CWD-infected deer are at risk to prion exposure.",
                    "offsetInBeginSection": 463,
                    "offsetInEndSection": 720,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17553219",
                    "text": "Chronic wasting disease (CWD) of deer and elk is a widespread health concern because its potential for crossspecies transmission is undetermined.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17020952",
                    "text": "Chronic wasting disease (CWD), a prion disease of deer and elk, is highly prevalent in some regions of North America.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18387626",
                    "text": "Chronic wasting disease (CWD), a prion disease of North American deer, elk and moose, affects both free-ranging and captive cervids.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18387626",
                    "text": "In western blots, the PrP(CWD) glycoform profile resembled that of CWD in deer, typified by a dominant diglycosylated glycoform.",
                    "offsetInBeginSection": 924,
                    "offsetInEndSection": 1052,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15542685",
                    "text": "We generated mice expressing cervid prion protein to produce a transgenic system simulating chronic wasting disease (CWD) in deer and elk.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545",
                    "text": "Chronic wasting disease (CWD) is an invariably fatal transmissible spongiform encephalopathy of white-tailed deer, mule deer, elk, and moose.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28193766",
                    "text": "The etiology of chronic wasting disease (CWD), a relatively new and burgeoning prion epidemic in deer, elk, and moose (members of the cervid family), is more enigmatic.",
                    "offsetInBeginSection": 497,
                    "offsetInEndSection": 665,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27711208",
                    "text": "The recent discovery of chronic wasting disease (CWD) in captive deer facilities in Texas has increased concern about the potential emergence of CWD in free-ranging deer.",
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 290,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a69031bb750ff445500001e",
            "body": "Can doxycycline cause photosensitivity?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/9214073",
                "http://www.ncbi.nlm.nih.gov/pubmed/17160610",
                "http://www.ncbi.nlm.nih.gov/pubmed/10233667",
                "http://www.ncbi.nlm.nih.gov/pubmed/21879777",
                "http://www.ncbi.nlm.nih.gov/pubmed/23182067",
                "http://www.ncbi.nlm.nih.gov/pubmed/26299894",
                "http://www.ncbi.nlm.nih.gov/pubmed/15262663",
                "http://www.ncbi.nlm.nih.gov/pubmed/17315050",
                "http://www.ncbi.nlm.nih.gov/pubmed/3684731",
                "http://www.ncbi.nlm.nih.gov/pubmed/6356325"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17160610",
                    "text": "Treatment with doxycycline is cheap and relatively safe, but gastrointestinal symptoms and photosensitivity reactions can be expected more often than with ceftriaxone.",
                    "offsetInBeginSection": 1913,
                    "offsetInEndSection": 2080,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10233667",
                    "text": "Chronic actinic dermatitis (CAD) is an uncommon, eczematous photosensitive eruption affecting predominantly elderly men and to which drug-induced photosensitivity may sometimes appear clinically identical.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21879777",
                    "text": "Tetracycline, doxycycline, nalidixic acid, voriconazole, amiodarone, hydrochlorothiazide, naproxen, piroxicam, chlorpromazine and thioridazine are among the most commonly implicated medications.",
                    "offsetInBeginSection": 1107,
                    "offsetInEndSection": 1301,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23182067",
                    "text": "CONCLUSION Topical or oral corticosteroids followed by prophylactic doxycycline can be effective in rapidly resolving acute flareups and preventing recurrences of NSAGU.",
                    "offsetInBeginSection": 1580,
                    "offsetInEndSection": 1749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23182067",
                    "text": "Eight (47%) commenced doxycycline prophylaxis.",
                    "offsetInBeginSection": 966,
                    "offsetInEndSection": 1012,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15262663",
                    "text": "BACKGROUND It has been hypothesized that certain Mycoplasma species may cause Gulf War veterans' illnesses (GWVIs), chronic diseases characterized by pain, fatigue, and cognitive symptoms, and that affected patients may benefit from doxycycline treatment.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17315050",
                    "text": "Anti-inflammatory-dose doxycycline should not be used by individuals with known hypersensitivity to tetracyclines or increased photosensitivity, or by pregnant or nursing women (anti-inflammatory-dose doxycycline is a pregnancy category-D medication).",
                    "offsetInBeginSection": 1381,
                    "offsetInEndSection": 1632,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3684731",
                    "text": "Doxycycline is considered by authoritative sources to be generally comparable in side effects to other tetracyclines and penicillins, with the exception that it increases photosensitivity.",
                    "offsetInBeginSection": 433,
                    "offsetInEndSection": 621,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3684731",
                    "text": "As part of a study investigating new methods of detecting adverse drug reactions, adult outpatients receiving new prescriptions for 1 of 4 antibiotics (doxycycline, penicillin VK, ampicillin, or tetracycline) were assigned to 1 of 2 methods of monitoring adverse drug reactions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 278,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6356325",
                    "text": "Antimicrobial therapy of travellers' diarrhoea with doxycycline or a combination of trimethoprim and sulphamethoxazole is effective only while the drugs are being taken.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e21b4b750ff445500003a",
            "body": "Are paralog genes co-regulated?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18493055",
                "http://www.ncbi.nlm.nih.gov/pubmed/27634932",
                "http://www.ncbi.nlm.nih.gov/pubmed/20621981",
                "http://www.ncbi.nlm.nih.gov/pubmed/15983874",
                "http://www.ncbi.nlm.nih.gov/pubmed/20660482",
                "http://www.ncbi.nlm.nih.gov/pubmed/28010187",
                "http://www.ncbi.nlm.nih.gov/pubmed/28716037",
                "http://www.ncbi.nlm.nih.gov/pubmed/20667114",
                "http://www.ncbi.nlm.nih.gov/pubmed/29166914",
                "http://www.ncbi.nlm.nih.gov/pubmed/24682282"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18493055",
                    "text": "By analyzing paralogs of testis-biased genes, we identified \"co-regulated\" paralogous pairs in which both genes are testis biased, \"anti-regulated\" pairs in which one paralog is testis biased and the other downregulated in testes, and \"neutral\" pairs in which one paralog is testis biased and the other constitutively expressed.",
                    "offsetInBeginSection": 511,
                    "offsetInEndSection": 839,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932",
                    "text": "In eukaryotes, genes are regulated in part by distal enhancer elements through looping interactions with gene promoters.",
                    "offsetInBeginSection": 279,
                    "offsetInEndSection": 399,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932",
                    "text": "Paralog genes arise from gene duplication events during evolution, which often lead to similar proteins that cooperate in common pathways and in protein complexes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20660482",
                    "text": "CPEB2, CPEB3 and CPEB4 are paralog proteins very similar among themselves referred as the CPEB2 subfamily.",
                    "offsetInBeginSection": 133,
                    "offsetInEndSection": 239,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28010187",
                    "text": "Other examined G. max homologs of membrane fusion genes include an endosomal bromo domain-containing protein1 (Bro1), syntaxin6 (SYP6), SYP131, SYP71, SYP8, Bet1, coatomer epsilon (\u03f5-COP), a coatomer zeta (\u03b6-COP) paralog and an ER to Golgi component (ERGIC) protein.",
                    "offsetInBeginSection": 1171,
                    "offsetInEndSection": 1439,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28010187",
                    "text": "PEN1 has homology to a Saccharomyces cerevisae gene that regulates a Secretion (Sec) protein, Suppressor of Sec 1 (Sso1p).",
                    "offsetInBeginSection": 363,
                    "offsetInEndSection": 485,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28010187",
                    "text": "Experiments made using the model agricultural Glycine max (soybean) have identified co-regulated gene expression of regulon components.",
                    "offsetInBeginSection": 753,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28010187",
                    "text": "The regulon is composed partially by the soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor (SNARE) syntaxin PEN1.",
                    "offsetInBeginSection": 221,
                    "offsetInEndSection": 362,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716037",
                    "text": "RESULTS Five paralog genes of dnmt3, namely dnmt3aa, dnmt3ab, dnmt3ba, dnmt3bb.1 and dnmt3bb.2 and one gene for dnmt1 were identified.",
                    "offsetInBeginSection": 533,
                    "offsetInEndSection": 667,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166914",
                    "text": "Such clusters could contain one or several operons, which are groups of co-transcribed genes.",
                    "offsetInBeginSection": 145,
                    "offsetInEndSection": 238,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a87145861bb38fb24000004",
            "body": "What causes Black Lung?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2933965",
                "http://www.ncbi.nlm.nih.gov/pubmed/17300721",
                "http://www.ncbi.nlm.nih.gov/pubmed/28450031",
                "http://www.ncbi.nlm.nih.gov/pubmed/26437452",
                "http://www.ncbi.nlm.nih.gov/pubmed/2806196",
                "http://www.ncbi.nlm.nih.gov/pubmed/23591042",
                "http://www.ncbi.nlm.nih.gov/pubmed/16304297",
                "http://www.ncbi.nlm.nih.gov/pubmed/29095661",
                "http://www.ncbi.nlm.nih.gov/pubmed/17516558",
                "http://www.ncbi.nlm.nih.gov/pubmed/16497850"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721",
                    "text": "CONCLUSION Cigarette smoke exposure to a guinea pig model causes oxidative damage, inflammation, apoptosis and lung injury that are prevented by supplementation of black tea.",
                    "offsetInBeginSection": 1426,
                    "offsetInEndSection": 1600,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721",
                    "text": "Since black tea has antioxidant property, we examined the preventive effect of black tea on cigarette smoke-induced oxidative damage, apoptosis and lung injury in a guinea pig model.",
                    "offsetInBeginSection": 191,
                    "offsetInEndSection": 373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28450031",
                    "text": "METHODS We collected survival time data for 105,121 Hispanic, non-Hispanic Asian, non-Hispanic black, and non-Hispanic white patients with early-stage (IA, IB, IIA, and IIB) lung cancer diagnosed between 2004 and 2013 from the Surveillance, Epidemiology, and End-Results registries.",
                    "offsetInBeginSection": 411,
                    "offsetInEndSection": 693,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28450031",
                    "text": "BACKGROUND Black patients with lung cancer diagnosed at early stages-for which surgical resection offers a potential cure-experience worse overall survival than do their white counterparts.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28450031",
                    "text": "Worse survival from competing causes of death, such as cardiovascular disease and other cancers-rather than from lung cancer itself-led to the disparity in overall survival among non-Hispanic blacks (adjusted relative risk, 1.07; 95%\u00a0CI, 1.02-1.12).",
                    "offsetInBeginSection": 1290,
                    "offsetInEndSection": 1540,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26437452",
                    "text": "In this study, we show that insoluble nanoparticulate carbon black (nCB) accumulates in human myeloid dendritic cells (mDCs) from emphysematous lung and in CD11c(+) lung antigen presenting cells (APC) of mice exposed to smoke.",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 500,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2806196",
                    "text": "The results of these studies support a preeminent role for elastase in neutrophil-induced lung lesions.",
                    "offsetInBeginSection": 1483,
                    "offsetInEndSection": 1586,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16304297",
                    "text": "CONCLUSIONS Our analysis suggests that the lower surgical rate among black patients with early stage lung cancer is mainly due to low rates of acceptance of surgical treatment.",
                    "offsetInBeginSection": 1448,
                    "offsetInEndSection": 1624,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29095661",
                    "text": "However, the study results are consistent with the mechanism that, at high enough concentrations, carbon black causes inflammation and oxidative stress in the lung leading to mutations, which is a secondary genotoxic mechanism.",
                    "offsetInBeginSection": 664,
                    "offsetInEndSection": 891,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17516558",
                    "text": "CONCLUSIONS The findings suggest that carbon black, or chemicals associated with the production of carbon black, had an effect on later stages of lung cancer carcinogenesis at two of the plants but that no such effect was found at the other plants.",
                    "offsetInBeginSection": 1330,
                    "offsetInEndSection": 1578,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f7e6ab750ff4455000052",
            "body": "List four principles of medical ethics.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11794075",
                "http://www.ncbi.nlm.nih.gov/pubmed/7463428",
                "http://www.ncbi.nlm.nih.gov/pubmed/26793677",
                "http://www.ncbi.nlm.nih.gov/pubmed/23975951",
                "http://www.ncbi.nlm.nih.gov/pubmed/21625670",
                "http://www.ncbi.nlm.nih.gov/pubmed/14519842",
                "http://www.ncbi.nlm.nih.gov/pubmed/15183570",
                "http://www.ncbi.nlm.nih.gov/pubmed/28953737",
                "http://www.ncbi.nlm.nih.gov/pubmed/10402417",
                "http://www.ncbi.nlm.nih.gov/pubmed/25587553"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11794075",
                    "text": "Only 6% of both graduates and students were able to list the four principles of medical ethics as described by Raanan.",
                    "offsetInBeginSection": 810,
                    "offsetInEndSection": 928,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7463428",
                    "text": "Through a critique of six positions regarding the aims of medical ethics, four principles are established which are the basis of a philosophy of education for medical ethics.",
                    "offsetInBeginSection": 264,
                    "offsetInEndSection": 438,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7463428",
                    "text": "The paper concludes with practical examples of a clinically-based medical ethics programme following from the four principles.",
                    "offsetInBeginSection": 594,
                    "offsetInEndSection": 720,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26793677",
                    "text": "There are four principles of medical ethics; Beneficence, Respect for autonomy, Non-maleficence, and Justice.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26793677",
                    "text": "It is not easy to apply to principles of medical ethics in the special circumstances of obstetrics and gynecology.",
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 224,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14519842",
                    "text": "It is hypothesised and argued that \"the four principles of medical ethics\" can explain and justify, alone or in combination, all the substantive and universalisable claims of medical ethics and probably of ethics more generally.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 228,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15183570",
                    "text": "The unique role of the chief ethics officer in a sports medicine office is described and guided by the four principles of ethics, as well as the principles and codes of ethics of the American Medical Association, the International Sports Medicine Federation, and the American Academy of Orthopaedic Surgeons.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 308,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28953737",
                    "text": "An ethical analysis was conducted using the four principles of medical ethics.",
                    "offsetInBeginSection": 710,
                    "offsetInEndSection": 788,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28953737",
                    "text": "Using the four principles of medical ethics, it was determined that significant ethical concerns exist with broadcasting these videos.",
                    "offsetInBeginSection": 1113,
                    "offsetInEndSection": 1247,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10402417",
                    "text": "This approach to treatment is discussed in the context of the four principles of medical ethics, namely respect for autonomy, justice, beneficence and non-maleficence.",
                    "offsetInBeginSection": 185,
                    "offsetInEndSection": 352,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e22b9b750ff445500003b",
            "body": "What is CellMaps?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27296979",
                "http://www.ncbi.nlm.nih.gov/pubmed/27775692",
                "http://www.ncbi.nlm.nih.gov/pubmed/20008397",
                "http://www.ncbi.nlm.nih.gov/pubmed/28682833",
                "http://www.ncbi.nlm.nih.gov/pubmed/22548703",
                "http://www.ncbi.nlm.nih.gov/pubmed/18544796"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979",
                    "text": "AVAILABILITY AND IMPLEMENTATION The application is available at: http://cellmaps.babelomics.org/ and the code can be found in: https://github.com/opencb/cell-maps The client is implemented in JavaScript and the server in C and Java.",
                    "offsetInBeginSection": 406,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979",
                    "text": "UNLABELLED : CellMaps is an HTML5 open-source web tool that allows displaying, editing, exploring and analyzing biological networks as well as integrating metadata into them.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27775692",
                    "text": "Pancreatic ductal adenocarcinoma (PDAC) develops in a highly complex and heterogeneous tissue environment and, generally, has a very poor prognosis.",
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 294,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27775692",
                    "text": "We sought to develop a tIA approach to assess the most common PDAC precursor lesions, pancreatic intraepithelial neoplasia (PanIN), in tissues from KrasLSL-G12D/+; Trp53LSL-R172H/+; Pdx-Cre (KPC) mice, a validated model of PDAC development.",
                    "offsetInBeginSection": 459,
                    "offsetInEndSection": 699,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27775692",
                    "text": "tIA profiling of training regions of PanIN and tumor microenvironment (TME) cells was utilized to guide identification of PanIN/TME tissue compartment stratification criteria.",
                    "offsetInBeginSection": 700,
                    "offsetInEndSection": 875,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27775692",
                    "text": "Together, our data demonstrated the utility of CellMap to enable objective and quantitative assessments, across entire tissue sections, of PDAC precursor lesions in preclinical and clinical models of this disease to support efforts leading to novel insights into disease progression, diagnostic markers, and potential therapeutic targets.",
                    "offsetInBeginSection": 1439,
                    "offsetInEndSection": 1777,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20008397",
                    "text": "In addition, one cannot easily escape into high-level holistic approaches, since the essence of all biological systems is that they are encoded as molecular descriptions in their genes and since genes are molecules and exert their functions through other molecules, the molecular explanation must constitute the core of understanding biological systems.",
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 696,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28682833",
                    "text": "To address this systematically, an ISH for peptidylprolyl isomerase B (PPIB) (cyclophilin B) mRNA was optimized and applied to a tissue microarray of archival non-small cell lung carcinoma cases, and then automated image analysis for PPIB was refined across 4 commercially available software platforms.",
                    "offsetInBeginSection": 239,
                    "offsetInEndSection": 541,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22548703",
                    "text": "Using a set of growth factor signalling networks as examples (epidermal growth factor, transforming growth factor-beta, tumor necrosis factor, and wingless), we find a multiplicity of network topologies in which receptors couple to downstream components through myriad alternate paths.",
                    "offsetInBeginSection": 1720,
                    "offsetInEndSection": 2005,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22548703",
                    "text": "This ensemble network has many features expected of complex signalling networks assembled from high-throughput data: a power law distribution of both node degree and edge annotations, and topological features of a \"bow tie\" architecture in which diverse pathways converge on a highly conserved set of enzymatic cascades focused around PI3K/AKT, MAPK/ERK, JAK/STAT, NF\u03baB, and apoptotic signaling.",
                    "offsetInBeginSection": 1022,
                    "offsetInEndSection": 1418,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8714e261bb38fb24000005",
            "body": "Is polyadenylation a process that stabilizes a protein by adding a string of Adenosine residues to the end of the molecule?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3037325",
                "http://www.ncbi.nlm.nih.gov/pubmed/2408761",
                "http://www.ncbi.nlm.nih.gov/pubmed/9933592",
                "http://www.ncbi.nlm.nih.gov/pubmed/16467265",
                "http://www.ncbi.nlm.nih.gov/pubmed/12270133",
                "http://www.ncbi.nlm.nih.gov/pubmed/2160581",
                "http://www.ncbi.nlm.nih.gov/pubmed/3019671",
                "http://www.ncbi.nlm.nih.gov/pubmed/15547135",
                "http://www.ncbi.nlm.nih.gov/pubmed/11557765",
                "http://www.ncbi.nlm.nih.gov/pubmed/9242905"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9933592",
                    "text": "The data show that the degradosome requires a single-stranded \"toehold\" 3' to a secondary structure to recognize and degrade the RNA molecule efficiently; polyadenylation can provide this single-stranded 3'-end.",
                    "offsetInBeginSection": 940,
                    "offsetInEndSection": 1151,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467265",
                    "text": "Polyadenylation is a process of endonucleolytic cleavage of the mRNA, followed by addition of up to 250 adenosine residues to the 3' end of the mRNA.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467265",
                    "text": "Polyadenylation is essential for eukaryotic mRNA expression, and CstF-64 is a subunit of the CstF polyadenylation factor that is required for accurate polyadenylation.",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 317,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12270133",
                    "text": "It is demonstrated that XCCA adds cytosine and adenosine residues to the ends of prepared tRNA and is therefore a functional CCA-adding enzyme.",
                    "offsetInBeginSection": 275,
                    "offsetInEndSection": 418,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2160581",
                    "text": "These included CYC1 (iso-1-cytochrome c), HIS4 (histidine biosynthesis), GAL7 (galactose-1-phosphate uridyltransferase), H2B2 (histone H2B2), PRT2 (a protein of unknown function), and CBP1 (cytochrome b mRNA processing).",
                    "offsetInBeginSection": 265,
                    "offsetInEndSection": 485,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3019671",
                    "text": "Processing at the L3 polyadenylation site of human adenovirus-2 involves endonucleolytic cleavage generating the 3' terminal sequence -UAOH to which adenosine residues are added.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15547135",
                    "text": "Nuclear accumulation was relieved by insertion of a stretch of DNA-encoded adenosine residues immediately upstream of the ribozyme element (a synthetic A tail).",
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 482,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15547135",
                    "text": "To investigate the role of 3' end formation in yeast mRNA export, we replaced the mRNA cleavage and polyadenylation signal with a self-cleaving hammerhead ribozyme element.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11557765",
                    "text": "We show that a 3'- to 5'-exoribonuclease activity is responsible for the preferential degradation of polyadenylated mRNAs as compared with non-polyadenylated mRNAs, and that 20-30 adenosine residues constitute the optimal poly(A) tail size for inducing degradation of RNA substrates in vitro.",
                    "offsetInBeginSection": 478,
                    "offsetInEndSection": 770,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9242905",
                    "text": "The diversity of polyadenylation sites suggests that mRNA polyadenylation in prokaryotes is a relatively indiscriminate process that can occur at all mRNA's 3'-ends and does not require specific consensus sequences as in eukaryotes.",
                    "offsetInBeginSection": 516,
                    "offsetInEndSection": 748,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f829eb750ff4455000054",
            "body": "Can multiple myeloma patients develop hyperviscosity syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7699907",
                "http://www.ncbi.nlm.nih.gov/pubmed/22827791",
                "http://www.ncbi.nlm.nih.gov/pubmed/2385441",
                "http://www.ncbi.nlm.nih.gov/pubmed/9046114",
                "http://www.ncbi.nlm.nih.gov/pubmed/694674",
                "http://www.ncbi.nlm.nih.gov/pubmed/17315105",
                "http://www.ncbi.nlm.nih.gov/pubmed/6155195",
                "http://www.ncbi.nlm.nih.gov/pubmed/10861819",
                "http://www.ncbi.nlm.nih.gov/pubmed/27079282",
                "http://www.ncbi.nlm.nih.gov/pubmed/1201229"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907",
                    "text": "Plasmapheresis is known as an efficient method for rapid improvement of the hyperviscosity syndrome, and double filtration plasmapheresis is most commonly used for plasma exchange of multiple myeloma patients in our country.",
                    "offsetInBeginSection": 520,
                    "offsetInEndSection": 744,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907",
                    "text": "Five to 10 percent of patients with multiple myeloma are suffered from the hyperviscosity syndrome because of increased serum viscosity due to the presence of myeloma protein.",
                    "offsetInBeginSection": 246,
                    "offsetInEndSection": 421,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22827791",
                    "text": "Hyperglobulinemia of multiple myeloma (MM) plays a role in hyperviscosity syndrome (HVS).",
                    "offsetInBeginSection": 205,
                    "offsetInEndSection": 294,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441",
                    "text": "The present report describes a patient with IgA myeloma complicated by hyperviscosity syndrome and multiple bone fractures.",
                    "offsetInBeginSection": 1290,
                    "offsetInEndSection": 1413,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441",
                    "text": "And this syndrome has been associated frequently with macroglobulinemia of Waldenstr\u00f6m, occasionally with immunoglobulin (Ig) G myeloma, rarely with IgA myeloma, and with other dysproteinemia.",
                    "offsetInBeginSection": 864,
                    "offsetInEndSection": 1057,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9046114",
                    "text": "PE is the most effective method in the treatment of hyperviscosity syndrome often seen with multiple myeloma and Waldenstr\u00f6m's macroglobulinemia, and it is therapy of choice for this complication.",
                    "offsetInBeginSection": 961,
                    "offsetInEndSection": 1158,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6155195",
                    "text": "Patients with multiple myeloma who have complications secondary to hyperviscosity are treated by chemotherapy and/or plasmapheresis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27079282",
                    "text": "It can cause a hyperviscosity syndrome secondary to the paraproteinaemia associated with the disease.",
                    "offsetInBeginSection": 112,
                    "offsetInEndSection": 213,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1201229",
                    "text": "Two cases of multiple myeloma with IgA gammopathy and the syndrome of serum hyperviscosity are reported.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1201229",
                    "text": "The hyperviscosity syndrome is being diagnosed with increasing frequency in association with IgA multiple myeloma, and should be investigated in all cases with monoclonal proteins exceeding a concentration of 3-0 g/dl.",
                    "offsetInBeginSection": 754,
                    "offsetInEndSection": 972,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e2578b750ff445500003d",
            "body": "Which package in Bioconductor has been developed with the aim to analyze differential DNA loops from sequencing data?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29028898",
                "http://www.ncbi.nlm.nih.gov/pubmed/22847932",
                "http://www.ncbi.nlm.nih.gov/pubmed/27347386",
                "http://www.ncbi.nlm.nih.gov/pubmed/24979058",
                "http://www.ncbi.nlm.nih.gov/pubmed/27008016",
                "http://www.ncbi.nlm.nih.gov/pubmed/26834993",
                "http://www.ncbi.nlm.nih.gov/pubmed/26184873",
                "http://www.ncbi.nlm.nih.gov/pubmed/24227674",
                "http://www.ncbi.nlm.nih.gov/pubmed/26578583",
                "http://www.ncbi.nlm.nih.gov/pubmed/26819470"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028898",
                    "text": "To systematically assess changes in DNA looping architecture between samples, we introduce diffloop, an R/Bioconductor package that provides a suite of functions for the quality control, statistical testing, annotation, and visualization of DNA loops.",
                    "offsetInBeginSection": 288,
                    "offsetInEndSection": 539,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932",
                    "text": "MOTIVATION RNA sequencing is becoming a standard for expression profiling experiments and many tools have been developed in the past few years to analyze RNA-Seq data.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932",
                    "text": "RESULTS We developed 'easyRNASeq', an R package that simplifies the processing of RNA sequencing data, hiding the complex interplay of the required packages behind a single functionality.",
                    "offsetInBeginSection": 558,
                    "offsetInEndSection": 745,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932",
                    "text": "AVAILABILITY The package is implemented in R (as of version 2.15) and is available from Bioconductor (as of version 2.10) at the URL: http://bioconductor.org/packages/release/bioc/html/easyRNASeq.html, where installation and usage instructions can be found.",
                    "offsetInBeginSection": 748,
                    "offsetInEndSection": 1005,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27347386",
                    "text": "In the context of the ever-growing need for tools analyzing\u00a0Ribo-seq reads, we have developed 'RiboProfiling', a new Bioconductor open-source\u00a0package.",
                    "offsetInBeginSection": 403,
                    "offsetInEndSection": 555,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24979058",
                    "text": "We have previously developed an R/Bioconductor package 'exomePeak' for detecting RNA methylation sites under a specific experimental condition or the identifying the differential RNA methylation sites in a case control study from MeRIP-Seq data.",
                    "offsetInBeginSection": 488,
                    "offsetInEndSection": 733,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24979058",
                    "text": "We therein provide here a detailed and easy-to-use protocol of using exomePeak R/Bioconductor package along with other software programs for analysis of MeRIP-Seq data, which covers raw reads alignment, RNA methylation site detection, motif discovery, differential RNA methylation analysis, and functional analysis.",
                    "offsetInBeginSection": 983,
                    "offsetInEndSection": 1298,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27008016",
                    "text": "The protocol provides a detailed description for the comparative analysis of DNA-IP sequencing data including basic data processing, quality controls, and identification of differential enrichment using the Bioconductor package \"MEDIPS\".",
                    "offsetInBeginSection": 638,
                    "offsetInEndSection": 875,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27008016",
                    "text": "We present a protocol for genome-wide comparative analysis of DNA-IP sequencing data to identify statistically significant differential sequencing coverage between two conditions by considering variation across replicates.",
                    "offsetInBeginSection": 415,
                    "offsetInEndSection": 637,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24227674",
                    "text": "RESULTS Here, we present a major update of the R/Bioconductor package MEDIPS, which allows for an arbitrary number of replicates per group and integrates sophisticated statistical methods for the detection of differential coverage between experimental conditions.",
                    "offsetInBeginSection": 625,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8715a961bb38fb24000006",
            "body": "Silent Allosteric Modulation of mGluR5 is a form of treatment for what disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28683325",
                "http://www.ncbi.nlm.nih.gov/pubmed/25148681",
                "http://www.ncbi.nlm.nih.gov/pubmed/25323624",
                "http://www.ncbi.nlm.nih.gov/pubmed/27496211",
                "http://www.ncbi.nlm.nih.gov/pubmed/24793143",
                "http://www.ncbi.nlm.nih.gov/pubmed/15608073",
                "http://www.ncbi.nlm.nih.gov/pubmed/27881780",
                "http://www.ncbi.nlm.nih.gov/pubmed/21067920",
                "http://www.ncbi.nlm.nih.gov/pubmed/19100966",
                "http://www.ncbi.nlm.nih.gov/pubmed/26063678"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325",
                    "text": "Our data show that mGluR5's role in A\u03b2o-dependent AD phenotypes is separate from its role in glutamate signaling and silent allosteric modulation of mGluR5 has promise as a disease-modifying AD intervention with a broad therapeutic window.",
                    "offsetInBeginSection": 821,
                    "offsetInEndSection": 1061,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325",
                    "text": "We used a potent mGluR5 silent allosteric modulator (SAM, BMS-984923) to separate its well-known physiological role in glutamate signaling from a pathological role in mediating amyloid-\u03b2 oligomer (A\u03b2o) action.",
                    "offsetInBeginSection": 184,
                    "offsetInEndSection": 395,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25323624",
                    "text": "The central activity of mGluR5 negative allosteric modulators (2-methyl-6-(phenylethynyl)pyridine (MPEP) and [(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) and positive allosteric modulators (S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone (ADX47273) and (7S)-3-tert-butyl-7-[3-(4-fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine (LSN2814617) was examined on sleep-wake architecture.",
                    "offsetInBeginSection": 803,
                    "offsetInEndSection": 1273,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27496211",
                    "text": "Herein we describe the structure activity relationships uncovered in the pursuit of an mGluR5 positive allosteric modulator (PAM) for the treatment of schizophrenia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 165,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24793143",
                    "text": "Metabotropic glutamate receptors (mGluRs) are high-profile G-protein coupled receptors drug targets because of their involvement in several neurological disease states, and mGluR5 in particular is a subtype whose controlled allosteric modulation, both positive and negative, can potentially be useful for the treatment of schizophrenia and relief of chronic pain, respectively.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 377,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15608073",
                    "text": "We found that 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) is a potent and selective positive allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067920",
                    "text": "Positive allosteric modulation of metabotropic glutamate receptor 5 (mGluR5) is regarded as a potential novel treatment for schizophrenic patients.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067920",
                    "text": "Herein we report the synthesis and SAR of 4-aryl piperazine and piperidine amides as potent mGluR5 positive allosteric modulators (PAMs).",
                    "offsetInBeginSection": 148,
                    "offsetInEndSection": 285,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19100966",
                    "text": "Following the establishment of a cocaine CPP, rats were treated with the mGluR5 positive allosteric modulator 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB; 0.3, 3 and 30 mg/kg) before extinction test sessions.",
                    "offsetInBeginSection": 559,
                    "offsetInEndSection": 780,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19100966",
                    "text": "CONCLUSIONS Positive allosteric modulation of mGluR5 function facilitates the extinction of a cocaine-associated contextual memory, which may represent a novel approach toward enhancing extinction learning in the context of drug addiction.",
                    "offsetInBeginSection": 1245,
                    "offsetInEndSection": 1484,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f853ab750ff4455000055",
            "body": "Which disease can be diagnosed with the \"probe to bone\" test?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7853630",
                "http://www.ncbi.nlm.nih.gov/pubmed/27369321",
                "http://www.ncbi.nlm.nih.gov/pubmed/1922909",
                "http://www.ncbi.nlm.nih.gov/pubmed/24356116",
                "http://www.ncbi.nlm.nih.gov/pubmed/7770390",
                "http://www.ncbi.nlm.nih.gov/pubmed/19485522",
                "http://www.ncbi.nlm.nih.gov/pubmed/21219428",
                "http://www.ncbi.nlm.nih.gov/pubmed/17259493",
                "http://www.ncbi.nlm.nih.gov/pubmed/19141236",
                "http://www.ncbi.nlm.nih.gov/pubmed/8138315"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630",
                    "text": "DESIGN We prospectively assessed infected pedal ulcers for detectable bone by probing with a sterile, blunt, stainless steel probe.",
                    "offsetInBeginSection": 72,
                    "offsetInEndSection": 203,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27369321",
                    "text": "The probe-to-bone (PTB) test is a commonly used clinical test for osteomyelitis (OM), but its utility has been questioned in clinical settings where the prevalence of OM is low.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1922909",
                    "text": "Bone biopsy in an invasive method of diagnosing aluminium related bone disease (ABD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24356116",
                    "text": "However, scintigraphy is a nuclear scanning test to trace bone healing during stress fracture and osteomyelitis and thus can be used to probe the osseointegration process in vivo in the context of the dental implant.",
                    "offsetInBeginSection": 82,
                    "offsetInEndSection": 298,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7770390",
                    "text": "CONCLUSIONS The minisatellite probes MS31 and MS43 were found to be sensitive, effective tests for bone marrow transplants which can be used in routine follow-up.",
                    "offsetInBeginSection": 835,
                    "offsetInEndSection": 997,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7770390",
                    "text": "This study was undertaken to evaluate the usefulness of the minisatellite probes MS31 and MS43 used as a routine follow-up test after bone marrow transplantation.",
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 386,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21219428",
                    "text": "CONCLUSIONS Clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain X-ray, or especially both, are positive.",
                    "offsetInBeginSection": 1470,
                    "offsetInEndSection": 1750,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21219428",
                    "text": "AIMS To investigate the accuracy of the sequential combination of the probe-to-bone test and plain X-rays for diagnosing osteomyelitis in the foot of patients with diabetes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 173,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21219428",
                    "text": "All patients with positive results on either the probe-to-bone test or plain X-ray underwent an appropriate surgical procedure, which included obtaining a bone specimen that was processed for histology and culture.",
                    "offsetInBeginSection": 537,
                    "offsetInEndSection": 751,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17259493",
                    "text": "OBJECTIVE We sought to assess the accuracy of the probe-to-bone (PTB) test in diagnosing foot osteomyelitis in a cohort of diabetic patients with bone culture proven disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e33e4b750ff4455000041",
            "body": "Describe annotatr",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28369316",
                "http://www.ncbi.nlm.nih.gov/pubmed/2209143",
                "http://www.ncbi.nlm.nih.gov/pubmed/17230075",
                "http://www.ncbi.nlm.nih.gov/pubmed/26579876",
                "http://www.ncbi.nlm.nih.gov/pubmed/18349498",
                "http://www.ncbi.nlm.nih.gov/pubmed/11441785",
                "http://www.ncbi.nlm.nih.gov/pubmed/18428249",
                "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                "http://www.ncbi.nlm.nih.gov/pubmed/23728744",
                "http://www.ncbi.nlm.nih.gov/pubmed/19855297"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17230075",
                    "text": "Describe common techniques for flap monitoring.",
                    "offsetInBeginSection": 421,
                    "offsetInEndSection": 468,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18349498",
                    "text": "We propose describing a manipulative technique using 6 characteristics: Rate of force application: Describe the rate at which the force was applied.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18349498",
                    "text": "Relative structural movement: Describe which structure or region was intended to remain stable and which structure or region was intended to move, with the moving structure or region being named first and the stable segment named second, separated by the word \"on.\"",
                    "offsetInBeginSection": 581,
                    "offsetInEndSection": 846,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11441785",
                    "text": "Using a similar term to describe different forms of pathology leads to a muddle.",
                    "offsetInBeginSection": 135,
                    "offsetInEndSection": 215,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11441785",
                    "text": "In this paper, we describe \"Clerambault's syndrome\" and \"Kandinsky-Clerambault's syndrome\" and discuss and clarify the confusion surrounding these different syndromes.",
                    "offsetInBeginSection": 216,
                    "offsetInEndSection": 383,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18428249",
                    "text": "Several support protocols describe methods for adenovirus growth and purification, biotinylation, inactivation with psoralen, and quantitation of the adenovirus particles.",
                    "offsetInBeginSection": 279,
                    "offsetInEndSection": 450,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We describe first a field deployable mass spectrometer, based on an ion trap analyzer, and variants of that system.",
                    "offsetInBeginSection": 375,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We describe four sensing and characterization technologies recently developed at Los Alamos National Laboratory; a select set of mass spectral and optical techniques is emphasized.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We then describe a hand-held, battery-operated optical spectrometer, usable in either absorption, or fluorescence excitation mode.",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 621,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728744",
                    "text": "The Basic Protocol describes the procedure for flagellar isolation using dibucaine to induce flagellar abscission; we also describe the pH shock method as an Alternate Protocol when flagellar regeneration is desirable.",
                    "offsetInBeginSection": 206,
                    "offsetInEndSection": 424,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8718c861bb38fb24000008",
            "body": "What are check point inhibitors?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27528363",
                "http://www.ncbi.nlm.nih.gov/pubmed/28878676",
                "http://www.ncbi.nlm.nih.gov/pubmed/26775673",
                "http://www.ncbi.nlm.nih.gov/pubmed/28865357",
                "http://www.ncbi.nlm.nih.gov/pubmed/27403706",
                "http://www.ncbi.nlm.nih.gov/pubmed/25956379",
                "http://www.ncbi.nlm.nih.gov/pubmed/27654928",
                "http://www.ncbi.nlm.nih.gov/pubmed/26942589",
                "http://www.ncbi.nlm.nih.gov/pubmed/27750243",
                "http://www.ncbi.nlm.nih.gov/pubmed/27167347"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363",
                    "text": "OBJECTIVE To clarify the role of immune check point inhibitors in GBM management.",
                    "offsetInBeginSection": 490,
                    "offsetInEndSection": 571,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363",
                    "text": "CONCLUSION Immune check-point inhibitors should be considered a promising treatment option in GBM.",
                    "offsetInBeginSection": 980,
                    "offsetInEndSection": 1078,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28878676",
                    "text": "Check point antibody inhibitors, such as anti-PD-1/PD-L1, are a novel class of inhibitors that function as a tumor suppressing factor via modulation of immune cell-tumor cell interaction.",
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 423,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28878676",
                    "text": "In recent times, more than four check point antibody inhibitors have been commercialized for targeting PD-1, PDL-1, and CTLA-4.",
                    "offsetInBeginSection": 588,
                    "offsetInEndSection": 715,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27403706",
                    "text": "check point inhibitors.",
                    "offsetInBeginSection": 296,
                    "offsetInEndSection": 319,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27403706",
                    "text": "Patients with BRAFv600 mutations can be treated with a combination of a BRAF-inhibitor and an MEK-inhibitor.",
                    "offsetInBeginSection": 84,
                    "offsetInEndSection": 192,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27403706",
                    "text": "AREAS COVERED We conducted a comprehensive review of the literature on the efficacy and predictive markers, safety, and pharmacoeconomics of ipilimumab in melanoma Expert commentary: Ipilimumab was the first check point inhibitor reaching the clinic, gaining FDA and EMA approval for metastatic melanoma in 2011.",
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 634,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25956379",
                    "text": "Check point kinase 1 (Chk1) is an important protein in G2 phase checkpoint arrest required by cancer cells to maintain cell cycle and to prevent cell death.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27654928",
                    "text": "These agents include monoclonal antibodies, deacetylase inhibitors, kinase inhibitors, agents affecting various signaling pathways, immune check point inhibitors, and other targeted therapies.",
                    "offsetInBeginSection": 359,
                    "offsetInEndSection": 551,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26942589",
                    "text": "Ongoing clinical trials are evaluating the role of check point inhibitors in combination with chemotherapy.",
                    "offsetInBeginSection": 1487,
                    "offsetInEndSection": 1594,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f87c5b750ff4455000056",
            "body": "Are patients with Sjogren syndrome at increased risk for lymphoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17562045",
                "http://www.ncbi.nlm.nih.gov/pubmed/2110929",
                "http://www.ncbi.nlm.nih.gov/pubmed/27336863",
                "http://www.ncbi.nlm.nih.gov/pubmed/20084442",
                "http://www.ncbi.nlm.nih.gov/pubmed/25368273",
                "http://www.ncbi.nlm.nih.gov/pubmed/24159176",
                "http://www.ncbi.nlm.nih.gov/pubmed/16462517",
                "http://www.ncbi.nlm.nih.gov/pubmed/19903539",
                "http://www.ncbi.nlm.nih.gov/pubmed/22208651",
                "http://www.ncbi.nlm.nih.gov/pubmed/24153350"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2110929",
                    "text": "Clinical features such as age, duration of disease, extent of lymphadenopathy, splenomegaly, or parotid swelling failed to identify those subsets of patients with lymphadenopathy at increased risk for lymphoma.",
                    "offsetInBeginSection": 1026,
                    "offsetInEndSection": 1236,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27336863",
                    "text": "The heightened risk of non-Hodgkin lymphoma (NHL) development in primary Sjogren syndrome (SS) is well established.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20084442",
                    "text": "These findings suggest that patients with pSS who have ACA may be a subgroup of patients at increased risk of extraglandular systemic manifestations and lymphoma.",
                    "offsetInBeginSection": 668,
                    "offsetInEndSection": 830,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25368273",
                    "text": "The average risk of lymphoma in RA may be composed of a markedly increased risk in patients with most severe disease.",
                    "offsetInBeginSection": 937,
                    "offsetInEndSection": 1054,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24159176",
                    "text": "Several autoimmune diseases, including primary Sj\u00f6gren's syndrome (pSS), are associated with an increased risk for lymphoma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24159176",
                    "text": "The rs2230926 exonic variant was associated with an increased risk for pSS complicated by lymphoma (odds ratio, 3.36 [95% confidence interval, 1.34-8.42], and odds ratio, 3.26 [95% confidence interval, 1.31-8.12], vs controls and pSS patients without lymphoma, respectively; P = .011).",
                    "offsetInBeginSection": 720,
                    "offsetInEndSection": 1005,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462517",
                    "text": "RECENT FINDINGS Despite a lack of a strong association between rheumatoid arthritis and cancer overall, studies show an increased risk for the development of lymphoma in rheumatoid arthritis.",
                    "offsetInBeginSection": 447,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462517",
                    "text": "Data substantiate an increased risk of certain cancers in systemic lupus erythematosus; the risk appears to be most heightened for lymphoma.",
                    "offsetInBeginSection": 911,
                    "offsetInEndSection": 1051,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22208651",
                    "text": "Furthermore, we review the emerging role of ELS and lymphoid chemokines in driving extranodal B cell lymphomagenesis in SS and we focus on recent evidence suggesting that ELS identify subsets of SS patients at increased risk of developing systemic manifestations and lymphoma.",
                    "offsetInBeginSection": 1313,
                    "offsetInEndSection": 1589,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24153350",
                    "text": "Sjogren's syndrome (SS) is a chronic autoimmune disorder with the highest risk for lymphoma development among all autoimmune diseases.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e3d21b750ff4455000043",
            "body": "What is BBCAnalyzer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28241736"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "RESULTS BBCAnalyzer (Bases By CIGAR Analyzer) provides a novel visual approach to facilitate this step of time-consuming, manual inspection of common mutation sites.",
                    "offsetInBeginSection": 501,
                    "offsetInEndSection": 666,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "CONCLUSIONS BBCAnalyzer provides a unique, novel approach to facilitate variant calling where classical tools frequently fail to call.",
                    "offsetInBeginSection": 1412,
                    "offsetInEndSection": 1546,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "BBCAnalyzer is able to visualize base counts at predefined positions or regions in any sequence alignment data that are available as BAM files.",
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 810,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "Video demonstrating the exemplary usage of the web application \"BBCAnalyzer\".",
                    "offsetInBeginSection": 2026,
                    "offsetInEndSection": 2103,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "Any expected mutations (e.g.",
                    "offsetInBeginSection": 373,
                    "offsetInEndSection": 401,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "Thereby, the tool provides a straightforward solution for evaluating any list of expected mutations like hotspot mutations, or even whole regions of interest.",
                    "offsetInBeginSection": 811,
                    "offsetInEndSection": 969,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "Information on the counted number of bases, the reference bases, known mutations or polymorphisms, called mutations and base qualities is summarized in a single plot.",
                    "offsetInBeginSection": 1060,
                    "offsetInEndSection": 1226,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "hotspot mutations), that have not been called by the software, need to be investigated manually.",
                    "offsetInBeginSection": 402,
                    "offsetInEndSection": 498,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "BACKGROUND Deriving valid variant calling results from raw next-generation sequencing data is a particularly challenging task, especially with respect to clinical diagnostics and personalized medicine.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "A documentation of the R package (Additional file 1) as well as the web application (Additional file 2) with detailed descriptions, examples of all input- and output elements, exemplary code as well as exemplary data are included.",
                    "offsetInBeginSection": 1671,
                    "offsetInEndSection": 1901,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a871a6861bb38fb24000009",
            "body": "What disease is the ALK tyrosine kinase associated with?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20223922",
                "http://www.ncbi.nlm.nih.gov/pubmed/27573755",
                "http://www.ncbi.nlm.nih.gov/pubmed/25407901",
                "http://www.ncbi.nlm.nih.gov/pubmed/25351247",
                "http://www.ncbi.nlm.nih.gov/pubmed/27217763",
                "http://www.ncbi.nlm.nih.gov/pubmed/23714228",
                "http://www.ncbi.nlm.nih.gov/pubmed/26811689",
                "http://www.ncbi.nlm.nih.gov/pubmed/24627688",
                "http://www.ncbi.nlm.nih.gov/pubmed/22998583",
                "http://www.ncbi.nlm.nih.gov/pubmed/25870797"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20223922",
                    "text": "NPM-ALK (nucleophosmin-anaplastic lymphoma kinase) and TPM3-ALK (nonmuscular tropomyosin 3-anaplastic lymphoma kinase) are oncogenic tyrosine kinases implicated in the pathogenesis of human ALK-positive lymphoma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 212,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25407901",
                    "text": "In contrast, ALK tyrosine kinase inhibitor (ALK TKI) crizotinib has shown superior effects in combating NSCLCs with EML4-ALK.",
                    "offsetInBeginSection": 450,
                    "offsetInEndSection": 575,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25407901",
                    "text": "It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib.",
                    "offsetInBeginSection": 254,
                    "offsetInEndSection": 449,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25351247",
                    "text": "Although tyrosine kinase inhibitors abrogating ALK activity are currently in clinical use for the treatment of ALK-positive (ALK(+)) disease, monotherapy with ALK tyrosine kinase inhibitors may not be an adequate solution for ALK(+) neuroblastoma patients.",
                    "offsetInBeginSection": 84,
                    "offsetInEndSection": 340,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27217763",
                    "text": "Crizotinib was the first ALK tyrosine kinase inhibitor licensed for the treatment of metastatic ALK-positive NSCLC based on a randomized Phase III trial.",
                    "offsetInBeginSection": 167,
                    "offsetInEndSection": 320,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23714228",
                    "text": "CASE PRESENTATION We report that a case of EML4-ALK-positive NSCLC with EGFR mutation had a response of stable disease to both an EGFR tyrosine kinase inhibitor (EGFR-TKI) and ALK inhibitor.",
                    "offsetInBeginSection": 355,
                    "offsetInEndSection": 545,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26811689",
                    "text": "Anaplastic lymphoma kinase (ALK) rearrangement lung cancer responds to ALK tyrosine kinase inhibitors.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24627688",
                    "text": "Rearrangement of anaplastic lymphoma kinase (ALK) gene is the best predictor of response to crizotinib, an ALK tyrosine kinase inhibitor.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22998583",
                    "text": "INTRODUCTION Anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor, has been initially identified through its involvement in chromosomal translocations associated with anaplastic large cell lymphoma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25870797",
                    "text": "Patients with non-small cell lung cancer (NSCLC) who harbor anaplastic lymphoma kinase (ALK) gene rearrangements can derive significant clinical benefit from ALK tyrosine kinase inhibitor.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f8dc6b750ff4455000058",
            "body": "Is trastuzumab associated cardiotoxicity reversible?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26836985",
                "http://www.ncbi.nlm.nih.gov/pubmed/19669637",
                "http://www.ncbi.nlm.nih.gov/pubmed/18514938",
                "http://www.ncbi.nlm.nih.gov/pubmed/24905295",
                "http://www.ncbi.nlm.nih.gov/pubmed/23282614",
                "http://www.ncbi.nlm.nih.gov/pubmed/18484781",
                "http://www.ncbi.nlm.nih.gov/pubmed/15177418",
                "http://www.ncbi.nlm.nih.gov/pubmed/21310845",
                "http://www.ncbi.nlm.nih.gov/pubmed/14613026",
                "http://www.ncbi.nlm.nih.gov/pubmed/19147689"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985",
                    "text": "The cardiotoxicity of antibodies has been associated to trastuzumab, a humanized anti-ErbB2 monoclonal antibody currently in clinical use for the therapy of breast carcinomas, which induces cardiac dysfunction when used in monotherapy, or in combination with anthracyclines.",
                    "offsetInBeginSection": 563,
                    "offsetInEndSection": 837,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985",
                    "text": "Two categories of cardiotoxic side effects of antineoplastic drugs have been previously proposed: Type I cardiotoxicity, defined as permanent cardiotoxicity, is usually caused by anthracyclines; Type II cardiotoxicity, considered as reversible cardiotoxicity, has been mainly related to monoclonal antibodies.",
                    "offsetInBeginSection": 253,
                    "offsetInEndSection": 562,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637",
                    "text": "INTRODUCTION Although having high clinical efficacy in the treatment of human epidermal growth factor receptor-2 (HER2+) metastatic breast cancer, trastuzumab has been associated with cardiotoxicity, and the etiology and pathogenesis of this condition is currently under investigation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 285,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637",
                    "text": "RESULTS The increased risk of cardiotoxicity is lower when trastuzumab is given as monotherapy (3%-7%) compared with anthracyclines + trastuzumab therapy (27%).",
                    "offsetInBeginSection": 442,
                    "offsetInEndSection": 602,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18514938",
                    "text": "Although reversible in most cases, cardiotoxicity frequently results in the discontinuation of trastuzumab.",
                    "offsetInBeginSection": 356,
                    "offsetInEndSection": 463,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18484781",
                    "text": "Cardiotoxicity has been shown to be potentiated when the agent is used concurrently or sequentially with an anthracycline, and this has limited the use of trastuzumab in some patients.",
                    "offsetInBeginSection": 533,
                    "offsetInEndSection": 717,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18484781",
                    "text": "Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor tyrosine kinase HER2/ErbB2.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21310845",
                    "text": "The long-term significance of these events, isolating known cardiotoxic effects of anthracyclines from those of trastuzumab, and the appropriateness of referring to trastuzumab-related cardiotoxicity as reversible rather than responsive to trastuzumab withdrawal and heart failure medical therapy, are issues that continue to be debated.",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 487,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21310845",
                    "text": "The use of trastuzumab in the adjuvant and metastatic treatment of breast cancer is associated with both symptomatic and asymptomatic cardiotoxicity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19147689",
                    "text": "Concomitant anthracycline therapy significantly increases the risk for cardiotoxicity during trastuzumab treatment, and such regimens are therefore not recommended.",
                    "offsetInBeginSection": 415,
                    "offsetInEndSection": 579,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e3fe3b750ff4455000044",
            "body": "Does the human lncRNA LINC-PINT promote tumorigenesis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                "http://www.ncbi.nlm.nih.gov/pubmed/24922071",
                "http://www.ncbi.nlm.nih.gov/pubmed/27708234",
                "http://www.ncbi.nlm.nih.gov/pubmed/28825722",
                "http://www.ncbi.nlm.nih.gov/pubmed/25185650",
                "http://www.ncbi.nlm.nih.gov/pubmed/26898939",
                "http://www.ncbi.nlm.nih.gov/pubmed/24751403",
                "http://www.ncbi.nlm.nih.gov/pubmed/29050257",
                "http://www.ncbi.nlm.nih.gov/pubmed/26169368",
                "http://www.ncbi.nlm.nih.gov/pubmed/26807174"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "RESULTS Here we characterize the function of the p53-regulated human lncRNA LINC-PINT in cancer.",
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 501,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "We find that LINC-PINT is downregulated in multiple types of cancer and acts as a tumor suppressor lncRNA by reducing the invasive phenotype of cancer cells.",
                    "offsetInBeginSection": 502,
                    "offsetInEndSection": 659,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "CONCLUSIONS Our findings support a conserved functional co-dependence between LINC-PINT and PRC2 and lead us to propose a new mechanism where the lncRNA regulates the availability of free PRC2 at the proximity of co-regulated genomic loci.",
                    "offsetInBeginSection": 970,
                    "offsetInEndSection": 1209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "This sequence mediates a specific interaction with PRC2, necessary for the LINC-PINT-dependent repression of a pro-invasion signature of genes regulated by the transcription factor EGR1.",
                    "offsetInBeginSection": 781,
                    "offsetInEndSection": 967,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24922071",
                    "text": "The lncRNA linc-ROR has been shown to contribute to the maintenance of induced pluripotent stem cells and embryonic stem cells.",
                    "offsetInBeginSection": 207,
                    "offsetInEndSection": 334,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24922071",
                    "text": "Thus our results indicate that linc-ROR functions as an important regulator of EMT and can promote breast cancer progression and metastasis through regulation of miRNAs.",
                    "offsetInBeginSection": 1046,
                    "offsetInEndSection": 1215,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24922071",
                    "text": "Specifically, linc-ROR prevented the degradation of mir-205 target genes, including the EMT inducer ZEB2.",
                    "offsetInBeginSection": 940,
                    "offsetInEndSection": 1045,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27708234",
                    "text": "Long intergenic non-protein coding RNA, p53 induced transcript (Linc-pint) is a long noncoding RNA (lncRNA) that regulates tumor cell viability and proliferation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26898939",
                    "text": "Together, these results indicate that linc-ROR acts as an important regulator of ZEB1, can promote invasion and metastasis in PC, and may represent a novel therapeutic target.",
                    "offsetInBeginSection": 828,
                    "offsetInEndSection": 1003,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29050257",
                    "text": "Long intergenic non-protein coding RNA, regulator of reprogramming (linc-ROR) is an intergenic long non-coding RNA (lncRNA) previously shown to contribute to tumorigenesis in several malignancies.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a871b8d61bb38fb2400000a",
            "body": "What body process does the Dentate Gyrus Mossy Cell control?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17765742",
                "http://www.ncbi.nlm.nih.gov/pubmed/18189312",
                "http://www.ncbi.nlm.nih.gov/pubmed/10531454",
                "http://www.ncbi.nlm.nih.gov/pubmed/9187278",
                "http://www.ncbi.nlm.nih.gov/pubmed/18077687",
                "http://www.ncbi.nlm.nih.gov/pubmed/14999076",
                "http://www.ncbi.nlm.nih.gov/pubmed/11043552",
                "http://www.ncbi.nlm.nih.gov/pubmed/8986870",
                "http://www.ncbi.nlm.nih.gov/pubmed/7721998",
                "http://www.ncbi.nlm.nih.gov/pubmed/1308178"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17765742",
                    "text": "The influence on granule cells is indirect, through hilar mossy cells and GABAergic neurons of the dentate gyrus, and appears to include direct projections in the case of CA3c pyramidal cells of ventral hippocampus.",
                    "offsetInBeginSection": 1638,
                    "offsetInEndSection": 1853,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312",
                    "text": "In the examined four monkey species, mossy cells were found to be calretinin-positive at the uncal pole and at variable length within the main body of the dentate gyrus but not in the tail part.",
                    "offsetInBeginSection": 580,
                    "offsetInEndSection": 774,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10531454",
                    "text": "These findings support hypotheses of temporal lobe epileptogenesis that involve mossy cell and somatostatinergic neuron loss and suggest that lateral inhibition in the dentate gyrus does not require mossy cells but, instead, may be generated directly by GABAergic interneurons.",
                    "offsetInBeginSection": 1462,
                    "offsetInEndSection": 1739,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10531454",
                    "text": "Kainate-treated rats lose an average of 52% of their GAD-negative hilar neurons (putative mossy cells) and 13% of their GAD-positive cells (GABAergic interneurons) in the dentate gyrus.",
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 508,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9187278",
                    "text": "Mossy cells in the hilus of the rat dentate gyrus are the main cells of origin of the dentate commissural and associational projections.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18077687",
                    "text": "Semilunar granule cells appear to represent a distinct excitatory neuron population in the dentate gyrus that may be an important target for mossy fiber sprouting in patients and rodent models of temporal lobe epilepsy.",
                    "offsetInBeginSection": 1050,
                    "offsetInEndSection": 1269,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14999076",
                    "text": "However, whether it is the disappearance of hilar mossy cells from the dentate gyrus circuitry after various insults or the subsequent synaptic-cellular alterations (e.g., reactive axonal sprouting) that lead to dentate hyperexcitability has not been rigorously tested, because of the lack of available techniques to rapidly remove specific classes of nonprincipal cells from neuronal networks.",
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 766,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8986870",
                    "text": "On the other hand, destruction of interneurons of the dentate gyrus (mossy cells and certain gamma-aminobutyricacid-ergic interneurons) by kainic acid-induced seizures was associated with a reduction of secretoneurin-like immunoreactivity in the inner molecular layer of the dentate gyrus.",
                    "offsetInBeginSection": 959,
                    "offsetInEndSection": 1248,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7721998",
                    "text": "These results establish the validity of Timm staining as a marker for mossy fiber sprouting and support the view that status epilepticus provokes the formation of a novel recurrent excitatory circuit in the dentate gyrus.",
                    "offsetInBeginSection": 1829,
                    "offsetInEndSection": 2050,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1308178",
                    "text": "The present results indicate that connections between granule cells and hilar mossy cells of the human dentate gyrus develop through an extended postnatal period of time that may last until the fifth year.",
                    "offsetInBeginSection": 1584,
                    "offsetInEndSection": 1789,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f922fb750ff4455000059",
            "body": "Can canagliflozin cause euglycemic diabetic ketoacidosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27375734",
                "http://www.ncbi.nlm.nih.gov/pubmed/28090050",
                "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
                "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
                "http://www.ncbi.nlm.nih.gov/pubmed/27088018",
                "http://www.ncbi.nlm.nih.gov/pubmed/27471597",
                "http://www.ncbi.nlm.nih.gov/pubmed/26912914",
                "http://www.ncbi.nlm.nih.gov/pubmed/27717592",
                "http://www.ncbi.nlm.nih.gov/pubmed/29099159",
                "http://www.ncbi.nlm.nih.gov/pubmed/29039237"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734",
                    "text": "We are reporting a timely case of atypical euglycemic diabetic ketoacidosis in a type 1 diabetic patient treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitor canagliflozin.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090050",
                    "text": "We herein report the case of a 27-year-old Asian woman with type 2 diabetes who was treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (canagliflozin) who developed euglycemic diabetic ketoacidosis and persistent diuresis in the absence of hyperglycemia.",
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 442,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
                    "text": "We present a case of euglycemic diabetic ketoacidosis secondary to canagliflozin in a type 2 diabetic patient.",
                    "offsetInBeginSection": 558,
                    "offsetInEndSection": 668,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
                    "text": "Ketoacidosis is a significant and often a life-threatening complication of diabetes mellitus seen mostly in type 1 diabetes mellitus as well as occasionally in type 2 diabetes mellitus.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
                    "text": "Diabetic ketoacidosis usually manifests with high blood glucose more than 250\u2009mg/dL, but euglycemic diabetic ketoacidosis is defined as ketoacidosis associated with blood glucose level less than 250\u2009mg/dL.",
                    "offsetInBeginSection": 186,
                    "offsetInEndSection": 395,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
                    "text": "SGLT2 inhibitors such as canagliflozin may predispose patients not only to diabetic ketoacidosis but also to prolonged glucosuria.",
                    "offsetInBeginSection": 1103,
                    "offsetInEndSection": 1233,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27088018",
                    "text": "However, some serious side effects, including severe anion gap metabolic acidosis and euglycemic diabetic ketoacidosis (DKA), have been reported.",
                    "offsetInBeginSection": 333,
                    "offsetInEndSection": 478,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29099159",
                    "text": "OBJECTIVE Canagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, one of a class of novel antiglycemic agents that are gaining in popularity in the treatment of diabetes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29099159",
                    "text": "CONCLUSION Treatment with canagliflozin was associated with development of euglycemic ketoacidosis.",
                    "offsetInBeginSection": 561,
                    "offsetInEndSection": 660,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29039237",
                    "text": "The risk of euglycemic diabetic ketoacidosis seems to be minimal when the drugs are prescribed properly.",
                    "offsetInBeginSection": 826,
                    "offsetInEndSection": 930,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e4136b750ff4455000045",
            "body": "Describe the Match BAM to VCF (MBV) method.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28186259",
                "http://www.ncbi.nlm.nih.gov/pubmed/28369524",
                "http://www.ncbi.nlm.nih.gov/pubmed/23765705",
                "http://www.ncbi.nlm.nih.gov/pubmed/27899667",
                "http://www.ncbi.nlm.nih.gov/pubmed/24451629",
                "http://www.ncbi.nlm.nih.gov/pubmed/14696220",
                "http://www.ncbi.nlm.nih.gov/pubmed/26153076",
                "http://www.ncbi.nlm.nih.gov/pubmed/19749478",
                "http://www.ncbi.nlm.nih.gov/pubmed/17891616",
                "http://www.ncbi.nlm.nih.gov/pubmed/25346813"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28186259",
                    "text": "Results We described here MBV (Match BAM to VCF); a method to quickly solve sample mislabeling and detect cross-sample contamination and PCR amplification bias.",
                    "offsetInBeginSection": 189,
                    "offsetInEndSection": 349,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369524",
                    "text": "Here, we describe NGSCheckMate, a user-friendly software package for verifying sample identities from FASTQ, BAM or VCF files.",
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 564,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369524",
                    "text": "Our evaluation shows that NGSCheckMate is effective for a variety of data types, including exome sequencing, whole-genome sequencing, RNA-seq, ChIP-seq, targeted sequencing and single-cell whole-genome sequencing, with a minimal requirement for sequencing depth (>0.5X).",
                    "offsetInBeginSection": 772,
                    "offsetInEndSection": 1042,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23765705",
                    "text": "BACKGROUND Transthoracic (TTE) and intracardiac echocardiography (ICE) have both been established as modalities for imaging guidance in mitral balloon valvuloplasty (MBV).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899667",
                    "text": "JBrowse now displays BAM, VCF and other annotation tracks, the additional genome assemblies and an embedded VISTA genome comparison viewer.",
                    "offsetInBeginSection": 418,
                    "offsetInEndSection": 557,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24451629",
                    "text": "Many current tool chains are based on the widely used file formats BAM and VCF or VCF-derivatives.",
                    "offsetInBeginSection": 203,
                    "offsetInEndSection": 301,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26153076",
                    "text": "The tool is a single command script that calls a series of modules based on user-defined options and takes sorted/indexed bam files or vcf files as input.",
                    "offsetInBeginSection": 607,
                    "offsetInEndSection": 761,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19749478",
                    "text": "CONCLUSIONS Valsartan, an angiotensin II receptor blocker, corrected the decreased MBV in association with regression of LVH in patients with HT.",
                    "offsetInBeginSection": 1286,
                    "offsetInEndSection": 1431,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17891616",
                    "text": "A perfusion quantification method was applied to obtain MBV maps.",
                    "offsetInBeginSection": 718,
                    "offsetInEndSection": 783,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25346813",
                    "text": "OVERVIEW OF LITERATURE Options for the treatment of VCFs include conservative management, kyphoplasty, and vertebroplasty.",
                    "offsetInBeginSection": 339,
                    "offsetInEndSection": 461,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a897601fcd1d6a10c000008",
            "body": "A SLEDAI score is associated with Systemic Lupus Erythematosus. What is a SLEDAI score?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11480850",
                "http://www.ncbi.nlm.nih.gov/pubmed/19762400",
                "http://www.ncbi.nlm.nih.gov/pubmed/10685800",
                "http://www.ncbi.nlm.nih.gov/pubmed/16681575",
                "http://www.ncbi.nlm.nih.gov/pubmed/17639400",
                "http://www.ncbi.nlm.nih.gov/pubmed/23172751",
                "http://www.ncbi.nlm.nih.gov/pubmed/27365721",
                "http://www.ncbi.nlm.nih.gov/pubmed/17477466",
                "http://www.ncbi.nlm.nih.gov/pubmed/22516994",
                "http://www.ncbi.nlm.nih.gov/pubmed/16354890"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11480850",
                    "text": "Sociodemographic, disease activity using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), therapy and laboratory variables were evaluated.",
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 539,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19762400",
                    "text": "The objective of this study is to determine if digital vasculitis (DV), a clinical manifestation with a high systemic lupus erythematosus disease activity index (SLEDAI) score, is associated with lupus severity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 211,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800",
                    "text": "OBJECTIVE To determine whether Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores correlate with the clinician's impression of level of disease activity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 170,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17639400",
                    "text": "A SLEDAI score of > or =6 was considered clinically significant.",
                    "offsetInBeginSection": 606,
                    "offsetInEndSection": 670,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23172751",
                    "text": "METHODS Patients who met \u22654 of the American College of Rheumatology criteria, had a score of \u22656 on the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and did not have an A score on the British Isles Lupus Assessment Group (BILAG)-2004 scale were eligible.",
                    "offsetInBeginSection": 177,
                    "offsetInEndSection": 458,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27365721",
                    "text": "Systemic lupus erythematosus disease activity index (SLEDAI), C3, C4 and anti-double stranded DNA levels were estimated and repeated monthly till remission.",
                    "offsetInBeginSection": 297,
                    "offsetInEndSection": 453,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17477466",
                    "text": "OBJECTIVE To determine the flare rate and the change in Safety of Estrogens in Lupus Erythematosus: National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI) score with disease flare in pediatric systemic lupus erythematosus (pSLE).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 262,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516994",
                    "text": "The antepartum SLEDAI score was 6.2\u00b11.6, the postpartum SLEDAI score  was 6.4\u00b12.9.",
                    "offsetInBeginSection": 673,
                    "offsetInEndSection": 757,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516994",
                    "text": "The impact of the disease duration, the use of cyclophosphamide, the highest systematic lupus erythematosus disease activity index  (SLEDAI) score during the disease and the antepartum SLEDAI score to the outcome of delivery were analyzed.",
                    "offsetInBeginSection": 313,
                    "offsetInEndSection": 552,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16354890",
                    "text": "Secondary outcomes included the maximum SLEDAI score, change in SLEDAI score, incidence of lupus flares, median time to first flare, systemic lupus erythematosus treatment, and adverse events.",
                    "offsetInBeginSection": 637,
                    "offsetInEndSection": 829,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f941eb750ff445500005b",
            "body": "What is the association between kidney donation risk of gestational complications?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27591246",
                "http://www.ncbi.nlm.nih.gov/pubmed/26090646",
                "http://www.ncbi.nlm.nih.gov/pubmed/26558022",
                "http://www.ncbi.nlm.nih.gov/pubmed/25941060",
                "http://www.ncbi.nlm.nih.gov/pubmed/19353771",
                "http://www.ncbi.nlm.nih.gov/pubmed/22252087",
                "http://www.ncbi.nlm.nih.gov/pubmed/12351541",
                "http://www.ncbi.nlm.nih.gov/pubmed/27271097",
                "http://www.ncbi.nlm.nih.gov/pubmed/25774590",
                "http://www.ncbi.nlm.nih.gov/pubmed/29031488"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591246",
                    "text": "A modest rise in uric acid levels beginning early after donation, and a small (1.4%) increase in the 8-year incidence of gout, have also been reported in comparisons to healthy nondonors.",
                    "offsetInBeginSection": 965,
                    "offsetInEndSection": 1152,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26090646",
                    "text": "Kidney donation seems to elevate the risks of gestational hypertension and pre-eclampsia.",
                    "offsetInBeginSection": 462,
                    "offsetInEndSection": 551,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26090646",
                    "text": "Living kidney donation is associated with an increased risk of end-stage renal disease, although this outcome is uncommon (<0\u00b75% increase in incidence at 15 years).",
                    "offsetInBeginSection": 296,
                    "offsetInEndSection": 461,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22252087",
                    "text": "BACKGROUND Although older maternal age is a risk factor for pregnancy complications, an increasing number of women delay conception until the age of 40, and some must resort to IVF with oocyte donation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12351541",
                    "text": "CONCLUSIONS There is a high risk of obstetric complications in singleton oocyte donation pregnancies, but the perinatal outcomes are favourable.",
                    "offsetInBeginSection": 1189,
                    "offsetInEndSection": 1333,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12351541",
                    "text": "LBW deliveries were significantly associated with PIH, STB, nulliparity and maternal smoking.",
                    "offsetInBeginSection": 950,
                    "offsetInEndSection": 1043,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27271097",
                    "text": "WIDER IMPLICATIONS Oocyte donation pregnancies are associated with a higher rate of placental disorders of pregnancy, such as gestational hypertension and pre-eclampsia.",
                    "offsetInBeginSection": 1320,
                    "offsetInEndSection": 1489,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27271097",
                    "text": "Oocyte donation also seems to be associated with lower fetal birthweight.",
                    "offsetInBeginSection": 1021,
                    "offsetInEndSection": 1094,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25774590",
                    "text": "It disproves a previous assumption of \"non-interference\" between kidney donation and pregnancy outcomes.",
                    "offsetInBeginSection": 408,
                    "offsetInEndSection": 512,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29031488",
                    "text": "The evaluations focused on the complications of nephrectomy in the short and long-term: kidney failure, hypertension, proteinuria, possibility of pregnancy, quality of life, and mortality.",
                    "offsetInBeginSection": 490,
                    "offsetInEndSection": 678,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e4592b750ff4455000047",
            "body": "What is the 959 Nematode Genomes initiative?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24058822",
                "http://www.ncbi.nlm.nih.gov/pubmed/22044053",
                "http://www.ncbi.nlm.nih.gov/pubmed/22058131",
                "http://www.ncbi.nlm.nih.gov/pubmed/28706308",
                "http://www.ncbi.nlm.nih.gov/pubmed/27415016",
                "http://www.ncbi.nlm.nih.gov/pubmed/26927083",
                "http://www.ncbi.nlm.nih.gov/pubmed/19262884",
                "http://www.ncbi.nlm.nih.gov/pubmed/19400640",
                "http://www.ncbi.nlm.nih.gov/pubmed/1367926",
                "http://www.ncbi.nlm.nih.gov/pubmed/18952001"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822",
                    "text": "To inspire, promote and coordinate genomic sequencing across the diversity of the phylum, we have launched a community wiki and the 959 Nematode Genomes initiative (www.nematodegenomes.org/).",
                    "offsetInBeginSection": 1003,
                    "offsetInEndSection": 1194,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822",
                    "text": "Just as the deciphering of the developmental lineage of the 959 cells of the adult hermaphrodite C. elegans was the gateway to broad advances in biomedical science, we hope that a nematode phylogeny with (at least) 959 sequenced species will underpin further advances in understanding the origins of parasitism, the dynamics of genomic change and the adaptations that have made Nematoda one of the most successful animal phyla.",
                    "offsetInBeginSection": 1195,
                    "offsetInEndSection": 1622,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044053",
                    "text": "These efforts are being coordinated through the 959 Nematode Genomes initiative.",
                    "offsetInBeginSection": 1379,
                    "offsetInEndSection": 1459,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22058131",
                    "text": "In this article, we describe '959 Nematode Genomes'--a community-curated semantic wiki to coordinate the sequencing efforts of individual labs to collectively sequence 959 genomes spanning the phylum Nematoda.",
                    "offsetInBeginSection": 130,
                    "offsetInEndSection": 339,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28706308",
                    "text": "The Journal of Nematology now offers publication of Nematode Genome Announcements (NGA) and Nematode Transcriptome Announcements (NTA).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27415016",
                    "text": "Characterization of four gene copies from a model parasitic nematode, Haemonchus contortus, demonstrated that each copy has acquired unique functional characteristics based on phenotype rescue of transgenic C. elegans and electrophysiology of receptors reconstituted in Xenopus oocytes.",
                    "offsetInBeginSection": 1343,
                    "offsetInEndSection": 1629,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19400640",
                    "text": "Both root-knot nematode genomes have compacted gene families compared with the free-living nematode Caenorhabditis elegans, and both encode large suites of enzymes that uniquely target the host plant.",
                    "offsetInBeginSection": 913,
                    "offsetInEndSection": 1113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19400640",
                    "text": "The recent completion of two root-knot nematode genomes opens the way for a comparative genomics approach to elucidate the success of these parasites.",
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 278,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18952001",
                    "text": "Recently, the Filarial Genome Project reported the draft sequence of the ~95 Mb genome of the human filarial parasite Brugia malayi - the first parasitic nematode genome to be sequenced.",
                    "offsetInBeginSection": 174,
                    "offsetInEndSection": 360,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18952001",
                    "text": "The Brugia genome also provides an opportunity to gain insight into genetic basis for mutualism, as Brugia, like a majority of filarial species, harbors an endosybiotic bacterium (Wolbachia).",
                    "offsetInBeginSection": 772,
                    "offsetInEndSection": 963,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a897927fcd1d6a10c00000a",
            "body": "What does A1C measure?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20923490",
                "http://www.ncbi.nlm.nih.gov/pubmed/18030866",
                "http://www.ncbi.nlm.nih.gov/pubmed/23990520",
                "http://www.ncbi.nlm.nih.gov/pubmed/28843470",
                "http://www.ncbi.nlm.nih.gov/pubmed/16336550",
                "http://www.ncbi.nlm.nih.gov/pubmed/28964455",
                "http://www.ncbi.nlm.nih.gov/pubmed/24511995",
                "http://www.ncbi.nlm.nih.gov/pubmed/18509211",
                "http://www.ncbi.nlm.nih.gov/pubmed/26630892",
                "http://www.ncbi.nlm.nih.gov/pubmed/18056888"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18030866",
                    "text": "A CONCEPTUAL MODEL FOR ASSESSING THE QUALITY OF GLYCEMIC CONTROL A continuous measure of A1C, as the cornerstone in quality assessment for diabetes, can incorporate each of the Institute of Medicine's (IOM)'s quality domains: effectiveness and equity, patient safety, patient-centered care, timeliness, and efficiency.",
                    "offsetInBeginSection": 933,
                    "offsetInEndSection": 1251,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18030866",
                    "text": "CONCLUSIONS A continuous measure of A1C can better capture than a dichotomous measure the complexity of glycemic control at a population level.",
                    "offsetInBeginSection": 1254,
                    "offsetInEndSection": 1397,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28843470",
                    "text": "RESULTS Among 253 dyads, the frequencies of patients compared to caregivers who could accurately describe what the A1C level assesses, identify the ideal A1C target, and identify the ideal BG range were 20 vs. 66, 31 vs. 56, and 72 vs. 76%, respectively.",
                    "offsetInBeginSection": 733,
                    "offsetInEndSection": 987,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28843470",
                    "text": "METHODS Patients (8 to 18 years) with T1D and caregivers completed questionnaires that queried their perceptions of (1) what the A1C level assesses, (2) the ideal A1C target, and (3) the ideal BG range.",
                    "offsetInBeginSection": 358,
                    "offsetInEndSection": 560,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16336550",
                    "text": "OBJECTIVE To study within-patient longitudinal changes in A1c levels at Veterans Health Administration (VHA) facilities as an alternative to cross-sectional measures of quality of diabetes care.",
                    "offsetInBeginSection": 181,
                    "offsetInEndSection": 375,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16336550",
                    "text": "PATIENTS Diabetic veteran users with A1c measurement performed using National Glycosylated Hemoglobin Standardization Project certified A1c lab assay methods.",
                    "offsetInBeginSection": 655,
                    "offsetInEndSection": 813,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28964455",
                    "text": "OBJECTIVES To estimate the impact of increased glycated hemoglobin (A1C) monitoring and treatment intensification for patients with type 2 diabetes (T2D) on quality measures and reimbursement within the Medicare Advantage Star (MA Star) program.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28964455",
                    "text": "Using the estimated changes in measured A1C levels, we calculated corresponding changes in the plan-level A1C quality measure, overall star rating, and reimbursement.",
                    "offsetInBeginSection": 554,
                    "offsetInEndSection": 720,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18509211",
                    "text": "We assessed differences in A1C performance measure threshold attainment by case mix factors for A1C >9% and examined how lowering the threshold to A1C >8% or >7% changed these differences.",
                    "offsetInBeginSection": 249,
                    "offsetInEndSection": 437,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056888",
                    "text": "OBJECTIVE Despite the standing of A1C as the most validated and widely used measure for average glycemic control over time, the relationship between A1C and glucose concentrations is not completely understood.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f98e6b750ff445500005d",
            "body": "Which ligament is most commonly injured in dashboard injury?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3425783",
                "http://www.ncbi.nlm.nih.gov/pubmed/7377448",
                "http://www.ncbi.nlm.nih.gov/pubmed/10623985",
                "http://www.ncbi.nlm.nih.gov/pubmed/15062581",
                "http://www.ncbi.nlm.nih.gov/pubmed/27623865",
                "http://www.ncbi.nlm.nih.gov/pubmed/598118",
                "http://www.ncbi.nlm.nih.gov/pubmed/18980604",
                "http://www.ncbi.nlm.nih.gov/pubmed/21257845",
                "http://www.ncbi.nlm.nih.gov/pubmed/22890899",
                "http://www.ncbi.nlm.nih.gov/pubmed/12621261"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783",
                    "text": "Hyperflexion was the most common mechanism of injury, followed by pretibial trauma in the hyperflexed knee or in the \"dashboard\" injury.",
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 574,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7377448",
                    "text": "The anterior cruciate ligament (50%) is most often injured followed by the medial collateral ligament (31%), lateral collateral ligament (13%), and posterior cruciate ligament (6%).",
                    "offsetInBeginSection": 765,
                    "offsetInEndSection": 946,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10623985",
                    "text": "The most common mechanism of injury in motor vehicle accidents is a dashboard injury or direct force to the proximal anterior tibia.",
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 258,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27623865",
                    "text": "CONCLUSIONS The anterior inferior tibiofibular ligament is the most commonly injured ligament in the syndesmosis in sports injury and results in subtle variations in the syndesmotic anatomy, which plain radiographs cannot assess.",
                    "offsetInBeginSection": 1181,
                    "offsetInEndSection": 1410,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/598118",
                    "text": "Legs trapped under the dashboard with simultaneous rotational, varus, valgus, or frontal forces by the inertial motion of the body produced serious injuries similar to those recieved in sports.",
                    "offsetInBeginSection": 502,
                    "offsetInEndSection": 695,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18980604",
                    "text": "The thigh, especially the hamstrings, was the overall most commonly injured region in both sexes, while the hip/groin was more commonly injured in male players and the knee in female players.",
                    "offsetInBeginSection": 568,
                    "offsetInEndSection": 759,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21257845",
                    "text": "BACKGROUND Humeral avulsion of the inferior glenohumeral ligament is a rare injury resulting from hyperabduction and external rotation, and it is most commonly seen with sports-related injuries, including those from volleyball.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21257845",
                    "text": "The anterior band of the inferior glenohumeral ligament is most commonly injured (93%), whereas the posterior band is infrequently injured.",
                    "offsetInBeginSection": 228,
                    "offsetInEndSection": 367,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890899",
                    "text": "The medial collateral ligament (MCL) is the most commonly injured ligament of the knee.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12621261",
                    "text": "Distal lateral collateral ligament injuries were commonly associated with distal biceps avulsions and seldom with popliteus tendon avulsions.",
                    "offsetInBeginSection": 1350,
                    "offsetInEndSection": 1491,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e49a4b750ff445500004b",
            "body": "Is LDB1-mediated enhancer looping dependent on cohesin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                "http://www.ncbi.nlm.nih.gov/pubmed/28636938",
                "http://www.ncbi.nlm.nih.gov/pubmed/25605944",
                "http://www.ncbi.nlm.nih.gov/pubmed/20720539",
                "http://www.ncbi.nlm.nih.gov/pubmed/23728302",
                "http://www.ncbi.nlm.nih.gov/pubmed/27135601",
                "http://www.ncbi.nlm.nih.gov/pubmed/20887946",
                "http://www.ncbi.nlm.nih.gov/pubmed/22682246",
                "http://www.ncbi.nlm.nih.gov/pubmed/25299688",
                "http://www.ncbi.nlm.nih.gov/pubmed/24874989"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "text": "Moreover, ENCODE data and our chromatin immunoprecipitation results indicate that cohesin is almost completely absent from validated and predicted LDB1-regulated erythroid enhancer-gene pairs.",
                    "offsetInBeginSection": 1172,
                    "offsetInEndSection": 1364,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28636938",
                    "text": "Both LDB1 and CTCF are required for enhancer-Car2 looping, and the domain of LDB1 contacted by CTCF is necessary to rescue Car2 transcription in LDB1-deficient cells.",
                    "offsetInBeginSection": 494,
                    "offsetInEndSection": 660,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28636938",
                    "text": "Genome-wide studies and CRISPR/Cas9 genome editing indicate that LDB1-CTCF enhancer looping underlies activation of a substantial fraction of erythroid genes.",
                    "offsetInBeginSection": 661,
                    "offsetInEndSection": 819,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28636938",
                    "text": "The LDB1 complex mediates enhancer-gene interactions at the \u03b2-globin locus through LDB1 self-interaction.",
                    "offsetInBeginSection": 230,
                    "offsetInEndSection": 336,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25605944",
                    "text": "LDB1-mediated enhancer:promoter looping appears to be required for both activation and repression of these target genes.",
                    "offsetInBeginSection": 658,
                    "offsetInEndSection": 778,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25605944",
                    "text": "Here we report the required actions of LIM domain-binding protein 1 (LDB1)/cofactor of LIM homeodomain protein 2/nuclear LIM interactor, interacting with the enhancer-binding protein achaete-scute complex homolog 1, to mediate looping to target gene promoters and target gene regulation in corticotrope cells.",
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 657,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20720539",
                    "text": "DNA looping is observed between the enhancers and promoters occupied by mediator and cohesin.",
                    "offsetInBeginSection": 745,
                    "offsetInEndSection": 838,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22682246",
                    "text": "Our findings establish Ldb1 as a critical effector of GATA1-mediated loop formation and indicate that chromatin looping causally underlies gene regulation.",
                    "offsetInBeginSection": 943,
                    "offsetInEndSection": 1098,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25299688",
                    "text": "CTCF and cohesin are two abundant looping proteins of interphase chromosomes of higher eukaryotes.",
                    "offsetInBeginSection": 453,
                    "offsetInEndSection": 551,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25299688",
                    "text": "In support of this model prediction it has recently been shown by others that CTCF and cohesin indeed are responsible primarily for short-range looping.",
                    "offsetInBeginSection": 1364,
                    "offsetInEndSection": 1516,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a897a06fcd1d6a10c00000b",
            "body": "What is the normal body temperature in dogs?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/495147",
                "http://www.ncbi.nlm.nih.gov/pubmed/25854787",
                "http://www.ncbi.nlm.nih.gov/pubmed/2759725",
                "http://www.ncbi.nlm.nih.gov/pubmed/22058348",
                "http://www.ncbi.nlm.nih.gov/pubmed/8733095",
                "http://www.ncbi.nlm.nih.gov/pubmed/1056280",
                "http://www.ncbi.nlm.nih.gov/pubmed/28216687",
                "http://www.ncbi.nlm.nih.gov/pubmed/21102554",
                "http://www.ncbi.nlm.nih.gov/pubmed/11913416",
                "http://www.ncbi.nlm.nih.gov/pubmed/6617751"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147",
                    "text": "The effect of intraventricular injection of thyroxine 1 microgram/animal on body temperature was studied in dogs under resting conditions: at normal ambient temperature, at high ambient temperature (35 degrees C) and during administration of pyrogen.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147",
                    "text": "Thyroxine exerted its central action on body temperature only in dogs performing physical exercise.",
                    "offsetInBeginSection": 387,
                    "offsetInEndSection": 486,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147",
                    "text": "Besides, changes in body temperature were elucidated in dogs performing physical exercise following I.V.",
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 355,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22058348",
                    "text": "All dogs with TB had a normal body temperature, and three had systemic disease and one had clinical signs limited to testicular disease.",
                    "offsetInBeginSection": 629,
                    "offsetInEndSection": 765,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21102554",
                    "text": "CONCLUSION These findings document an association between obesity and reduced body temperature in dogs and support the hypothesis that obesity in this and other species of homeotherms may result from an increase in metabolic efficiency achieved by a regulated lowering of body temperature.",
                    "offsetInBeginSection": 1097,
                    "offsetInEndSection": 1386,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21102554",
                    "text": "METHODS We compared the rectal temperature of lean dogs and obese dogs by (a) conducting cross-sectional measurements in 287 dogs of many breeds varying greatly in body size, (b) conducting longitudinal measurements in individual dogs over 7-10 years and (c) tracking rectal temperature of lean and obese dogs at 3-h intervals for 48 consecutive hours in the laboratory.",
                    "offsetInBeginSection": 447,
                    "offsetInEndSection": 817,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11913416",
                    "text": "Compared with normal gravity controls, exposed dogs showed a slower growth rate and a reduced amount of body fat.",
                    "offsetInBeginSection": 557,
                    "offsetInEndSection": 670,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11913416",
                    "text": "Initially, centrifuged dogs showed transient decreases in heart rate and body temperature along with changes in their diurnal rhythm patterns.",
                    "offsetInBeginSection": 414,
                    "offsetInEndSection": 556,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11913416",
                    "text": "In spite of the various changes noted, results from this and other studies affirm the view that dogs can tolerate and adapt to sustained loads as high as 2.5 g without serious impairment of their body structure and function.",
                    "offsetInBeginSection": 1038,
                    "offsetInEndSection": 1262,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6617751",
                    "text": "The effects of morphine and pentobarbital on body temperature and heart rate were studied in a line of pointer dogs characterized as genetically nervous.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70d12899e2c3af26000001",
            "body": "List symptoms of Heerfordt syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17637529",
                "http://www.ncbi.nlm.nih.gov/pubmed/22565854",
                "http://www.ncbi.nlm.nih.gov/pubmed/20184241",
                "http://www.ncbi.nlm.nih.gov/pubmed/26885424",
                "http://www.ncbi.nlm.nih.gov/pubmed/25087562",
                "http://www.ncbi.nlm.nih.gov/pubmed/18454397",
                "http://www.ncbi.nlm.nih.gov/pubmed/27549672",
                "http://www.ncbi.nlm.nih.gov/pubmed/25685372",
                "http://www.ncbi.nlm.nih.gov/pubmed/1405089",
                "http://www.ncbi.nlm.nih.gov/pubmed/21706840"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17637529",
                    "text": "This case demonstrates the importance of being aware of the leading clinical signs and symptoms in case of Heerfordt syndrome.",
                    "offsetInBeginSection": 774,
                    "offsetInEndSection": 900,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22565854",
                    "text": "Angiography revealed a dense pattern of hyperfluorescent lesions and these observations resulted in the diagnosis of Heerfordt syndrome.",
                    "offsetInBeginSection": 401,
                    "offsetInEndSection": 537,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241",
                    "text": "Various clinical symptoms indicated Heerfordt syndrome.",
                    "offsetInBeginSection": 638,
                    "offsetInEndSection": 693,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241",
                    "text": "We found no cases of familial sarcoidosis with Heerfordt syndrome in the literature.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26885424",
                    "text": "Case\u2009\u20092.",
                    "offsetInBeginSection": 604,
                    "offsetInEndSection": 616,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25087562",
                    "text": "Other examinations revealed bilateral hilar lymphadenopathy, high serum titer of angiotensin coenzyme, and no response in a tuberculin-tested, non-caseating epithelioid granuloma from lip biopsy, leading to the diagnosis of complete Heerfordt syndrome.",
                    "offsetInBeginSection": 479,
                    "offsetInEndSection": 731,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18454397",
                    "text": "BACKGROUND Heerfordt syndrome is rare and is characterized by fever, uveitis, parotid gland enlargement, and facial nerve palsy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18454397",
                    "text": "Chest computed tomography and transbronchial lymph node biopsy set the diagnosis of sarcoidosis.",
                    "offsetInBeginSection": 668,
                    "offsetInEndSection": 764,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18454397",
                    "text": "We hereby present a case of Heerfordt syndrome with unilateral facial nerve palsy as a presentation of sarcoidosis.",
                    "offsetInBeginSection": 129,
                    "offsetInEndSection": 244,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685372",
                    "text": "Heerfordt's syndrome as a cause of facial palsy is very rare.",
                    "offsetInBeginSection": 124,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e4b72b750ff445500004c",
            "body": "Is there any link between ERCC1-XPF and cohesin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                "http://www.ncbi.nlm.nih.gov/pubmed/14512883",
                "http://www.ncbi.nlm.nih.gov/pubmed/20518486",
                "http://www.ncbi.nlm.nih.gov/pubmed/24158589",
                "http://www.ncbi.nlm.nih.gov/pubmed/12509251",
                "http://www.ncbi.nlm.nih.gov/pubmed/14706347",
                "http://www.ncbi.nlm.nih.gov/pubmed/11707424",
                "http://www.ncbi.nlm.nih.gov/pubmed/15199134",
                "http://www.ncbi.nlm.nih.gov/pubmed/26074087",
                "http://www.ncbi.nlm.nih.gov/pubmed/10882712"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "text": "We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders.",
                    "offsetInBeginSection": 806,
                    "offsetInEndSection": 1051,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "text": "Using an in vivo biotinylation tagging approach in mice, we show that the nucleotide excision repair (NER) structure-specific endonuclease ERCC1-XPF complex interacts with the insulator binding protein CTCF, the cohesin subunits SMC1A and SMC3 and with MBD2; the factors co-localize with ATRX at the promoters and control regions (ICRs) of imprinted genes during postnatal hepatic development.",
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 521,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "text": "Loss of Ercc1 or exposure to MMC triggers the localization of CTCF to heterochromatin, the dissociation of the CTCF-cohesin complex and ATRX from promoters and ICRs, altered histone marks and\u00a0the aberrant developmental expression of imprinted genes without altering DNA methylation.",
                    "offsetInBeginSection": 522,
                    "offsetInEndSection": 805,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20518486",
                    "text": "This binding between FANCG and the ERCC1-XPF endonuclease, combined with our previous studies which show that FANCG is involved in the incision step mediated by ERCC1-XPF, establishes a link between an FA protein and the critical unhooking step of the ICL repair process.",
                    "offsetInBeginSection": 1428,
                    "offsetInEndSection": 1699,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24158589",
                    "text": "Occurrence of theses variations adversely affected the regular interaction between ERCC1 and XPF protein.",
                    "offsetInBeginSection": 875,
                    "offsetInEndSection": 980,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12509251",
                    "text": "ERCC1-XPF is also involved in recombinational repair processes distinct from NER.",
                    "offsetInBeginSection": 127,
                    "offsetInEndSection": 208,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14706347",
                    "text": "Bulky DNA lesions are mainly repaired by nucleotide excision repair (NER), in which the interaction of ERCC1 with XPA protein recruits the ERCC1-XPF complex, which acts as a structure-specific endonuclease in the repair process.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 228,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26074087",
                    "text": "The ERCC1 and ERCC4 genes encode the two subunits of the ERCC1-XPF nuclease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26074087",
                    "text": "ERCC1-XPF interacts with other proteins including XPA, RPA, SLX4 and TRF2 to perform its functions.",
                    "offsetInBeginSection": 756,
                    "offsetInEndSection": 855,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10882712",
                    "text": "However, in mammalian cells there is evidence that the ERCC1-XPF nuclease has a specialized additional function during interstrand DNA cross-link repair, beyond its role in nucleotide excision repair.",
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 392,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8afbf2fcd1d6a10c00001c",
            "body": "In quadruped mammals, what bones make up the stifle?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17266668",
                "http://www.ncbi.nlm.nih.gov/pubmed/19378290",
                "http://www.ncbi.nlm.nih.gov/pubmed/24323904",
                "http://www.ncbi.nlm.nih.gov/pubmed/21113010",
                "http://www.ncbi.nlm.nih.gov/pubmed/19378269",
                "http://www.ncbi.nlm.nih.gov/pubmed/23554931",
                "http://www.ncbi.nlm.nih.gov/pubmed/3218668",
                "http://www.ncbi.nlm.nih.gov/pubmed/25709597",
                "http://www.ncbi.nlm.nih.gov/pubmed/7649818",
                "http://www.ncbi.nlm.nih.gov/pubmed/23977887"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17266668",
                    "text": "In the stifle joints of quadrupeds, the MFL is a substantial structure and appears to be related to the caudal tibial slope.",
                    "offsetInBeginSection": 1234,
                    "offsetInEndSection": 1358,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378290",
                    "text": "Based on this survey, I suggest that olecranon orientation can be used for inferring the elbow joint angles of quadruped mammals with prominent olecranons, regardless of taxon, body size, and locomotor guild.",
                    "offsetInBeginSection": 919,
                    "offsetInEndSection": 1127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24323904",
                    "text": "High-resolution microtomographic scans were collected of the lunate, scaphoid, and capitate in 41 individuals and eight genera (Homo, Gorilla, Pan, Papio, Pongo, Symphalangus, Hylobates, and Ateles).",
                    "offsetInBeginSection": 632,
                    "offsetInEndSection": 831,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113010",
                    "text": "Monophasic lateral bending and long-axis rotation, biphasic sagittal bending and maximal amplitude of sagittal bending at the lumbo-sacral joint were also found in other quadruped mammals and may represent general aspects of mammalian symmetric gaits.",
                    "offsetInBeginSection": 1270,
                    "offsetInEndSection": 1521,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113010",
                    "text": "Given the importance of thoraco-lumbar spine movements in the locomotion of mammals, it is surprising that in vivo three-dimensional (3-D) data on the intervertebral movement of the mammalian thoraco-lumbar vertebral column during symmetrical gaits is limited to horses and dogs.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 279,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378269",
                    "text": "Determining scapular position is a major issue in reconstructing the skeletal systems of extinct quadruped archosaurs and mammals, because the proximal portion of the scapulae has no direct skeletal joint with the vertebrae or ribs.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 232,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378269",
                    "text": "This implies that the location of robust ribs is associated with the arrangement of the serratus muscle, and provides a probable candidate for determination of the scapular position for extinct quadruped archosaurs and mammals.",
                    "offsetInBeginSection": 1209,
                    "offsetInEndSection": 1436,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3218668",
                    "text": "MACN-SC 101 may represent the incipient divergence of a generalized platyrrhine arboreal quadruped toward a more suspensory form.",
                    "offsetInBeginSection": 951,
                    "offsetInEndSection": 1080,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3218668",
                    "text": "Primate scapula and ulna fragments of uncertain taxonomic affinity (MACN-SC 101) have been recovered from the Pinturas deposits at Arroyo Feo, Santa Cruz, Argentina in association with Santacrucian (Early Miocene) land mammals.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23977887",
                    "text": "CONCLUSIONS AND CLINICAL RELEVANCE Compared with results for quadruped dogs, the vertebral column, carpus, and ipsilateral hip and stifle joints had significant biomechanical changes after amputation of a thoracic limb.",
                    "offsetInBeginSection": 1323,
                    "offsetInEndSection": 1542,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70d42899e2c3af26000002",
            "body": "Mutation of which gene causes arterial tortuosity syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18818946",
                "http://www.ncbi.nlm.nih.gov/pubmed/16550171",
                "http://www.ncbi.nlm.nih.gov/pubmed/18774132",
                "http://www.ncbi.nlm.nih.gov/pubmed/19028722",
                "http://www.ncbi.nlm.nih.gov/pubmed/19622975",
                "http://www.ncbi.nlm.nih.gov/pubmed/20735855",
                "http://www.ncbi.nlm.nih.gov/pubmed/22488877",
                "http://www.ncbi.nlm.nih.gov/pubmed/17935213",
                "http://www.ncbi.nlm.nih.gov/pubmed/19781076",
                "http://www.ncbi.nlm.nih.gov/pubmed/25373504"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946",
                    "text": "This syndrome is caused by mutations in the SLC2A10 gene.",
                    "offsetInBeginSection": 212,
                    "offsetInEndSection": 269,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946",
                    "text": "This mutation in the SLC2A10 gene replaces a cysteine encoding codon with a stop signal.",
                    "offsetInBeginSection": 655,
                    "offsetInEndSection": 743,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16550171",
                    "text": "GLUT10 deficiency is associated with upregulation of the TGFbeta pathway in the arterial wall, a finding also observed in Loeys-Dietz syndrome, in which aortic aneurysms associate with arterial tortuosity.",
                    "offsetInBeginSection": 568,
                    "offsetInEndSection": 773,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132",
                    "text": "This syndrome is caused by mutation in SLC2A10 gene which encodes for the facilitative glucose transporter, GLUT10.",
                    "offsetInBeginSection": 310,
                    "offsetInEndSection": 425,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132",
                    "text": "In the single patient of Family 1, sequencing of the candidate gene, SLC2A10, identified a novel missense c.313C>T mutation encoding a p.Arg105Cys substitution in the second extracellular domain of GLUT10.",
                    "offsetInBeginSection": 718,
                    "offsetInEndSection": 923,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19028722",
                    "text": "Mutations in the SLC2A10 gene cause arterial tortuosity syndrome (ATS) in humans.",
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 218,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19622975",
                    "text": "BACKGROUND Arterial tortuosity syndrome is a rare, autosomal recessive, severe, connective tissue disorder caused by a mutation in the SLC2A10 gene.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20735855",
                    "text": "BACKGROUND Recent data indicate that loss-of-function mutation in the gene encoding the facilitative glucose transporter GLUT10 (SLC2A10) causes arterial tortuosity syndrome via upregulation of the TGF-\u03b2 pathway in the arterial wall, a mechanism possibly causing vascular changes in diabetes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 293,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20735855",
                    "text": "CONCLUSION Our data demonstrate that genetic polymorphism of the SLC2A10 gene is an independent risk factor for PAD in type 2 diabetes.",
                    "offsetInBeginSection": 1186,
                    "offsetInEndSection": 1321,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19781076",
                    "text": "ATS is caused by mutations in SLC2A10 gene, encoding for the facilitative glucose transporter 10 (GLUT10).",
                    "offsetInBeginSection": 290,
                    "offsetInEndSection": 396,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f940bb750ff445500005a",
            "body": "What is the aim of the 4D nucleome project?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28905911",
                "http://www.ncbi.nlm.nih.gov/pubmed/29168505",
                "http://www.ncbi.nlm.nih.gov/pubmed/26338265",
                "http://www.ncbi.nlm.nih.gov/pubmed/28745542",
                "http://www.ncbi.nlm.nih.gov/pubmed/28961756",
                "http://www.ncbi.nlm.nih.gov/pubmed/26080430",
                "http://www.ncbi.nlm.nih.gov/pubmed/28385536",
                "http://www.ncbi.nlm.nih.gov/pubmed/26028501",
                "http://www.ncbi.nlm.nih.gov/pubmed/27052789",
                "http://www.ncbi.nlm.nih.gov/pubmed/23468323"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911",
                    "text": "The 4D Nucleome Network aims to develop and apply approaches to map the structure and dynamics of the human and mouse genomes in space and time with the goal of gaining deeper mechanistic insights into how the nucleus is organized and functions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338265",
                    "text": "The 4D nucleome has the potential to render challenges in neuropsychiatric pharmacogenomics more tractable.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28745542",
                    "text": "The recent conference 4D Nucleome: The Cell Nucleus in Space and Time, which was held in Krak\u00f3w in May 2017, was an opportunity to appreciate the growing number of conceptual approaches and newly emerging analytical techniques that are revolutionizing our understanding of the structure of chromatin and the nucleus.",
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 589,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961756",
                    "text": "Results The 4D Nucleome Analysis Toolbox (NAT) is a user-friendly and powerful MATLAB toolbox for time series analysis of genome-wide chromosome conformation capture (Hi-C) data and gene expression (RNA-seq).",
                    "offsetInBeginSection": 165,
                    "offsetInEndSection": 373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080430",
                    "text": "The 4D organization of the interphase nucleus, or the 4D Nucleome (4DN), reflects a dynamical interaction between 3D genome structure and function and its relationship to phenotype.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 181,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28385536",
                    "text": "These examples in regulatory pharmacoepigenomics illustrate how ongoing research using the 4D nucleome provides a foundation to further insight into previously unrecognized psychotropic drug pharmacodynamic pathways in the human CNS.",
                    "offsetInBeginSection": 1335,
                    "offsetInEndSection": 1568,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23468323",
                    "text": "Finally, the nidus segmentation is dilated and used for an automatic identification of feeding arteries and draining veins by integrating hemodynamic information from the 4D MRA datasets.",
                    "offsetInBeginSection": 902,
                    "offsetInEndSection": 1089,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23468323",
                    "text": "Each dataset consists of a high-resolution 3D and a 4D magnetic resonance angiography (MRA) image sequence.",
                    "offsetInBeginSection": 485,
                    "offsetInEndSection": 592,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23468323",
                    "text": "The aim of this work is to present and evaluate a computer-aided nidus segmentation technique and subsequent angiographic characterization of the connected vessels that can be visualized in 3D.",
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 380,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23468323",
                    "text": "CONCLUSION The presented computer-aided method enables a reproducible and fast extraction of the AVM nidus as well as an automatic angiographic characterization of the connected vessels, which can be used to support image-based research projects and therapy planning of AVMs.",
                    "offsetInBeginSection": 1470,
                    "offsetInEndSection": 1745,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8b1264fcd1d6a10c00001d",
            "body": "Fusarium oxysporum f. sp lycopersici. is a plant pathogen in plants producing what common food?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10517025",
                "http://www.ncbi.nlm.nih.gov/pubmed/24909710",
                "http://www.ncbi.nlm.nih.gov/pubmed/18624637",
                "http://www.ncbi.nlm.nih.gov/pubmed/24024636",
                "http://www.ncbi.nlm.nih.gov/pubmed/24561899",
                "http://www.ncbi.nlm.nih.gov/pubmed/18945093",
                "http://www.ncbi.nlm.nih.gov/pubmed/18944618",
                "http://www.ncbi.nlm.nih.gov/pubmed/28956188",
                "http://www.ncbi.nlm.nih.gov/pubmed/9237400",
                "http://www.ncbi.nlm.nih.gov/pubmed/11319099"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 530,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 530,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025",
                    "text": "Fusarium oxysporum f. sp.",
                    "offsetInBeginSection": 198,
                    "offsetInEndSection": 223,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24909710",
                    "text": "lycopersici (FOL).",
                    "offsetInBeginSection": 387,
                    "offsetInEndSection": 405,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24561899",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 456,
                    "offsetInEndSection": 468,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24561899",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 456,
                    "offsetInEndSection": 468,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18945093",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 706,
                    "offsetInEndSection": 718,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18945093",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 706,
                    "offsetInEndSection": 718,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18945093",
                    "text": "lycopersici and F. oxysporum f. sp.",
                    "offsetInBeginSection": 775,
                    "offsetInEndSection": 810,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9237400",
                    "text": "Fusarium oxysporum f. sp.",
                    "offsetInBeginSection": 154,
                    "offsetInEndSection": 179,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70d43b99e2c3af26000003",
            "body": "Does prolactinoma increase osteoporosis risk?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11293923",
                "http://www.ncbi.nlm.nih.gov/pubmed/22553947",
                "http://www.ncbi.nlm.nih.gov/pubmed/20205855",
                "http://www.ncbi.nlm.nih.gov/pubmed/26319389",
                "http://www.ncbi.nlm.nih.gov/pubmed/17578827",
                "http://www.ncbi.nlm.nih.gov/pubmed/15816365",
                "http://www.ncbi.nlm.nih.gov/pubmed/9550540",
                "http://www.ncbi.nlm.nih.gov/pubmed/27446618",
                "http://www.ncbi.nlm.nih.gov/pubmed/15191331",
                "http://www.ncbi.nlm.nih.gov/pubmed/25472533"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11293923",
                    "text": "The relative risk for developing osteoporosis in women with prolactinoma was found to be 4.5, indicating that hyperprolactinemia in women is a major risk factor for osteoporosis.",
                    "offsetInBeginSection": 1145,
                    "offsetInEndSection": 1323,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553947",
                    "text": "CONCLUSION In the premenopausal women, patients with prolactinoma or craniopharyngioma are often accompanied with osteopenia or osteoporosis, and disease duration and hypogonadism are the risk factors of bone loss in prolactinoma.",
                    "offsetInBeginSection": 1085,
                    "offsetInEndSection": 1315,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553947",
                    "text": "OBJECTIVE Patients with prolactinoma seem to be at high risk for osteopenia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855",
                    "text": "Prolactinoma in old people may present insidiously with chronic anaemia and osteoporosis with or without sexual dysfunction.",
                    "offsetInBeginSection": 249,
                    "offsetInEndSection": 373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26319389",
                    "text": "Hyperprolactinaemia related to prolactinoma significantly (more than functional hyperprolactiaemia) increases the risk of osteopenia, osteoporosis and bone fractures.",
                    "offsetInBeginSection": 1014,
                    "offsetInEndSection": 1180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26319389",
                    "text": "High serum prolactin levels lead to increase of the risk of osteopenia or/and osteoporosis.",
                    "offsetInBeginSection": 782,
                    "offsetInEndSection": 873,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26319389",
                    "text": "Important group of patients threatened by osteoporosis and bone fracture is constituted by women which use antipsychotic drugs (which induce hyperprolactinaemia).",
                    "offsetInBeginSection": 1181,
                    "offsetInEndSection": 1343,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17578827",
                    "text": "INTRODUCTION Osteopenia and osteoporosis because of hyperprolactinaemia caused by prolactinoma may be followed by an increased risk of fracture.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15816365",
                    "text": "In conclusion, men with prolactinoma have high prevalence of osteopenia and osteoporosis.",
                    "offsetInBeginSection": 1442,
                    "offsetInEndSection": 1531,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9550540",
                    "text": "Humans with prolactinoma are at risk for osteoporosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 54,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6fa31ab750ff445500005e",
            "body": "Which method has been developed for assignment of enhancers to target genes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29070071",
                "http://www.ncbi.nlm.nih.gov/pubmed/22084256",
                "http://www.ncbi.nlm.nih.gov/pubmed/26390058",
                "http://www.ncbi.nlm.nih.gov/pubmed/26446758",
                "http://www.ncbi.nlm.nih.gov/pubmed/26780995",
                "http://www.ncbi.nlm.nih.gov/pubmed/8974006",
                "http://www.ncbi.nlm.nih.gov/pubmed/24278002",
                "http://www.ncbi.nlm.nih.gov/pubmed/9620363",
                "http://www.ncbi.nlm.nih.gov/pubmed/18482403",
                "http://www.ncbi.nlm.nih.gov/pubmed/18202183"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071",
                    "text": "We devised a machine learning approach, McEnhancer, which links target genes to putative enhancers via a semi-supervised learning algorithm that predicts gene expression patterns based on enriched sequence features.",
                    "offsetInBeginSection": 178,
                    "offsetInEndSection": 393,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071",
                    "text": "Transcriptional enhancers regulate spatio-temporal gene expression.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 67,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22084256",
                    "text": "This is especially true in mammalian systems, where regulation often occurs through long-range enhancers in gene-rich neighborhoods, rather than proximal promoters, preventing straightforward assignment of a binding site to a target gene.",
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 592,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26390058",
                    "text": "We carried out an integrative analysis of enhancer landscape and gene expression dynamics during hematopoietic differentiation using DNase-seq, histone mark ChIP-seq and RNA sequencing to model how the early establishment of enhancers and regulatory locus complexity govern gene expression changes at cell state transitions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 324,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26390058",
                    "text": "Our method suggests a new mechanistic role for PU.1 at transition peaks during B cell specification and can be used to correct assignments of enhancers to genes.",
                    "offsetInBeginSection": 898,
                    "offsetInEndSection": 1059,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26446758",
                    "text": "After reviewing models of enhancer function, we discuss recent methods for identifying target genes of enhancers.",
                    "offsetInBeginSection": 736,
                    "offsetInEndSection": 849,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26780995",
                    "text": "Various experimental and computational approaches including chromatin signature profiling have been developed to predict enhancers on a genome-wide scale, although each method has its advantages and disadvantages.",
                    "offsetInBeginSection": 95,
                    "offsetInEndSection": 308,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26780995",
                    "text": "Enhancers are distal cis-regulatory DNA elements that increase the expression of target genes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8974006",
                    "text": "This communication reports the assignment of NF45, interleukin enhancer binding factor 2 gene (ILF2), to human chromosome 1 (1q11-qter and 1p11-p12) by polymerase chain reaction (PCR) amplification of ILF2-specific DNA sequences from well-characterized human-rodent somatic cell hybrid DNA.",
                    "offsetInBeginSection": 550,
                    "offsetInEndSection": 840,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9620363",
                    "text": "This communication reports the assignment of the gene encoding the large NFAT subunit, NF90 or interleukin enhancer binding factor 3 gene (ILF3), to human chromosome 19 (19q11-qter and 19p11-p13.1) by polymerase chain reaction (PCR) amplification of ILF3-specific DNA sequences from well-characterized human-rodent somatic cell hybrid DNAs.",
                    "offsetInBeginSection": 705,
                    "offsetInEndSection": 1045,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8dc6b4fcd1d6a10c000026",
            "body": "List 2 approved drug treatments for Inflammatory Bowel Disease (IBD).",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27753694",
                "http://www.ncbi.nlm.nih.gov/pubmed/23051720",
                "http://www.ncbi.nlm.nih.gov/pubmed/21484967",
                "http://www.ncbi.nlm.nih.gov/pubmed/21936033",
                "http://www.ncbi.nlm.nih.gov/pubmed/27570643",
                "http://www.ncbi.nlm.nih.gov/pubmed/28868386",
                "http://www.ncbi.nlm.nih.gov/pubmed/28961959",
                "http://www.ncbi.nlm.nih.gov/pubmed/25572840",
                "http://www.ncbi.nlm.nih.gov/pubmed/17129810",
                "http://www.ncbi.nlm.nih.gov/pubmed/26631943"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694",
                    "text": "BACKGROUND Currently, 200 genetic risk loci have been identified for inflammatory bowel disease (IBD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694",
                    "text": "CONCLUSIONS We confirm that proteins encoded by IBD candidate genes are targeted by approved IBD therapies.",
                    "offsetInBeginSection": 1283,
                    "offsetInEndSection": 1390,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23051720",
                    "text": "First-line treatments were defined as the following drug categories: 5-aminosalicylates, budesonide, systemic steroids, azathioprine, 6-mercaptopurine, methotrexate, infliximab, adalimumab and certolizumab pegol.",
                    "offsetInBeginSection": 452,
                    "offsetInEndSection": 664,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23051720",
                    "text": "The following drug categories were not included: cyclosporine and tacrolimus (not yet approved by Swissmedic for IBD treatment).",
                    "offsetInBeginSection": 665,
                    "offsetInEndSection": 793,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23051720",
                    "text": "BACKGROUND AND AIMS Medical therapy of inflammatory bowel disease (IBD) is becoming more complex, given the increasing choice of drugs to treat Crohn's disease (CD) and ulcerative colitis (UC).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21936033",
                    "text": "Infliximab, adalimumab, and certolizumab are monoclonal antibodies against tumor necrosis factor-\u03b1 (TNF\u03b1), a proinflammatory cytokine with an increased expression in the inflamed tissues of inflammatory bowel disease (IBD) patients.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 234,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21936033",
                    "text": "Currently, infliximab is the only anti-TNF drug that has been approved for use in refractory pediatric Crohn's disease (CD).",
                    "offsetInBeginSection": 235,
                    "offsetInEndSection": 359,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27570643",
                    "text": "Inflammatory Bowel Disease (IBD) is a chronic and relapsing disorder, which affects millions people worldwide.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961959",
                    "text": "The therapeutic landscape for inflammatory bowel disease (IBD) is rapidly evolving.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26631943",
                    "text": "More recently, vedolizumab, an anti-\u03b14\u03b27 integrin monoclonal antibody, has been approved for the treatment of Crohn's disease and ulcerative colitis.",
                    "offsetInBeginSection": 893,
                    "offsetInEndSection": 1044,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70e4b399e2c3af26000008",
            "body": "Glecaprevir and Pibrentasvir are used for tratment of which disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28688001",
                "http://www.ncbi.nlm.nih.gov/pubmed/28800195",
                "http://www.ncbi.nlm.nih.gov/pubmed/28807904",
                "http://www.ncbi.nlm.nih.gov/pubmed/28412293",
                "http://www.ncbi.nlm.nih.gov/pubmed/29020583",
                "http://www.ncbi.nlm.nih.gov/pubmed/28818546",
                "http://www.ncbi.nlm.nih.gov/pubmed/28128852",
                "http://www.ncbi.nlm.nih.gov/pubmed/28925068",
                "http://www.ncbi.nlm.nih.gov/pubmed/29152781",
                "http://www.ncbi.nlm.nih.gov/pubmed/28929412"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195",
                    "text": "Glecaprevir and pibrentasvir are direct-acting antiviral agents being developed as combination therapy for the treatment of chronic hepatitis C virus infection.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195",
                    "text": "The results of these studies demonstrate that race/ethnicity has no clinically meaningful impact on direct-acting antiviral agent exposures, safety, or tolerability of the glecaprevir and pibrentasvir combination.",
                    "offsetInBeginSection": 1388,
                    "offsetInEndSection": 1601,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28807904",
                    "text": "The combination of glecaprevir (formerly ABT-493), a nonstructural protein 3/4A (NS3/4A) protease inhibitor, and pibrentasvir (formerly ABT-530), an NS5A protein inhibitor, is being developed as treatment for HCV genotype 1 to 6 infection.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 239,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28807904",
                    "text": "The pharmacokinetics, pharmacodynamics, safety, and tolerability of methadone or buprenorphine-naloxone when coadministered with the glecaprevir-pibrentasvir combination in HCV-negative subjects on stable opioid maintenance therapy were investigated in a phase 1, single-center, two-arm, multiple-dose, open-label sequential study.",
                    "offsetInBeginSection": 240,
                    "offsetInEndSection": 571,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28412293",
                    "text": "LAY SUMMARY The combination of direct-acting antivirals glecaprevir and pibrentasvir comprise a once-daily, all-oral, pangenotypic treatment for HCV genotype 1-6 infection.",
                    "offsetInBeginSection": 1749,
                    "offsetInEndSection": 1921,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29020583",
                    "text": "METHODS We conducted a multicenter, open-label, phase 3 trial to evaluate the efficacy and safety of treatment with the combination of the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 12 weeks in adults who had HCV genotype 1, 2, 3, 4, 5, or 6 infection and also had compensated liver disease (with or without cirrhosis) with severe renal impairment, dependence on dialysis, or both.",
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 876,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28128852",
                    "text": "This phase 2, open-label study (MAGELLAN-1) evaluated the efficacy and safety of glecaprevir (GLE) + pibrentasvir (PIB) \u00b1 ribavirin (RBV) in HCV genotype 1-infected patients with prior virologic failure to HCV DAA-containing therapy.",
                    "offsetInBeginSection": 503,
                    "offsetInEndSection": 737,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28128852",
                    "text": "CONCLUSION The combination of GLE and PIB was highly efficacious and well tolerated in patients with HCV genotype 1 infection and prior failure of DAA-containing therapy; RBV coadministration did not improve efficacy.",
                    "offsetInBeginSection": 1588,
                    "offsetInEndSection": 1805,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28925068",
                    "text": "A recently approved, pan-genotypic, direct-acting antiviral regimen, glecaprevir and pibrentasvir, may simplify prescribing.",
                    "offsetInBeginSection": 550,
                    "offsetInEndSection": 674,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28929412",
                    "text": "A fixed-dose combination tablet of the hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) glecaprevir and the HCV NS5A inhibitor pibrentasvir [glecaprevir/pibrentasvir; MAVIRET\u2122 (EU); MAVYRET\u2122 (USA)] has been developed by AbbVie.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 237,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6fa417b750ff445500005f",
            "body": "Describe the RNA Centric Annotation System (RCAS)",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28334930",
                "http://www.ncbi.nlm.nih.gov/pubmed/17145711",
                "http://www.ncbi.nlm.nih.gov/pubmed/20689021",
                "http://www.ncbi.nlm.nih.gov/pubmed/12537574",
                "http://www.ncbi.nlm.nih.gov/pubmed/27546377",
                "http://www.ncbi.nlm.nih.gov/pubmed/24633242",
                "http://www.ncbi.nlm.nih.gov/pubmed/15099404",
                "http://www.ncbi.nlm.nih.gov/pubmed/20592237",
                "http://www.ncbi.nlm.nih.gov/pubmed/24722185",
                "http://www.ncbi.nlm.nih.gov/pubmed/25368315"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930",
                    "text": "Here, we present the RNA Centric Annotation System (RCAS), an R package, which is designed to ease the process of creating gene-centric annotations and analysis for the genomic regions of interest obtained from various RNA-based omics technologies.",
                    "offsetInBeginSection": 288,
                    "offsetInEndSection": 536,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930",
                    "text": "The meta-gene profiles, gene-centric annotation, motif analysis and gene-set analysis provided by RCAS provide contextual knowledge which is necessary for understanding the functional aspects of different biological events that involve RNAs.",
                    "offsetInBeginSection": 966,
                    "offsetInEndSection": 1207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17145711",
                    "text": "The database is now built around a sophisticated genome browser (Ensembl), our own microarray information management and annotation system (MIMAS) used to extensively describe experimental data obtained with high-density oligonucleotide microarrays (GeneChips) and a comprehensive system for online editing of database entries (MediaWiki).",
                    "offsetInBeginSection": 410,
                    "offsetInEndSection": 749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20689021",
                    "text": "Such set-centric features address a host of applications, including microarray data analysis, cross-database annotation mapping and gene-disorder associations for drug targeting.",
                    "offsetInBeginSection": 1011,
                    "offsetInEndSection": 1189,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20689021",
                    "text": "Its gene-centric content is automatically mined and integrated from over 80 digital sources, resulting in a web-based deep-linked card for each of >73,000 human gene entries, encompassing the following categories: protein coding, pseudogene, RNA gene, genetic locus, cluster and uncategorized.",
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 446,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24633242",
                    "text": "Here we describe an automated pipeline for genome annotation that integrates RNA-seq and gene-boundary data sets, which we call Generalized RNA Integration Tool, or GRIT.",
                    "offsetInBeginSection": 151,
                    "offsetInEndSection": 321,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24633242",
                    "text": "The identification of full length transcripts entirely from short-read RNA sequencing data (RNA-seq) remains a challenge in the annotation of genomes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15099404",
                    "text": "CONCLUSIONS As the proteomic data for several organisms begins to accumulate, BioBuilder will prove to be an invaluable platform for functional annotation and development of customizable protein centric databases.",
                    "offsetInBeginSection": 1025,
                    "offsetInEndSection": 1238,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20592237",
                    "text": "Integration of proteomics, transcriptomics, RNA polymerase, and sigma factor-binding information with deep-sequencing-based analysis of primary 5'-end transcripts allowed for a most precise annotation.",
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 606,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24722185",
                    "text": "Correct and complete annotation in addition to the underlying genomic sequence is particularly important when interpreting the results of RNA-seq experiments where short sequence reads are mapped against the genome and assigned to genes according to the annotation.",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 383,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76018c83b0d9ea6600000e",
            "body": "List the ten types of conjoined twins.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/1412053",
                "http://www.ncbi.nlm.nih.gov/pubmed/12483645",
                "http://www.ncbi.nlm.nih.gov/pubmed/3267350",
                "http://www.ncbi.nlm.nih.gov/pubmed/29064095",
                "http://www.ncbi.nlm.nih.gov/pubmed/2754585",
                "http://www.ncbi.nlm.nih.gov/pubmed/24193193",
                "http://www.ncbi.nlm.nih.gov/pubmed/19429398",
                "http://www.ncbi.nlm.nih.gov/pubmed/27369817",
                "http://www.ncbi.nlm.nih.gov/pubmed/7112433",
                "http://www.ncbi.nlm.nih.gov/pubmed/8787375"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12483645",
                    "text": "RESULTS Three sets of female conjoined twins underwent successful separation 2 pygopagus, one ischiopagus tripus) with 5 surviving infants.",
                    "offsetInBeginSection": 577,
                    "offsetInEndSection": 716,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12483645",
                    "text": "This study reviews the authors' experience with the perineal reconstruction of these types of conjoined twins.",
                    "offsetInBeginSection": 209,
                    "offsetInEndSection": 319,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29064095",
                    "text": "Eight different types of conjoined twins have been described in the literature.",
                    "offsetInBeginSection": 154,
                    "offsetInEndSection": 233,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2754585",
                    "text": "Magnetic resonance imaging (MRI) was used for the first time in the preoperative planning for separation of conjoined twins.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 124,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193",
                    "text": "OBJECTIVES Conjoined twins are rare.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 36,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193",
                    "text": "In evaluating conjoined twins, 2-dimensional ultrasound is the criterion standard.",
                    "offsetInBeginSection": 796,
                    "offsetInEndSection": 878,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19429398",
                    "text": "This article provides some additions and corrections on a recently published case report concerning a pair of di-symmetrical cephalopagus conjoined twins.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 154,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27369817",
                    "text": "We describe the urologic presentation, evaluation, and treatment of thoracoomphalopagus conjoined twins.",
                    "offsetInBeginSection": 485,
                    "offsetInEndSection": 589,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7112433",
                    "text": "The most common types of conjoined twins were thoracoomphalopagus (28%), thoracopagus (18%), omphalopagus (10%), parasitic twins (10%), and craniopagus (6%).",
                    "offsetInBeginSection": 555,
                    "offsetInEndSection": 712,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8787375",
                    "text": "A case study describes the perioperative management of conjoined twins at Texas Children's Hospital's, Houston.",
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 420,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70e6e899e2c3af26000009",
            "body": "What is the mechanism of action of Fremanezumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                "http://www.ncbi.nlm.nih.gov/pubmed/28642283",
                "http://www.ncbi.nlm.nih.gov/pubmed/29171818",
                "http://www.ncbi.nlm.nih.gov/pubmed/28862758",
                "http://www.ncbi.nlm.nih.gov/pubmed/28644160",
                "http://www.ncbi.nlm.nih.gov/pubmed/27960628",
                "http://www.ncbi.nlm.nih.gov/pubmed/28240610",
                "http://www.ncbi.nlm.nih.gov/pubmed/29110503",
                "http://www.ncbi.nlm.nih.gov/pubmed/9721431",
                "http://www.ncbi.nlm.nih.gov/pubmed/16425669"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                    "text": "To investigate the basis for this selective inhibitory effect, and further explore the mechanism of action of CGRP-mAbs, we tested the effect of fremanezumab on the cortical spreading depression-evoked activation of mechanosensitive primary afferent meningeal nociceptors that innervate the cranial dura, using single-unit recording in the trigeminal ganglion of anesthetized male rats.",
                    "offsetInBeginSection": 742,
                    "offsetInEndSection": 1128,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                    "text": "The selectivity in its peripheral inhibitory action may partly account for fremanezumab's selective inhibition of high-threshold, as a result of a predominant A-\u03b4 input to high-threshold neurons, but not wide dynamic-range dorsal horn neurons, and why it may not be effective in all migraine patients.SIGNIFICANCE STATEMENT Recently, we reported that humanized CGRP monoclonal antibodies (CGRP-mAbs) prevent activation and sensitization of high-threshold (HT) but not wide-dynamic range trigeminovascular neurons by cortical spreading depression (CSD).",
                    "offsetInBeginSection": 1474,
                    "offsetInEndSection": 2027,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                    "text": "We recently tested the effect of fremanezumab (TEV-48125), a CGRP-mAb, on the activity of second-order trigeminovascular dorsal horn neurons that receive peripheral input from the cranial dura, and found a selective inhibition of high-threshold but not wide-dynamic range class of neurons.",
                    "offsetInBeginSection": 452,
                    "offsetInEndSection": 741,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                    "text": "As the main CGRP-mAb site of action appears to be situated outside the brain, we conclude that the initiation of the headache phase of migraine depends on activation of meningeal nociceptors, and that for selected patients, activation of the A\u03b4-HT pain pathway may be sufficient for the generation of headache perception.",
                    "offsetInBeginSection": 2295,
                    "offsetInEndSection": 2617,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283",
                    "text": "However, their mechanism of action is unknown.",
                    "offsetInBeginSection": 1875,
                    "offsetInEndSection": 1921,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283",
                    "text": "To answer this question, we used single-unit recording to determine the effects of fremanezumab (30 mg/kg, IV) and its isotype control Ab on spontaneous and evoked activity in naive and cortical spreading depression (CSD)-sensitized trigeminovascular neurons in the spinal trigeminal nucleus of anesthetized male and female rats.",
                    "offsetInBeginSection": 571,
                    "offsetInEndSection": 900,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283",
                    "text": "The study demonstrates that, in both sexes, fremanezumab inhibited naive high-threshold (HT) neurons, but not wide-dynamic range trigeminovascular neurons, and that the inhibitory effects on the neurons were limited to their activation from the intracranial dura but not facial skin or cornea.",
                    "offsetInBeginSection": 901,
                    "offsetInEndSection": 1194,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9721431",
                    "text": "Its unique mechanism of action has created great interest in its use as a biochemical probe of signal transduction pathways that has provided insight into its molecular mechanism of action.",
                    "offsetInBeginSection": 98,
                    "offsetInEndSection": 287,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9721431",
                    "text": "This article reviews the current state of our understanding of the mechanism of action of rapamune.",
                    "offsetInBeginSection": 288,
                    "offsetInEndSection": 387,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16425669",
                    "text": "However, its mechanism of action is far from clear.",
                    "offsetInBeginSection": 387,
                    "offsetInEndSection": 438,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6fa61ab750ff4455000060",
            "body": "Which tool exists for microsatellite (SSR) loci detection and primer design?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27366148",
                "http://www.ncbi.nlm.nih.gov/pubmed/11292858",
                "http://www.ncbi.nlm.nih.gov/pubmed/12582546",
                "http://www.ncbi.nlm.nih.gov/pubmed/23324172",
                "http://www.ncbi.nlm.nih.gov/pubmed/10912681",
                "http://www.ncbi.nlm.nih.gov/pubmed/18631390",
                "http://www.ncbi.nlm.nih.gov/pubmed/25223041",
                "http://www.ncbi.nlm.nih.gov/pubmed/28575007",
                "http://www.ncbi.nlm.nih.gov/pubmed/11292857",
                "http://www.ncbi.nlm.nih.gov/pubmed/15836642"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148",
                    "text": "FullSSR is a new bioinformatic tool for microsatellite (SSR) loci detection and primer design using genomic data from NGS assay.",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 278,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11292858",
                    "text": "A modified selectively amplified microsatellite polymorphic loci assay is used to generate multi-locus SSR fingerprints that provide a source of polymorphic DNA markers (SAMs) for use in genetic studies.",
                    "offsetInBeginSection": 165,
                    "offsetInEndSection": 368,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11292858",
                    "text": "SAMs can then be converted to locus-specific SSR markers with the design and synthesis of a single primer specific to the conserved region flanking the repeat.",
                    "offsetInBeginSection": 570,
                    "offsetInEndSection": 729,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12582546",
                    "text": "These 66 mapped microsatellite (SSR) loci add to the existing 384 microsatellite loci earlier mapped in bread wheat.",
                    "offsetInBeginSection": 903,
                    "offsetInEndSection": 1019,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23324172",
                    "text": "We selected a set of 500 microsatellite loci identified in contigs with minimum 100X coverage for primer design and synthesis, and tested a subset of 269 primer pairs, 198 of which were polymorphic on 11 representative B. ruziziensis accessions.",
                    "offsetInBeginSection": 889,
                    "offsetInEndSection": 1134,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23324172",
                    "text": "Recently, next-generation sequencing technologies have been applied to generate sequence data for the identification of microsatellite regions and primer design.",
                    "offsetInBeginSection": 448,
                    "offsetInEndSection": 609,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10912681",
                    "text": "Sixty-five SSR primer pairs were used to amplify 71 marker loci and genotype 13 monosomic and 27 monotelodisomic cotton cytogenetic stocks.",
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 265,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18631390",
                    "text": "CONCLUSION The combined approach of identifying SSR-enriched fragments by FIASCO coupled with the primer design and in silico amplification using phpSSRMiner represents an efficient and low cost pipeline for the large-scale development of microsatellite markers in plants.The approach described here could be readily adapted and utilized in other non-related species with none or limited genomic resources.",
                    "offsetInBeginSection": 1548,
                    "offsetInEndSection": 1954,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25223041",
                    "text": "In total, 1890 EST-SSR loci were identified, of which, 1296 SSR sequences could be used for primer design.",
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 305,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11292857",
                    "text": "Alternatively, sequence tag primers can be used to directly amplify corresponding SSR loci from genomic DNA, thereby reducing the cost of developing a microsatellite marker to the synthesis of just one sequence-specific primer.",
                    "offsetInBeginSection": 1106,
                    "offsetInEndSection": 1333,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70e88699e2c3af2600000a",
            "body": "Describe mechanism of action of Nusinersen.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27939059",
                "http://www.ncbi.nlm.nih.gov/pubmed/28884620",
                "http://www.ncbi.nlm.nih.gov/pubmed/29105153",
                "http://www.ncbi.nlm.nih.gov/pubmed/28485722",
                "http://www.ncbi.nlm.nih.gov/pubmed/28229309",
                "http://www.ncbi.nlm.nih.gov/pubmed/29091570",
                "http://www.ncbi.nlm.nih.gov/pubmed/26865511",
                "http://www.ncbi.nlm.nih.gov/pubmed/29130140",
                "http://www.ncbi.nlm.nih.gov/pubmed/28799578",
                "http://www.ncbi.nlm.nih.gov/pubmed/28369979"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059",
                    "text": "INTERPRETATION Administration of multiple intrathecal doses of nusinersen showed acceptable safety and tolerability, pharmacology consistent with its intended mechanism of action, and encouraging clinical efficacy.",
                    "offsetInBeginSection": 2944,
                    "offsetInEndSection": 3158,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059",
                    "text": "METHODS This open-label, phase 2, escalating dose clinical study assessed the safety and tolerability, pharmacokinetics, and clinical efficacy of multiple intrathecal doses of nusinersen (6 mg and 12 mg dose equivalents) in patients with infantile-onset spinal muscular atrophy.",
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 626,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884620",
                    "text": "Clinical use of nusinersen is also reviewed.",
                    "offsetInBeginSection": 750,
                    "offsetInEndSection": 794,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29105153",
                    "text": "We review the chemistry, pharmacology and mechanisms of action of ASOs, pre-clinical data and clinical trials in neuromuscular diseases and discuss some ethical, regulatory and policy considerations in the clinical development and use of ASOs.",
                    "offsetInBeginSection": 797,
                    "offsetInEndSection": 1040,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28485722",
                    "text": "Recent approval of nusinersen provides a much-needed boost for antisense technology that is just beginning to realize its potential.",
                    "offsetInBeginSection": 1124,
                    "offsetInEndSection": 1256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28485722",
                    "text": "Here, we provide a historical account of events that led to the discovery of ISS-N1 and describe the impact of independent validations that raised the profile of ISS-N1 as one of the most potent antisense targets for the treatment of a genetic disease.",
                    "offsetInBeginSection": 871,
                    "offsetInEndSection": 1123,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29091570",
                    "text": "METHODS We conducted a randomized, double-blind, sham-controlled, phase 3 efficacy and safety trial of nusinersen in infants with spinal muscular atrophy.",
                    "offsetInBeginSection": 339,
                    "offsetInEndSection": 493,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511",
                    "text": "OBJECTIVE To examine safety, tolerability, pharmacokinetics, and preliminary clinical efficacy of intrathecal nusinersen (previously ISIS-SMNRx), an antisense oligonucleotide designed to alter splicing of SMN2 mRNA, in patients with childhood spinal muscular atrophy (SMA).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 273,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29130140",
                    "text": "OBJECTIVE This study describes the early results of technical success, complications and radiation dose of intrathecal delivery of nusinersen using cone-beam CT guidance with two-axis fluoroscopic navigational overlay.",
                    "offsetInBeginSection": 651,
                    "offsetInEndSection": 869,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29130140",
                    "text": "CONCLUSION Cone-beam CT guidance with two-axis navigational overlay is a safe, effective method for gaining transforaminal intrathecal access in children with spinal abnormalities and hardware precluding the use of standard techniques.",
                    "offsetInBeginSection": 1674,
                    "offsetInEndSection": 1909,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6fa9f7b750ff4455000061",
            "body": "Describe Click-PEGylation",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28366801",
                "http://www.ncbi.nlm.nih.gov/pubmed/18590303",
                "http://www.ncbi.nlm.nih.gov/pubmed/23534985",
                "http://www.ncbi.nlm.nih.gov/pubmed/23106398",
                "http://www.ncbi.nlm.nih.gov/pubmed/28116403",
                "http://www.ncbi.nlm.nih.gov/pubmed/23496167",
                "http://www.ncbi.nlm.nih.gov/pubmed/22243664",
                "http://www.ncbi.nlm.nih.gov/pubmed/28205176",
                "http://www.ncbi.nlm.nih.gov/pubmed/16055055",
                "http://www.ncbi.nlm.nih.gov/pubmed/20024305"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28366801",
                    "text": "To establish a more robust method for redox-selective PEGylation, we have utilised a Click chemistry approach, where free thiol groups are first labelled with a reagent modified to contain an alkyne moiety, which is subsequently Click-reacted with a PEG molecule containing a complementary azide function.",
                    "offsetInBeginSection": 1551,
                    "offsetInEndSection": 1856,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28366801",
                    "text": "Here we show how the Click-PEGylation technique can be used to interrogate the redox state of proteins.",
                    "offsetInBeginSection": 2068,
                    "offsetInEndSection": 2171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18590303",
                    "text": "In this work, we investigate the PEGylation of porous silicon wafers using click chemistry.",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23534985",
                    "text": "To study the potential of the tyrosine click reaction to introduce poly(ethylene glycol) chains onto proteins (PEGylation), we demonstrate that this novel reagent provides for the selective PEGylation of chymotrypsinogen, whereas traditional succinimide-based PEGylation targeting lysine residues provided a more diverse range of PEGylated products.",
                    "offsetInBeginSection": 954,
                    "offsetInEndSection": 1303,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23534985",
                    "text": "Finally, we applied the tyrosine click reaction to create a novel antibody-drug conjugate.",
                    "offsetInBeginSection": 1304,
                    "offsetInEndSection": 1394,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23534985",
                    "text": "With proteins we studied the compatibility of the tyrosine click reaction with cysteine and lysine-targeted labeling approaches and demonstrate that chemoselective trifunctionalization of proteins is readily achieved.",
                    "offsetInBeginSection": 423,
                    "offsetInEndSection": 640,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23106398",
                    "text": "Protein PEGylation (attaching PEG chains to proteins) has been widely used in pharmaceuticals and nanotechnology.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23496167",
                    "text": "BACKGROUND PEGylation, association of poly(ethylene glycol) (PEG) to drug molecules or drug-bearing particles, is one of the most promising techniques on the way to improve the pharmacokinetic features of a drug which, in turn, leads to pharmacodynamic improvements.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 266,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28205176",
                    "text": "Here, we describe the method of PEGylation, which uses a cysteine-reactive molecule, maleimide polyethylene glycol (mPEG), to determine the cytosolic accessibility of introduced cysteine residues.",
                    "offsetInBeginSection": 188,
                    "offsetInEndSection": 384,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20024305",
                    "text": "Copper-free, strain-promoted click reaction with azides showed excellent kinetics, and a functionalised aza-cyclooctyne was applied in fast and efficient PEGylation of enzymes.",
                    "offsetInBeginSection": 84,
                    "offsetInEndSection": 260,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70ea8299e2c3af2600000b",
            "body": "Does Evolocumab improve cognitive function?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28207168",
                "http://www.ncbi.nlm.nih.gov/pubmed/28813214",
                "http://www.ncbi.nlm.nih.gov/pubmed/28744103",
                "http://www.ncbi.nlm.nih.gov/pubmed/28988500",
                "http://www.ncbi.nlm.nih.gov/pubmed/29121222",
                "http://www.ncbi.nlm.nih.gov/pubmed/26868195",
                "http://www.ncbi.nlm.nih.gov/pubmed/25773607",
                "http://www.ncbi.nlm.nih.gov/pubmed/28812389",
                "http://www.ncbi.nlm.nih.gov/pubmed/28291870",
                "http://www.ncbi.nlm.nih.gov/pubmed/27667740"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168",
                    "text": "EBBINGHAUS will evaluate whether the addition of evolocumab to statin therapy affects cognitive function over time in patients with stable cardiovascular disease.",
                    "offsetInBeginSection": 1748,
                    "offsetInEndSection": 1910,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214",
                    "text": "Conclusions In a randomized trial involving patients who received either evolocumab or placebo in addition to statin therapy, no significant between-group difference in cognitive function was observed over a median of 19 months.",
                    "offsetInBeginSection": 2301,
                    "offsetInEndSection": 2529,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214",
                    "text": "Background Findings from clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 275,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28744103",
                    "text": "Appropriate candidates for evolocumab primarily are individuals at high cardiovascular risk, including those with familial hypercholesterolemia and/or established cardiovascular disease, who are already on statin therapy.",
                    "offsetInBeginSection": 769,
                    "offsetInEndSection": 990,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28744103",
                    "text": "At this time, the use of evolocumab monotherapy seems appropriate only for individuals deemed statin-intolerant despite attempting several statins.",
                    "offsetInBeginSection": 991,
                    "offsetInEndSection": 1138,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28744103",
                    "text": "Furthermore, evolocumab did not affect neurocognitive function and was not associated with antidrug-antibody production in over 60,000 patient-years of drug exposure.",
                    "offsetInBeginSection": 602,
                    "offsetInEndSection": 768,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28988500",
                    "text": "Evolocumab is an injectable, fully human monoclonal antibody and a member of the newest class of low density lipoprotein cholesterol (LDL-C) lowering agents called proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 229,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28988500",
                    "text": "This review will focus on the overall safety of evolocumab including cognitive impairment, very low LDL-C levels, new onset diabetes and glucose abnormalities, effect on vitamin E and steroid hormones, liver and muscle abnormalities, and immunogenicity and injection site reactions.",
                    "offsetInBeginSection": 624,
                    "offsetInEndSection": 906,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26868195",
                    "text": "INTERPRETATION Evolocumab markedly reduces atherogenic lipoproteins in patients with type 2 diabetes, an effect that is consistent across subgroups and similar to that seen in patients without type 2 diabetes.",
                    "offsetInBeginSection": 2339,
                    "offsetInEndSection": 2548,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773607",
                    "text": "BACKGROUND Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in short-term studies.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75dff883b0d9ea66000003",
            "body": "Name curated data resources for ChIP-seq data",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26969372",
                "http://www.ncbi.nlm.nih.gov/pubmed/24253304",
                "http://www.ncbi.nlm.nih.gov/pubmed/27789702",
                "http://www.ncbi.nlm.nih.gov/pubmed/29069466",
                "http://www.ncbi.nlm.nih.gov/pubmed/22495751",
                "http://www.ncbi.nlm.nih.gov/pubmed/27863463",
                "http://www.ncbi.nlm.nih.gov/pubmed/28529706",
                "http://www.ncbi.nlm.nih.gov/pubmed/19892823",
                "http://www.ncbi.nlm.nih.gov/pubmed/21097880",
                "http://www.ncbi.nlm.nih.gov/pubmed/21113027"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24253304",
                    "text": "Within this database, we collected all publicly available ChIP-Seq data on CRs in human and mouse and categorized the data into four cohorts: the reader, writer, eraser and remodeler cohorts, together with curated introductions and ChIP-Seq data analysis results.",
                    "offsetInBeginSection": 761,
                    "offsetInEndSection": 1024,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702",
                    "text": "Although rapidly accumulating publicly available ChIP-seq, DNase-seq and ATAC-seq data are a valuable resource for the systematic investigation of gene regulation processes, a lack of standardized curation, quality control and analysis procedures have hindered extensive reuse of these data.",
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 527,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702",
                    "text": "To overcome this challenge, we built the Cistrome database, a collection of ChIP-seq and chromatin accessibility data (DNase-seq and ATAC-seq) published before January 1, 2016, including 13 366 human and 9953 mouse samples.",
                    "offsetInBeginSection": 528,
                    "offsetInEndSection": 751,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22495751",
                    "text": "We have created CistromeMap as a web server to provide a comprehensive knowledgebase of all of the publicly available ChIP-Seq and DNase-Seq data in mouse and human.",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 283,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27863463",
                    "text": "CONCLUSIONS The various ChIP-Seq command line tools and web services either complement or compare favorably to related bioinformatics resources in terms of computational efficiency, ease of access to public data and interoperability with other web-based tools.",
                    "offsetInBeginSection": 888,
                    "offsetInEndSection": 1148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27863463",
                    "text": "RESULTS Here we present the ChIP-Seq command line tools and web server, implementing basic algorithms for ChIP-seq data analysis starting with a read alignment file.",
                    "offsetInBeginSection": 295,
                    "offsetInEndSection": 460,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28529706",
                    "text": "Therefore, a relational database in which available ChIP-Seq datasets are curated is essential.",
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 533,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28529706",
                    "text": "Results: We present Expresso (database and webserver) as a tool for the collection and integration of available Arabidopsis ChIP-Seq peak data, which in turn can be linked to a user's gene expression data.",
                    "offsetInBeginSection": 534,
                    "offsetInEndSection": 739,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28529706",
                    "text": "Known target genes of transcription factors were identified by motif analysis of publicly available GEO ChIP-Seq data sets.",
                    "offsetInBeginSection": 740,
                    "offsetInEndSection": 863,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097880",
                    "text": "MPromDb (Mammalian Promoter Database) is a curated database that strives to annotate gene promoters identified from ChIP-seq results with the goal of providing an integrated resource for mammalian transcriptional regulation and epigenetics.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 240,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a72284b2dc08e987e000001",
            "body": "Can radius fracture cause carpal tunnel syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29169594",
                "http://www.ncbi.nlm.nih.gov/pubmed/23026468",
                "http://www.ncbi.nlm.nih.gov/pubmed/21505639",
                "http://www.ncbi.nlm.nih.gov/pubmed/21786553",
                "http://www.ncbi.nlm.nih.gov/pubmed/27454517",
                "http://www.ncbi.nlm.nih.gov/pubmed/26566562",
                "http://www.ncbi.nlm.nih.gov/pubmed/11514776",
                "http://www.ncbi.nlm.nih.gov/pubmed/7524581",
                "http://www.ncbi.nlm.nih.gov/pubmed/26304737",
                "http://www.ncbi.nlm.nih.gov/pubmed/23569022"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594",
                    "text": "Carpal tunnel syndrome (CTS) after distal radius fractures can present in 3 forms: acute, transient, and delayed.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594",
                    "text": "Prophylactic carpal tunnel release in the absence of signs and symptoms of CTS after a distal radius fracture is not indicated.",
                    "offsetInBeginSection": 314,
                    "offsetInEndSection": 441,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026468",
                    "text": "Delayed carpal tunnel syndrome presenting after a distal radius fracture has healed is best managed in standard fashion.",
                    "offsetInBeginSection": 465,
                    "offsetInEndSection": 585,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026468",
                    "text": "Carpal tunnel syndrome is a common condition and is a well-recognized phenomenon following a distal radius fracture.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21505639",
                    "text": "We report the incidence of late onset post-operative carpal tunnel syndrome (late carpal tunnel syndrome) and late median nerve neuropathy after volar plating of distal radius fracture by conducting a retrospective study on volar plating for distal radius fracture performed during 2002 to 2006.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 295,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21786553",
                    "text": "CONCLUSION Simultaneous anterior transverse carpal ligament resection can effectively prevent the delayed carpal tunnel syndrome occurrence for the distal radius fracture with open reduction by palm side.",
                    "offsetInBeginSection": 1211,
                    "offsetInEndSection": 1415,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27454517",
                    "text": "Carpal tunnel syndrome is a common complication associated with distal radius fractures.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27454517",
                    "text": "Being well known and accepted techniques of carpal tunnel release, we believe that the techniques described in this paper provide a viable alternative for carpal tunnel release in the setting of distal radius fracture fixation; with the added advantages of the original minimally invasive techniques.",
                    "offsetInBeginSection": 628,
                    "offsetInEndSection": 928,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566562",
                    "text": "We report a case of acute rupture of the flexor pollicis longus and flexor carpi radialis tendons with acute carpal tunnel syndrome after a Gustilo-Anderson type II open distal radius fracture.",
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 334,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7524581",
                    "text": "Chronic pressure here may cause carpal tunnel syndrome.",
                    "offsetInBeginSection": 651,
                    "offsetInEndSection": 706,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75f1f383b0d9ea66000006",
            "body": "Can Logic Alignment Free (LAF) be used for bacterial genomes classification?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26664519",
                "http://www.ncbi.nlm.nih.gov/pubmed/15984937",
                "http://www.ncbi.nlm.nih.gov/pubmed/22312592",
                "http://www.ncbi.nlm.nih.gov/pubmed/25313296",
                "http://www.ncbi.nlm.nih.gov/pubmed/21906634",
                "http://www.ncbi.nlm.nih.gov/pubmed/25573913",
                "http://www.ncbi.nlm.nih.gov/pubmed/22829725",
                "http://www.ncbi.nlm.nih.gov/pubmed/26446672",
                "http://www.ncbi.nlm.nih.gov/pubmed/15342561",
                "http://www.ncbi.nlm.nih.gov/pubmed/22174282"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519",
                    "text": "In this paper, we present Logic Alignment Free (LAF), a method that combines alignment-free techniques and rule-based classification algorithms in order to assign biological samples to their taxa.",
                    "offsetInBeginSection": 315,
                    "offsetInEndSection": 511,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519",
                    "text": "We apply LAF successfully to the classification of bacterial genomes to their corresponding taxonomy.",
                    "offsetInBeginSection": 690,
                    "offsetInEndSection": 791,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519",
                    "text": "Alignment-free algorithms can be used to estimate the similarity of biological sequences and hence are often applied to the phylogenetic reconstruction of genomes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15984937",
                    "text": "The findings can be readily introduced into software for gene prediction, sequence alignment or microbial genomes classification.",
                    "offsetInBeginSection": 795,
                    "offsetInEndSection": 924,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22312592",
                    "text": "We have therefore developed an alignment-free algorithm for rapidly detecting horizontal gene transfer between closely related bacterial genomes.",
                    "offsetInBeginSection": 526,
                    "offsetInEndSection": 671,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22312592",
                    "text": "Our implementation of this algorithm is called alfy for \"ALignment Free local homologY\" and is freely available from http://guanine.evolbio.mpg.de/alfy/.",
                    "offsetInBeginSection": 672,
                    "offsetInEndSection": 825,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22829725",
                    "text": "By constructing a multiple alignment map between target contig sequences and two reference bacterial genome sequences, this program also provides very useful comparative genomics analysis of draft bacterial genomes.",
                    "offsetInBeginSection": 566,
                    "offsetInEndSection": 781,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26446672",
                    "text": "RESULTS We propose an alignment-free supervised metagenomic classification method called DectICO.",
                    "offsetInBeginSection": 443,
                    "offsetInEndSection": 540,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26446672",
                    "text": "CONCLUSIONS The alignment-free supervised classification method DectICO can accurately classify metagenomic samples without dependence on known microbial genomes.",
                    "offsetInBeginSection": 1359,
                    "offsetInEndSection": 1521,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26446672",
                    "text": "Alignment-free supervised classification is important for discriminating between the multifarious components of metagenomic samples, because it can be accomplished independently of known microbial genomes.",
                    "offsetInBeginSection": 235,
                    "offsetInEndSection": 440,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a722a052dc08e987e000002",
            "body": "Is Marfan syndrome associated with chordal rupture?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10441700",
                "http://www.ncbi.nlm.nih.gov/pubmed/14658812",
                "http://www.ncbi.nlm.nih.gov/pubmed/7790334",
                "http://www.ncbi.nlm.nih.gov/pubmed/17317544",
                "http://www.ncbi.nlm.nih.gov/pubmed/1888465",
                "http://www.ncbi.nlm.nih.gov/pubmed/18172522",
                "http://www.ncbi.nlm.nih.gov/pubmed/2278175",
                "http://www.ncbi.nlm.nih.gov/pubmed/9136539",
                "http://www.ncbi.nlm.nih.gov/pubmed/6837414",
                "http://www.ncbi.nlm.nih.gov/pubmed/15755703"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700",
                    "text": "The neonatal Marfan syndrome is an autosomal dominantly inherited disease with an extremely poor prognosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700",
                    "text": "This report gives a clinical and echocardiographic description of an infant with a mutation in exon 29 of the fibrillin-1 gene (FBN1), a region in which this severe form of Marfan syndrome seems to cluster.",
                    "offsetInBeginSection": 108,
                    "offsetInEndSection": 314,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812",
                    "text": "Three patients underwent mitral annuloplasty and chordal shortening.",
                    "offsetInBeginSection": 772,
                    "offsetInEndSection": 840,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812",
                    "text": "CONCLUSION This experience in mitral valve procedures indicated that the connective tissue defect might compromise the results of such surgery, but that mitral valve operations could be performed satisfactorily in young Marfan syndrome patients, despite complications of left ventricular dilatation.",
                    "offsetInBeginSection": 1109,
                    "offsetInEndSection": 1408,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7790334",
                    "text": "It is worthy to report this case because of rarities such as Marfan's syndrome accompanied by Prinzmetal's variant angina, perioperative coronary artery spasm in modified Bentall's operation, and perioperative chordal rupture of the mitral valve and progression of mitral valve regurgitation.",
                    "offsetInBeginSection": 659,
                    "offsetInEndSection": 951,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7790334",
                    "text": "In a modified Bentall's operation (button technique), perioperative severe coronary artery spasm occurred in spite of the preventive use of nitroglycerin infusion, which resulted in profound ventricular fibrillation and subsequent chordal rupture of the mitral valve with Sellers IV regurgitation.",
                    "offsetInBeginSection": 130,
                    "offsetInEndSection": 427,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1888465",
                    "text": "Gargoylism promotes abnormal thickening of collagen fibers in the fibrosa via acid-mucopolysaccharide (aMPS) overproduction, but Marfan syndrome weakens the valves in spite of increased aMPS.",
                    "offsetInBeginSection": 345,
                    "offsetInEndSection": 536,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1888465",
                    "text": "Spontaneous chordal rupture is partly related to myxomatous change, but that in the elderly cases shows only simple disruption of collagen fibers with loss of the spongiosa tissue.",
                    "offsetInBeginSection": 1330,
                    "offsetInEndSection": 1510,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18172522",
                    "text": "Repair of the mitral valve in children who have Marfan syndrome is especially difficult due to the presence of generalized connective tissue disorder, which may lead to future elongation and rupture of chordae tendineae that were unaffected at the time of mitral valve repair.",
                    "offsetInBeginSection": 205,
                    "offsetInEndSection": 481,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6837414",
                    "text": "It is concluded that chordal rupture in patients with the mitral valve prolapse syndrome does not always result in severe hemodynamic deterioration and may go undetected unless a high index of suspicion is maintained.",
                    "offsetInBeginSection": 605,
                    "offsetInEndSection": 822,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75f2fc83b0d9ea66000007",
            "body": "What is TCGA2BED?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28049410"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "We also provide and maintain an automatically updated data repository with publicly available Copy Number Variation, DNA-methylation, DNA-seq, miRNA-seq, and RNA-seq (V1,V2) experimental data of TCGA converted into the BED format, and their associated clinical and biospecimen meta data in attribute-value text format.",
                    "offsetInBeginSection": 814,
                    "offsetInEndSection": 1132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "RESULTS We propose TCGA2BED a software tool to search and retrieve TCGA data, and convert them in the structured BED format for their seamless use and integration.",
                    "offsetInBeginSection": 417,
                    "offsetInEndSection": 580,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "Furthermore, TCGA2BED extends TCGA data with information extracted from other genomic databases (i.e., NCBI Entrez Gene, HGNC, UCSC, and miRBase).",
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 813,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "CONCLUSIONS The availability of the valuable TCGA data in BED format reduces the time spent in taking advantage of them: it is possible to efficiently and effectively deal with huge amounts of cancer genomic data integratively, and to search, retrieve and extend them with additional information.",
                    "offsetInBeginSection": 1135,
                    "offsetInEndSection": 1431,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "In this work, we focus on The Cancer Genome Atlas, a comprehensive archive of tumoral data containing the results of high-throughout experiments, mainly Next Generation Sequencing, for more than 30 cancer types.",
                    "offsetInBeginSection": 203,
                    "offsetInEndSection": 414,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "BACKGROUND Data extraction and integration methods are becoming essential to effectively access and take advantage of the huge amounts of heterogeneous genomics and clinical data increasingly available.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "The BED format facilitates the investigators allowing several knowledge discovery analyses on all tumor types in TCGA with the final aim of understanding pathological mechanisms and aiding cancer treatments.",
                    "offsetInBeginSection": 1432,
                    "offsetInEndSection": 1639,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "Additionally, it supports the conversion in CSV, GTF, JSON, and XML standard formats.",
                    "offsetInBeginSection": 581,
                    "offsetInEndSection": 666,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a722ccd2dc08e987e000003",
            "body": "What is the mechanism of action of Tezepelumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
                "http://www.ncbi.nlm.nih.gov/pubmed/28368013",
                "http://www.ncbi.nlm.nih.gov/pubmed/28583618",
                "http://www.ncbi.nlm.nih.gov/pubmed/21054454",
                "http://www.ncbi.nlm.nih.gov/pubmed/20350658",
                "http://www.ncbi.nlm.nih.gov/pubmed/9721431",
                "http://www.ncbi.nlm.nih.gov/pubmed/11068911",
                "http://www.ncbi.nlm.nih.gov/pubmed/23089283",
                "http://www.ncbi.nlm.nih.gov/pubmed/12939711",
                "http://www.ncbi.nlm.nih.gov/pubmed/15649562"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454",
                    "text": "WHAT IS NEW AND CONCLUSION Further research is needed to uncover the mechanism of analgesic action of paracetamol.",
                    "offsetInBeginSection": 1072,
                    "offsetInEndSection": 1186,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454",
                    "text": "METHODS A literature search was conducted of clinical and preclinical literature and the information obtained was organized and reviewed from the perspective of its contribution to an understanding of the mechanism of analgesic action of paracetamol.",
                    "offsetInBeginSection": 576,
                    "offsetInEndSection": 826,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454",
                    "text": "WHAT IS KNOWN AND BACKGROUND Although paracetamol (acetaminophen), N-(4-Hydroxyphenyl)acetamide, is one of the world's most widely used analgesics, the mechanism by which it produces its analgesic effect is largely unknown.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 223,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11068911",
                    "text": "The aims of this paper are to examine what is currently known about its mechanism of action, to compare the action with that of a widely investigated aliphatic dialdehyde, glutaraldehyde (GTA), and to put forward a hypothesis that would, in the light of current knowledge, explain how OPA inactivates micro-organisms, including GTA-resistant Mycobacterium chelonae.",
                    "offsetInBeginSection": 135,
                    "offsetInEndSection": 500,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089283",
                    "text": "What kind of action understanding, if any, can be ascribed to the mirror mechanism?",
                    "offsetInBeginSection": 298,
                    "offsetInEndSection": 381,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089283",
                    "text": "Since its discovery in the monkey and human brain, many have claimed that the mirror mechanism is critically involved in understanding action.",
                    "offsetInBeginSection": 119,
                    "offsetInEndSection": 261,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12939711",
                    "text": "Induction of apoptosis, antibody-dependent cell cytotoxicity (ADCC), and complement-mediated cell death (CDC) is the proposed mechanism of action of these antibodies.",
                    "offsetInBeginSection": 481,
                    "offsetInEndSection": 647,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15649562",
                    "text": "There is considerable evidence that indicates that ribavirin triphosphate (RTP) can interact with the various viral RNA polymerases, and it seems likely that this interaction is important to the mechanism of action of ribavirin.",
                    "offsetInBeginSection": 442,
                    "offsetInEndSection": 670,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15649562",
                    "text": "Thirty years after its synthesis, the mechanism of action of ribavirin is still not completely understood.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15649562",
                    "text": "Although much is known about the metabolism and biochemical effects of ribavirin in human cells, there is still much to be learned about the precise mechanism of action of ribavirin with the various viruses.",
                    "offsetInBeginSection": 107,
                    "offsetInEndSection": 314,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75f5aa83b0d9ea66000008",
            "body": "Describe JACUSA",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28049429",
                "http://www.ncbi.nlm.nih.gov/pubmed/17230075",
                "http://www.ncbi.nlm.nih.gov/pubmed/2209143",
                "http://www.ncbi.nlm.nih.gov/pubmed/18349498",
                "http://www.ncbi.nlm.nih.gov/pubmed/18428249",
                "http://www.ncbi.nlm.nih.gov/pubmed/26579876",
                "http://www.ncbi.nlm.nih.gov/pubmed/18428297",
                "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                "http://www.ncbi.nlm.nih.gov/pubmed/25323285",
                "http://www.ncbi.nlm.nih.gov/pubmed/11441785"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17230075",
                    "text": "Describe common techniques for flap monitoring.",
                    "offsetInBeginSection": 421,
                    "offsetInEndSection": 468,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18349498",
                    "text": "We propose describing a manipulative technique using 6 characteristics: Rate of force application: Describe the rate at which the force was applied.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18349498",
                    "text": "Relative structural movement: Describe which structure or region was intended to remain stable and which structure or region was intended to move, with the moving structure or region being named first and the stable segment named second, separated by the word \"on.\"",
                    "offsetInBeginSection": 581,
                    "offsetInEndSection": 846,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18428249",
                    "text": "Several support protocols describe methods for adenovirus growth and purification, biotinylation, inactivation with psoralen, and quantitation of the adenovirus particles.",
                    "offsetInBeginSection": 279,
                    "offsetInEndSection": 450,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We describe first a field deployable mass spectrometer, based on an ion trap analyzer, and variants of that system.",
                    "offsetInBeginSection": 375,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We describe four sensing and characterization technologies recently developed at Los Alamos National Laboratory; a select set of mass spectral and optical techniques is emphasized.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We then describe a hand-held, battery-operated optical spectrometer, usable in either absorption, or fluorescence excitation mode.",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 621,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25323285",
                    "text": "We report a pathologically proven angiomyoma around the knee joint in a middle aged man, describe its clinical and imaging features, and outlay an approach in diagnosing this rare entity as a differential for painful subcutaneous mass lesions.",
                    "offsetInBeginSection": 515,
                    "offsetInEndSection": 758,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11441785",
                    "text": "Using a similar term to describe different forms of pathology leads to a muddle.",
                    "offsetInBeginSection": 135,
                    "offsetInEndSection": 215,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11441785",
                    "text": "In this paper, we describe \"Clerambault's syndrome\" and \"Kandinsky-Clerambault's syndrome\" and discuss and clarify the confusion surrounding these different syndromes.",
                    "offsetInBeginSection": 216,
                    "offsetInEndSection": 383,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a722d9f2dc08e987e000004",
            "body": "What is mechanism of action of Benralizumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
                "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
                "http://www.ncbi.nlm.nih.gov/pubmed/27097165",
                "http://www.ncbi.nlm.nih.gov/pubmed/28109128",
                "http://www.ncbi.nlm.nih.gov/pubmed/28737051",
                "http://www.ncbi.nlm.nih.gov/pubmed/26205082",
                "http://www.ncbi.nlm.nih.gov/pubmed/28530840",
                "http://www.ncbi.nlm.nih.gov/pubmed/26775606",
                "http://www.ncbi.nlm.nih.gov/pubmed/28971769",
                "http://www.ncbi.nlm.nih.gov/pubmed/29086236"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
                    "text": "As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma.",
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 249,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165",
                    "text": "Benralizumab is an anti-interleukin-5 receptor \u03b1 monoclonal antibody that depletes blood and airway eosinophils.",
                    "offsetInBeginSection": 215,
                    "offsetInEndSection": 328,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165",
                    "text": "CONCLUSIONS Benralizumab reduced asthma exacerbation and improved lung function and asthma control in adults with uncontrolled eosinophilic asthma.",
                    "offsetInBeginSection": 1393,
                    "offsetInEndSection": 1540,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28109128",
                    "text": "Benralizumab is a humanized, afucosylated, anti-interleukin-5 receptor \u03b1, immunoglobulin G (IgG) 1 \u03ba monoclonal antibody.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28109128",
                    "text": "Stochastic simulations supported an every-8-week dosing schedule of benralizumab for a phase IIb study in patients with uncontrolled asthma.",
                    "offsetInBeginSection": 945,
                    "offsetInEndSection": 1085,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28737051",
                    "text": "Anti-IL-5-based therapies (mepolizumab and reslizumab are humanized monoclonal antibodies (hmAbs) that recognize free IL-5, benralizumab is a hmAb directed at the \u03b1 subunit of the IL-5R) target the IL-5-signaling in eosinophilic asthma.",
                    "offsetInBeginSection": 299,
                    "offsetInEndSection": 536,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28737051",
                    "text": "Other benefits of benralizumab are fast (within 24\u00a0h) depletion of peripheral blood eosinophils, potent suppressive activity of bone marrow eosinophils and eosinophil precursors, tissue eosinophil apoptosis regardless of the presence of eosinophil survival factors and even at low IL-5R densities.",
                    "offsetInBeginSection": 952,
                    "offsetInEndSection": 1250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28971769",
                    "text": "Ligustrazine and SP600125 are small molecules and compounds and lebrikizumab, benralizumab and dupilumab are large molecule antibodies investigational product, though are being considered as novel agents for the pharmacotherapy of asthma.",
                    "offsetInBeginSection": 562,
                    "offsetInEndSection": 800,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28971769",
                    "text": "Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor \u03b1 monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils.",
                    "offsetInBeginSection": 801,
                    "offsetInEndSection": 968,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29086236",
                    "text": "Benralizumab is a monoclonal antibody that targets interleukin-5 receptor \u03b1 to deplete blood eosinophils and improve the clinical outcomes of allergic asthma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75f6e083b0d9ea66000009",
            "body": "Which data simulator is available for CLIP-SEQ experiments?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26776207",
                "http://www.ncbi.nlm.nih.gov/pubmed/28254606",
                "http://www.ncbi.nlm.nih.gov/pubmed/21389147",
                "http://www.ncbi.nlm.nih.gov/pubmed/21037263",
                "http://www.ncbi.nlm.nih.gov/pubmed/24451213",
                "http://www.ncbi.nlm.nih.gov/pubmed/28605404",
                "http://www.ncbi.nlm.nih.gov/pubmed/25652745",
                "http://www.ncbi.nlm.nih.gov/pubmed/21994224",
                "http://www.ncbi.nlm.nih.gov/pubmed/28336542",
                "http://www.ncbi.nlm.nih.gov/pubmed/26539468"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207",
                    "text": "To this date, however, it has not been assessed which of the available tools are most appropriate for the analysis of CLIP-Seq data.",
                    "offsetInBeginSection": 325,
                    "offsetInEndSection": 457,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21037263",
                    "text": "In this study, we introduce a novel database, starBase (sRNA target Base), which we have developed to facilitate the comprehensive exploration of miRNA-target interaction maps from CLIP-Seq and Degradome-Seq data.",
                    "offsetInBeginSection": 421,
                    "offsetInEndSection": 634,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24451213",
                    "text": "Here, we present PIPE-CLIP, a Galaxy framework-based comprehensive online pipeline for reliable analysis of data generated by three types of CLIP-seq protocol: HITS-CLIP, PAR-CLIP and iCLIP.",
                    "offsetInBeginSection": 232,
                    "offsetInEndSection": 422,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652745",
                    "text": "DESCRIPTION Here, we constructed a database, CLIPdb, to describe RBP-RNA interactions based on 395 publicly available CLIP-seq data sets for 111 RBPs from four organisms: human, mouse, worm and yeast.",
                    "offsetInBeginSection": 426,
                    "offsetInEndSection": 626,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652745",
                    "text": "We consistently annotated the CLIP-seq data sets and RBPs, and developed a user-friendly interface for rapid navigation of the CLIP-seq data.",
                    "offsetInBeginSection": 627,
                    "offsetInEndSection": 768,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652745",
                    "text": "We applied a unified computational method to identify transcriptome-wide binding sites, making the binding sites directly comparable and the data available for integration across different CLIP-seq studies.",
                    "offsetInBeginSection": 769,
                    "offsetInEndSection": 975,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652745",
                    "text": "CONCLUSION Manually curated metadata and uniformly identified binding sites of publicly available CLIP-seq data sets will be a foundation for further integrative and comparative analyses.",
                    "offsetInBeginSection": 1266,
                    "offsetInEndSection": 1453,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652745",
                    "text": "Large amounts of crosslinking immunoprecipitation (CLIP)-seq data (including HITS-CLIP, PAR-CLIP, and iCLIP) have been recently produced to reveal transcriptome-wide binding sites of RBPs at the single-nucleotide level.",
                    "offsetInBeginSection": 204,
                    "offsetInEndSection": 423,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21994224",
                    "text": "RESULTS We describe Pyicos, a powerful toolkit for the analysis of mapped reads from diverse HTS experiments: ChIP-Seq, either punctuated or broad signals, CLIP-Seq and RNA-Seq.",
                    "offsetInBeginSection": 355,
                    "offsetInEndSection": 532,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26539468",
                    "text": "Our findings can serve as a general guideline for CLIP experiments design and the comprehensive analysis of CLIP-Seq data.",
                    "offsetInBeginSection": 894,
                    "offsetInEndSection": 1016,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a72302b2dc08e987e000005",
            "body": "Treatment of which disease was studied in the Gore REDUCE Clinical Study?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29090661",
                "http://www.ncbi.nlm.nih.gov/pubmed/28222987",
                "http://www.ncbi.nlm.nih.gov/pubmed/27872317",
                "http://www.ncbi.nlm.nih.gov/pubmed/17704480",
                "http://www.ncbi.nlm.nih.gov/pubmed/26808286",
                "http://www.ncbi.nlm.nih.gov/pubmed/10847965",
                "http://www.ncbi.nlm.nih.gov/pubmed/24947948",
                "http://www.ncbi.nlm.nih.gov/pubmed/18559363",
                "http://www.ncbi.nlm.nih.gov/pubmed/22288601",
                "http://www.ncbi.nlm.nih.gov/pubmed/8957386"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29090661",
                    "text": "Aims The Gore REDUCE Clinical Study (REDUCE) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.",
                    "offsetInBeginSection": 194,
                    "offsetInEndSection": 507,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29090661",
                    "text": "The trial should determine whether patent foramen ovale closure with the Gore septal occluders is safe and more effective than medical therapy alone for the prevention of recurrent clinical ischemic stroke or new silent brain infarct; the neuroimaging data will provide an opportunity to further support the proof of concept.",
                    "offsetInBeginSection": 1629,
                    "offsetInEndSection": 1954,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987",
                    "text": "CONCLUSIONS Our multicenter experience with the GORE TIGRIS Vascular Stent demonstrates continued good results\u00a0at\u00a02\u00a0years for endovascular treatment of challenging obstructive superficial femoral artery and popliteal artery disease.",
                    "offsetInBeginSection": 1517,
                    "offsetInEndSection": 1752,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987",
                    "text": "This study therefore investigated the performance of the GORE TIGRIS Vascular Stent at three different centers in France in patients with symptomatic peripheral artery disease.",
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 427,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987",
                    "text": "METHODS This retrospective, single-arm, multicenter cohort study included 215 patients with peripheral artery disease (Rutherford-Becker category 2-6) who were treated with the GORE TIGRIS Vascular Stent, a dual-component stent consisting of a nitinol wire frame combined with a fluoropolymer-interconnecting structure.",
                    "offsetInBeginSection": 430,
                    "offsetInEndSection": 749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27872317",
                    "text": "METHODS A prospective, single-center pilot study recruited 30 symptomatic patients (mean age 64 years; 18 men) to evaluate the safety and early efficacy of the new Gore balloon-expandable covered endoprosthesis for the treatment of de novo or restenotic common and/or external iliac artery lesions.",
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 413,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17704480",
                    "text": "The Gore TAG endoprosthesis (W. L. Gore and Associates, Flagstaff, Ariz) was the first to enter clinical trials for the treatment of thoracic aortic aneurysms, confirming its safety and efficacy as well as its short-term advantages over open surgical repair.",
                    "offsetInBeginSection": 104,
                    "offsetInEndSection": 362,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26808286",
                    "text": "BACKGROUND The aim of this study is to assess the safety and the short-term results of endovascular treatment of common iliac artery (CIA) aneurysms using the new GORE EXCLUDER iliac branch endoprosthesis (IBE) device.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 218,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24947948",
                    "text": "The aim of this study is to present our short-terms results in the treatment of laparoscopic paraesophageal hiatal hernia (LPHH) with a synthetic polyglycolic acid:trimethylene carbonate mesh (Gore Bio A(\u00ae)).",
                    "offsetInBeginSection": 317,
                    "offsetInEndSection": 526,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288601",
                    "text": "CONCLUSION Implanting a Gore Bio-A\u00ae Fistula Plug is a simple, minimally invasive, safe and potentially effective procedure to treat complex anal fistula.",
                    "offsetInBeginSection": 1258,
                    "offsetInEndSection": 1412,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a760e5583b0d9ea66000018",
            "body": "Which comparisons demonstrate the applicability of StereoGene in regulatory genomics?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                "http://www.ncbi.nlm.nih.gov/pubmed/15814024",
                "http://www.ncbi.nlm.nih.gov/pubmed/10207157",
                "http://www.ncbi.nlm.nih.gov/pubmed/23440612",
                "http://www.ncbi.nlm.nih.gov/pubmed/23175757",
                "http://www.ncbi.nlm.nih.gov/pubmed/16407459",
                "http://www.ncbi.nlm.nih.gov/pubmed/18282510",
                "http://www.ncbi.nlm.nih.gov/pubmed/26388177",
                "http://www.ncbi.nlm.nih.gov/pubmed/17567996",
                "http://www.ncbi.nlm.nih.gov/pubmed/17201929"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                    "text": "These analyses provide examples for the broad applicability of StereoGene for regulatory genomics.",
                    "offsetInBeginSection": 1473,
                    "offsetInEndSection": 1571,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                    "text": "We apply our method to numerous comparisons of ChIP-Seq datasets from the Human Epigenome Atlas and FANTOM CAGE to demonstrate its wide applicability.",
                    "offsetInBeginSection": 1062,
                    "offsetInEndSection": 1212,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15814024",
                    "text": "This paper reviews methods of identifying conserved regulatory elements of developmental genes by comparative genomics, including new attempts to detect conserved features beyond simple sequence similarities.",
                    "offsetInBeginSection": 555,
                    "offsetInEndSection": 763,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23440612",
                    "text": "The sequencing of many vertebrate species over the last decade has opened up the possibility of using comparative genomics as a powerful tool to elucidate regulatory elements in the vertebrate genome.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23440612",
                    "text": "Its genome has been used in large-scale genome comparisons to locate vertebrate specific regulatory elements and also it has been an excellent model system to test out the predicted DNA sequences for their ability to drive reporter gene expression in vivo.",
                    "offsetInBeginSection": 258,
                    "offsetInEndSection": 514,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23175757",
                    "text": "RESULTS We present a framework for reconstructing gene regulatory networks from genetical genomics data where genotype and phenotype correlation measures are used to derive an initial graph which is subsequently reduced by pruning strategies to minimize false positive predictions.",
                    "offsetInBeginSection": 557,
                    "offsetInEndSection": 838,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18282510",
                    "text": "By subjecting eukaryotic genomic sequences to computational comparisons and subsequent experimentation, we are inching our way toward a more comprehensive catalog of common regulatory motifs that lie behind fundamental biological processes.",
                    "offsetInBeginSection": 773,
                    "offsetInEndSection": 1013,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18282510",
                    "text": "Despite remarkable recent advances in genomics that have enabled us to identify most of the genes in the human genome, comparable efforts to define transcriptional cis-regulatory elements that control gene expression are lagging behind.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26388177",
                    "text": "CONCLUSIONS The proposed motif-based regulon inference approach can discover the organism-specific regulatory interactions on a single genome, which may be missed by current comparative genomics techniques due to their limitations.",
                    "offsetInBeginSection": 1488,
                    "offsetInEndSection": 1719,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17567996",
                    "text": "We find that sets of putative transcriptional regulatory sequences, defined by ENCODE experimental data, have a wide span of evolutionary histories, ranging from stringent constraint shown by deep phylogenetic comparisons to recent selection on lineage-specific elements.",
                    "offsetInBeginSection": 201,
                    "offsetInEndSection": 472,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a72329e2dc08e987e000006",
            "body": "Falciform ligament sign is characteristic to which disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23133059",
                "http://www.ncbi.nlm.nih.gov/pubmed/19716250",
                "http://www.ncbi.nlm.nih.gov/pubmed/26577973",
                "http://www.ncbi.nlm.nih.gov/pubmed/2003436",
                "http://www.ncbi.nlm.nih.gov/pubmed/16807665",
                "http://www.ncbi.nlm.nih.gov/pubmed/3881894",
                "http://www.ncbi.nlm.nih.gov/pubmed/2910743",
                "http://www.ncbi.nlm.nih.gov/pubmed/23259725",
                "http://www.ncbi.nlm.nih.gov/pubmed/10495995",
                "http://www.ncbi.nlm.nih.gov/pubmed/907474"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133059",
                    "text": "Primary tumor of falciform ligament is exceedingly uncommon.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 60,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19716250",
                    "text": "RESULTS All specific air distributions were more frequently present in patients with gastroduodenal perforation than lower GI tract perforation, but only the falciform ligament sign was statistically significant (p<0.05).",
                    "offsetInBeginSection": 1158,
                    "offsetInEndSection": 1379,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26577973",
                    "text": "Pathologies of the falciform ligament are extremely rare entities ranging from cyst and hematoma to abscess and gangrene.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2003436",
                    "text": "One or more of these signs were present in 26 cases (59%) of pneumoperitoneum, including the right-upper-quadrant gas sign in 18 cases (41%), Rigler's sign in 14 cases (32%), and the falciform ligament and football signs in one case each (2%).",
                    "offsetInBeginSection": 697,
                    "offsetInEndSection": 940,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3881894",
                    "text": "The demonstration of a vessel in the falciform ligament, traditionally presumed to be a reopened umbilical vein, is an important sonographic sign of portal hypertension.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2910743",
                    "text": "Cullen's sign can be seen to be secondary to the tracking of liberated pancreatic enzymes to the anterior abdominal wall from the inflamed gastrohepatic ligament and across the falciform ligament.",
                    "offsetInBeginSection": 721,
                    "offsetInEndSection": 917,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23259725",
                    "text": "Abscess formation of the falciform ligament is incredibly rare and perplexing when encountered for the first time.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23259725",
                    "text": "It is reported to occur in the setting of cholecystitis and cholangitis, but the pathophysiology is poorly understood.In this case report, we present a 73-year-old man with falciform ligament abscess following cholangitis from an obstructive ampullary carcinoma.",
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 377,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23259725",
                    "text": "We hypothesize that cholangitis, with secondary portal pyaemia and tracking via the paraumbilical veins, can cause infectious seeding of the falciform ligament, with consequent abscess formation.",
                    "offsetInBeginSection": 2219,
                    "offsetInEndSection": 2414,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10495995",
                    "text": "Internal hernia through a defect in the falciform ligament is extremely rare, with six reported cases including our own in Japan.",
                    "offsetInBeginSection": 576,
                    "offsetInEndSection": 705,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        }
    ]
}
